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Abstract
Rare disorders affect less than one in 2000 individuals, placing a huge burden on
individuals, families and the health care system. Gene discovery is the starting point in
understanding the molecular mechanisms underlying these diseases. The advent of nextgeneration sequencing has accelerated discovery of disease-causing genetic variants and
is showing numerous benefits for research and medicine. I describe the application of
next-generation sequencing, namely LipidSeq™ ‒ a targeted resequencing panel for the
identification of dyslipidemia-associated variants ‒ and whole-exome sequencing, to
identify genetic determinants of several rare diseases. Utilization of next-generation
sequencing plus associated bioinformatics led to the discovery of disease-associated
variants for 71 patients with lipodystrophy, two with early-onset obesity, and families
with brachydactyly, cerebral atrophy, microcephaly-ichthyosis, and widow’s peak
syndrome. Understanding these variants and their contribution to disease can increase
understanding of disease mechanisms and help with the development of therapeutic
interventions in the future.
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Chapter 1 – Introduction
1.1

Rare disease burden in Canada

In Canada, rare diseases are defined as conditions affecting less than one in every 2000
individuals1. Rare disorders place a significant burden on individuals, their families and
the health care system, as there is often a lack of specialized services, social awareness,
and clinical recognition. Furthermore, Canadian families with rare diseases face
extraordinary challenges, including countless futile medical tests, unnecessary surgeries,
financial hardships, social isolation, shortages in treatment options, and early mortality.
In the case of rare diseases, the term “diagnostic odyssey” describes the burden of these
diseases on the individual, familial and systemic levels. The diagnostic odyssey details
the time between the first concerns of a rare disorder to the time when a diagnosis is
made2. In the diagnostic odyssey, more than half of the affected individuals with rare
diseases are children, with 30% not living to see their fifth birthday. Further, 40% of
individuals with rare diseases will receive an incorrect diagnosis, 25% will wait 5‒25
years for a diagnosis, and 50% will never be diagnosed in the course of their lifetime3.
Ultra-rare diseases – those limited to a handful of individuals – are often referred to as
“orphan diseases”. The term orphan disease describes an exceptionally rare disease
historically neglected by the pharmaceutical industry, due to the assumed low financial
incentive in devising proper treatments or cures. Because orphan diseases may affect only
single individuals, families or communities, these individuals face even greater
challenges than those with more prevalent rare diseases. Furthermore, these diseases are
often chronically debilitating and life threatening4. With the hardships facing the
individuals, their families and the health care system, and the lack of treatment options
available, there is a pressing need to study rare diseases, and develop novel therapeutic
interventions.
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1.1.1

Many rare diseases are of genetic origin

To date, there are an estimated 7000 rare diseases. As most of these 7000 rare diseases
are predicted to be of genetic origin due to severity and familial recurrence, gene
discovery is the critical starting point for the understanding of the molecular mechanisms
underlying these diseases, the development of targeted treatments, and the end of the
diagnostic odyssey for these patients. Developing therapies is crucial, as fewer than fivepercent of the 7000 rare diseases known-to-date offer effective therapeutic interventions5.
Previously, rare disease research was limited to standard genetic techniques including
homozygosity mapping and candidate gene sequencing6. Although these were largely
successful in identifying the molecular bases of >3500 rare disorders, limitations
including time requirements and high costs have led to the advent of new and improved
technologies, and the use of next-generation sequencing (NGS) – deoxyribonucleic acid
(DNA) sequencing technologies capable of rapidly generating a massive amount of DNA
sequence data – in rare disease studies7.

1.1.2

Research problem and motivation

Although the genetic basis of many rare diseases has been clarified using genetic
techniques, many rare diseases, rare disease subtypes and orphan diseases remain
genetically unexplained. With the success of NGS in elucidating the genetic basis of
numerous rare diseases, I propose the use of NGS technologies in rare disease cases not
previously subjected to NGS. By using these modern NGS technologies, my goal is to
identify genetic determinants underlying several genetically unexplained rare diseases.
Understanding these genetic variants and their contribution to disease can increase
understanding of disease mechanisms and pave the way for the development of novel
treatments in the future.
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1.2

Rare human genetic diseases

There are many illustrative examples of rare human genetic diseases, notably
lipodystrophy, extreme early-onset obesity, brachydactyly, and autosomal recessive
cerebral atrophy. Further, research consortiums such as CARE for RARE
(CARE4RARE) and Finding of Rare Disease Genes in Canada (FORGE Canada)
collectively pursue research on the molecular basis of rare diseases.

1.2.1

Inherited lipodystrophies

Lipodystrophies are rare disorders characterized by selective and variable loss of adipose
tissue, with excess accumulation of fat in otherwise unusual sites including the liver and
muscle8. This results in a generalized muscular appearance with hypertrophy often arising
in the extremities, more specifically, in the calves and arms. The genetic form of
lipodystrophy is familial, and includes congenital generalized lipodystrophy (CGL) and
familial partial lipodystrophy (FPLD). Affected individuals are predisposed to insulin
resistance, which often progresses to other metabolic complications including diabetes,
hypertension, metabolic syndrome and hypertriglyceridemia9. Furthermore, individuals
with lipodystrophy are vulnerable to severe metabolic derangements including acute
pancreatitis, hepatic cirrhosis and premature cardiovascular disease10. Women with
severe lipodystrophy often acquire polycystic ovary disease and suffer from infertility,
highlighting the aggressiveness of the disorder11. Although the global prevalence is less
than one in a million, milder forms of lipodystrophy are commonly misdiagnosed as
common central obesity or metabolic syndrome, suggesting that lipodystrophy is an
underestimated condition12. This is concerning as a clear diagnosis of lipodystrophy can
allow for earlier care, better management, and improved prognosis.

1.2.1.1

Congenital generalized lipodystrophy

First reported by Berardinelli and Seip in 1954 and 1959, CGL, also known as complete
lipodystrophy or Berardinelli-Seip syndrome, is an extremely rare (less than one in 12
million people) disorder characterized by the absence of metabolically active adipose
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tissue from birth13,14. Due to the absence of functioning adipocytes, lipids are stored in
unusual sites in the body such as the liver and muscle, subsequently leading to a marked
muscular appearance.
As the more severe form of the inherited lipodystrophies, individuals with complete
lipodystrophy generally present with insulin resistance, rapid aging of bones, hepatic
steatosis, hypertriglyceridemia, early-onset diabetes and high blood pressure, often
developing into metabolic syndrome. In addition, individuals with CGL acquire
hepatomegaly and skeletal muscle hypertrophy; hypertrophic cardiomyopathy is also
reported in 25% of individuals and is a common cause of mortality8.
To date, there is no cure for CGL. Treatment is through cosmetic procedures, diet,
hypoglycemic drugs and lipid-lowering drugs. With regards to medication, the
management of CGL is through the medicated treatment of each symptom. Although
there has been recent success in CGL treatment with Metreleptin – a leptin replacement
that aids in the control of metabolic processes in the body, such as triglyceride and blood
sugar management – this drug has yet to be approved in Canada.

1.2.1.2

Familial partial lipodystrophy

The second, milder form of lipodystrophy is FPLD, characterized by the selective loss of
adipose tissue from the body (most often the limbs) during childhood or puberty.
Although affected regions may include the face, neck and extremities, the body fat in the
intra-abdominal or truncal region are often spared, and some individuals present with
excess fat deposition in the face and neck15. Most individuals presenting with FPLD in
the clinic are females, with the metabolic complications more severe in women. Most
women remain fertile; however, some women present with hirsutism and polycystic
ovary syndrome, leading to fertility issues. Additionally, some patients develop
cardiomyopathy, myopathy, and features of multisystem dystrophy16,17.
Similar to CGL, the treatment for FPLD includes lifestyle modifications including diet
changes and exercise. Again, the treatment revolves around treating each individual
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symptom (i.e. Metformin for diabetes, statins for high cholesterol) rather than the disease
as a whole18.

1.2.2

Extreme early-onset obesity

Extreme early-onset obesity, or excess adiposity, is defined as a body mass index
[(weight in kilograms ÷ height in meters)2] greater than or equal to the 85th and 95th
percentile for gender and age, respectively. In Canada, childhood-onset obesity is a
pressing health concern with the rates having tripled over the last three decades.
Currently, approximately one in seven children are obese, with rates depending on factors
such as age, biological sex, location of residence, and socioeconomic status19. As obesity
is a significant risk factor for coronary heart disease, high blood pressure, ischemic stroke
and diabetes, it places a major toll on children and their families. This burden is
especially apparent in the health care system, as early-onset obesity is associated with
increased incidence of adult obesity, hepatic steatosis, and cardiovascular disease. For the
first time in history, the complications associated with obesity are leading to a decrease in
life expectancy of 2‒5 years20.
In the past, obesity was mainly attributed to environmental changes, specifically the
intake of high-energy food in combination with a sedentary lifestyle. In recent years, the
heritability of obesity has been established, with genetic factors explaining most
differences between populations21. In fact, obesity risk in children is 10-fold greater when
both parents are obese than when both parents are of a normal weight21. Aside from
lifestyle alterations and medications for the management of associated co-morbidities (i.e.
high blood pressure, diabetes), there is no direct treatment or cure for extreme early-onset
obesity.
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1.2.3

Isolated brachydactyly

Brachydactyly is an inherited malformation characterized by the shortening of the fingers
and toes due to deficiencies in the development of the phalanges, metacarpals, and/or
metatarsals. Although brachydactyly can be a common feature in complex malformation
syndromes, there are many cases of congenital, isolated forms of brachydactyly. These
isolated brachydactyly syndromes represent one of the ten categories of hand
malformations as classified by Temtamy and McKusick22. The prevalence of isolated
brachydactyly is rare, with the exception of types A3 and D, where prevalence varies
between populations, reportedly averaging around 2%23. Aside from these exceptions,
most forms of brachydactyly are limited to a few pedigrees. In addition to shortened
fingers and toes, other features of brachydactyly include short stature, syndactyly (fused
digits), polydactyly (extra digits), and symphalangism (stiff digits) depending on the
subtype (Table 1.2.3). Although brachydactyly is best diagnosed using genetic testing, it
can also be diagnosed using clinical, anthropometric and radiological means. Treatment
for brachydactyly is strictly cosmetic, through elective surgeries.
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Table 1.2.3. Clinical features of isolated brachydactyly.
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1.2.4

Cerebral atrophy

Neurodegenerative diseases are diseases characterized by the progressive loss of neural
cells from the brain. Although some neurogenerative diseases are more prevalent, such as
Alzheimer disease, many neurodegenerative diseases are rare, such as the ataxias or
spastic paraplegias24,25. Cerebral atrophy, the loss of neurons and neuronal connections in
the brain, is a common feature of many rare neurodegenerative diseases. In 2013, my
laboratory described a case of autosomal recessive cerebral atrophy, a novel
neurodegenerative disorder in an Old Order Amish family. In this specific case of
cerebral atrophy, the affected individuals featured additional symptoms including
microcephaly, seizures and psychomotor retardation26. Cerebral atrophy is diagnosed
through radiological imaging of the brain.

1.2.5

FORGE Canada and CARE for RARE

In Canada, two Consortiums study the genetic basis of over 200 rare diseases with
pediatric onset. These coalitions, FORGE Canada and CARE4RARE, represent the first
and second phases of a nationwide project led by Dr. Kym Boycott and Dr. Alex
MacKenzie of the Children’s Hospital of Eastern Ontario Research Institute.

1.2.5.1

Project overview

The goal of the previous FORGE Canada and current CARE4RARE project was to study
the genetic causes of over 200 rare diseases affecting children. In order to do this, the
organizers formed a consortium composed of 21 research sites and hospitals, 80
physicians, and 50 scientists. The approach of the project was to use high power DNA
sequencing in order to identify novel disease genes. The recruitment of this project,
which ended in March 2017, included over 4000 patients with 950 different rare
diseases27.
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Several criteria required satisfaction in order to qualify for either the FORGE Canada or
CARE4RARE Projects. These criteria included the following:
1) Unrelated patients and/or families with the same disorder OR,
2) Single families with multiple affected family members (+/‒ consanguinity) AND,
3) Meet the following inclusion sub-criteria:
a. Onset is in childhood or adolescence
b. The disease is most likely due to a single gene (monogenic)
c. DNA is accessible for the proband and available family members
d. Clinical material is of high quality

1.2.5.2

Project significance

In sum, the FORGE Canada Project has identified mutations in disease genes for 105 of
362 families. Further, since 2011, the CARE4RARE Project has successfully resulted in
the publication of 139 manuscripts on the discovery of 135 novel disease-causing
genes27. These results have provided closure and ended the diagnostic odyssey for the
individuals and the families through the provision of a diagnosis.

1.2.5.3

FORGE Canada and CARE for RARE cases

The Blackburn Cardiovascular Genetics Laboratory has been involved in several FORGE
Canada and CARE4RARE Projects. There are currently 11 projects in progress, namely:
FORGE 214 (Angelman-like syndrome), FORGE 122 (Dystonia, ataxia and intellectual
disability), FORGE 11 (Osteopetrosis), FORGE 352 (Microcephaly-ichthyosis), C4R 572
(Autosomal dominant isolated cryptophthalmos), C4R 573 (Widow’s peak syndrome),
C4R 575 (Amyoplasia), C4R 592 (Metaphyseal chondrodysplasia), C4R 664
(Craniosynostosis), C4R 907 (Heterotaxy disorder), and C4R 924 (Craniorachischisis).
The details of each case are listed in Table 1.2.5.3.
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Table 1.2.5.3. Clinical description and pedigrees for all CARE for RARE and
FORGE Canada cases.
Case

Clinical Description

FORGE 214,
Angelman-like
syndrome





FORGE 122,
Dystonia, ataxia and
intellectual
disability*








FORGE 11,
Osteopetrosis





Three children equally
affected, parents are
healthy first cousins with
Iraqi ancestry
Features include:
significant global
developmental delay,
delayed speech,
repetitive behaviour and
similar physical features
such as triangular face,
wide mouth, pointed
chin and fifth finger
clinodactyly
Three affected siblings
with a progressive,
childhood-onset ataxia
syndrome
Not known to be
consanguineous
Features include:
progressive gate ataxia
beginning between ages
2-5, wheelchair-bound
by early adolescence and
dysarthria
Two oldest siblings are
non-verbal with limited
responsiveness and
minimal spontaneous
movement

Old Order Mennonite
and Low-German
Speaking Mennonite
families
Features include: optic
atrophy, macrocephaly,
mid-facial hypoplasia,
micrognathia, abnormal
eruption of teeth, broad
halluces and short stature

Pedigree
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FORGE 352,
Microcephalyichthyosis*A






C4R 572, Autosomal
dominant isolated
cryptophthalmos





C4R 573, Widow’s
peak syndrome*




C4R 575,
Amyoplasia





Old Order Amish
families
Additional features
include: failure to thrive,
feeding difficulties,
developmental delay,
lethality in the first year
of life, enlarged
ventricles and early
delivery around 33
weeks gestation
Recurrence in the family

Female child born to
term to nonconsanguineous parents
Female displays
complete bilateral
isolated
cryptophthalmos, a
condition resulting in the
overgrowth of skin over
the eye

Non-consanguineous
family
Widow’s peak syndrome
features: a characteristic
widow’s peak hairline,
delayed development,
inability to touch the
shoulders, dysmorphic
face and the inability to
supinate the arms

Three unrelated families
with amyoplasia,
characterized by a
generalized lack of
muscular development
and growth in newborns
Both probands present
with severe muscle
hypoplasia
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C4R 592,
Metaphyseal
chondrodysplasia





C4R 664,
Craniosynostosis*






C4R 907, Heterotaxy
disorder





C4R 924,
Craniorachischisis*



Metaphyseal
chondrodysplasia
features short stature
with abnormally short
arms and legs
No abnormal facial
features were present in
the patients of interest

Non-consanguineous
family
Craniosynostosis is a
birth defect resulting in
the abnormal
development of the skull
Digital anomalies also
present
Two affected children
born to consanguineous
parents of Lebanese
descent
Disorder features:
heterotaxy with
holoprosencephaly,
bilateral ectopic thymus,
fused kidneys, annular
pancreas, bi-lobed right
lung, absent olfactory
nerves, dysplastic optic
nerves and chiasm and a
single umbilical artery
Stillborn baby presented
with craniorachischisis, a
severe neural tube defect
with anencephaly and
spina bifida

For each pedigree, biological males are represented as squares and biological females as circles. Shaded shapes indicate the individual is affected with the disorder.
Double lines indicate consanguineous relationships. In some pedigrees, hashed lines represent individuals in which sequencing has been performed. When shown,
asterisks represent patients in which DNA is available.
Abbreviations are as follows: FORGE, Finding of Rare Disease Genes Canada project.
*The red asterisk represents the projects I was directly involved in or was working with undergraduate students on. The remaining cases without an asterisk are those
in which I assume an administrative role.
A
Note: for the microcephaly-ichthyosis pedigree, the shaded shapes are individuals clinically diagnosed with microcephaly-ichthyosis, the shapes with vertical curved
lines are those with histidyl-tRNA synthetase disorder, the horizontal curved lines are individuals with congenital hypoventilation syndrome, and the shape filled with
the plus sign is an individual clinically diagnosed with cystinosis.
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1.3

The human genome sequence

In the year 1990, the International Human Genome Sequencing Consortium, composed of
public and private researchers, began the publically funded Human Genome Project, a
13-year project with the goal of determining the DNA sequence of the human genome.
With the sequencing of over three billion base pairs and approximately 21,000 genes, the
group of researchers began a revolution in the fight against human disease by introducing
a trove of genetic information applicable for numerous fields including developmental
biology, physiology, evolution and medicine28,29.

1.3.1

Variation within the human genome

Human genetic variation refers to the genetic differences within and among populations.
A variant form of a gene is an allele, where humans inherit one allele from each parent at
each genetic locus, or position. Each pair of alleles represent the genotype of a gene,
which can be classified as homozygous or heterozygous, referring to two identical alleles
or two different alleles, respectively. Genetic variation is manifested as single nucleotide
changes, insertions and deletions, repetitive elements and structural rearrangements of the
DNA sequence30. A mutation is a permanent change in the DNA sequence. The term
genetic “variant” has been gaining popularity over the term “mutation” in the field, and
refers to a benign or pathogenic alteration, or one of unknown significance.
Many decades prior to the availability of DNA sequencing technology or the sequence of
the human genome, researchers first became aware of differences in the genome through
the study of chromosome number and structure31. This led to the advent of molecular
biology, a multifaceted field in biology with one branch focused on the structure and
function of nucleic acids and proteins essential for life. Research into molecular biology
gave way to the understanding of the variation present in the human genome, notably the
implications of this variation and relationship to disease. Now, with the sequence of the
human genome available, researchers are able to study the impact of variation in the
genome, where the variation is composed of single nucleotide changes, insertions and
deletions, copy-number variations, repeat variations, and structural variations, all with
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potential disruptive effects on the genome. Although some variation can be benign, some
defects in the genome can cause genetic diseases, health conditions caused by variation in
the genome.

1.3.1.1

Single nucleotide variation

Single nucleotide variations (SNVs) are the most common class of genome variation,
with single nucleotide changes occurring approximately once every 500–1000 nucleotide
bases in the human genome sequence32. Each SNV represents a change in a single DNA
building block or a nucleotide base – composed of Thymine, Adenine, Cytosine and
Guanine, often shortened to T, A, C and G – commonly referred to as point mutations.
An example of a SNV may be a replacement of a Thymine with a Cytosine (T>C) in a
specific stretch of DNA. When these SNVs occur in a region coding for an amino acid
(three nucleotides, also referred to as a codon), these SNVs can result in either
synonymous (no change in amino acid) or non-synonymous changes (change from one
amino acid to another).
The wobble effect is the effect caused by the redundancy of the genetic code. More
specifically, each amino acid (with the exception of methionine and tryptophan) may be
coded by multiple codons, or multiple three letter codes composed of A, T, C or G. As
there are more codons than amino acids, the third base is not as discriminatory for the
amino acid as the first two bases. Due to the redundancy in the DNA code, many SNV
changes are tolerated or inconsequential. However, in certain cases, these changes can
lead to pathogenic missense or nonsense changes, referring to a change in one amino acid
to another, or a change in one amino acid to one coding for the truncation of a protein
downstream.
Due to the high frequency of these SNVs in the genome and the fact that some SNVs are
seen in approximately 1% of the population, SNVs often act as biological markers or
contribute to phenotypic traits (observable and measurable features)33. For example,
personal differences in SNPs may cause alterations at the level of the cell, or influence
drug metabolism. In some circumstances, SNVs are associated with disease and act by
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driving a disease phenotype (the observable characteristics of an individual) or
contributing to phenotypic traits. These disease-causing SNVs are most often exonic,
non-synonymous SNVs – those in the coding region causing a substitution in amino acid.

1.3.1.1.1 Splicing variation
Splicing is the editing of precursor messenger ribonucleic acid (mRNA) to mature
mRNA. During splicing, introns (nucleotide sequences in a gene discarded during
splicing) are removed, and exons (the part of the gene that codes for the final mRNA,
which is translated into protein) are ligated together. Splice site mutations refer to genetic
variants that insert, delete or change the nucleotides in the specific region where splicing
takes place. As these variants can result in the retention of intronic DNA in the mRNA or
result in the loss of exons from mature mRNA, variants in the splice site can have large
effects on human health and disease. In fact, an estimated 15-50% of human disease
variants are those that alter splicing elements34. An example of a mutation in a splice site
leading to disease is seen in hypoparathyroidism, where a G to C substitution in the first
nucleotide base of intron 2 in the parathyroid hormone gene (PTH) causes exon skipping
(the loss of an exon), and parathyroid hormone deficiency35.

1.3.1.1.2 Insertions and deletions
Another form of variation present at the nucleotide level are micro insertions or deletions
affecting 1‒50 base pairs, collectively known as “INDELs”. In terms of occurrence,
INDELs represent a common alteration in the genome, second only to SNVs36. These
INDELs alter the number of DNA bases in a gene by either adding or removing a piece
of DNA. When occurring in functionally important sites in the human genome, these
INDELs are likely to influence human traits or drive disease36. A notable example is TaySachs disease in the Ashkenazi Jewish, where a four base pair insertion (c.1278insTATC)
alters the reading frame of the hexosaminidase A gene (HEXA)37. This mutation leads to
an infantile form of Tay-Sachs disease where the most common features include
deterioration of both mental and physical abilities, and mortality approximately at the age
of four. INDELs can either occur inframe when in a multiple of three (deletion or gain in
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amino acids) or out-of-frame, where there is a change in amino acids downstream of the
insertion or deletion, with a possible inframe occurrence of a stop codon. This is referred
to as a frameshift and may alter or abolish the function of the resulting protein. Further,
INDELs can result in aberrant splicing when occurring in splice sites.

1.3.1.2

Repetitive elements

The human genome consists of millions of copies of transposable elements (TE) and
other repetitive sequences, altogether contributing up to two-thirds of the human
genome38. These repetitive elements – most commonly tandem repetitive elements or
interspersed repetitive elements that do not encode proteins – are labelled “junk” DNA.
Although considered junk or inconsequential, a growing body of evidence has been
accumulating in recent years clarifying the role of these repetitive regions in the
regulation of gene expression39. Continued research into these repeat sequences is
exploiting the role of these elements in gene expression.
Although most repetitive elements in the genome are harboured outside of the coding
region, some repeat sequences lie within genes and are subject to mutation. For example,
triplet repeat expansions (TREs) – trinucleotide repeats (i.e. CAGCAGCAG) abnormally
expanded in certain genes or introns – are dynamic mutations that occur in regions with
trinucleotide repeats. These TREs are the cause of TRE disorders such as Fragile X
syndrome or Huntington’s disease.

1.3.1.3

Structural variation

Structural variation (SV) affects a region of DNA approximately one kilo base (1-kb) or
larger40. SVs, including inversions, balanced translocations or genomic imbalances, have
long been associated with chromosomal rearrangements and genetic disorders. SVs can
arise through various mechanisms including non-allelic homologous recombination (HR),
non-homologous end joining (NHEJ), or replication-error41.
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1.3.1.3.1 Copy-number variation
Copy-number variation (CNV) is a form of structural variation where there is a change in
copy-number involving a DNA fragment over 1-kb40. CNVs can include deletions,
insertions or duplications present in variable copy-number in comparison to the reference
genome. As CNVs are regions of variable copy number, they may change gene
expression levels, and alter transcription levels to values higher or lower than expected in
a reference genome. Due to the change in gene expression, CNVs may play a large role in
phenotypic variation. Further, since CNVs encompass significantly more nucleotide
content per genome than single nucleotide polymorphisms (SNPs; up to 10-fold greater
or up to 12% of the genome), CNVs play an important role in genetic diversity, disease
and evolution42,43.

1.3.2

Germline versus somatic variation

Germline variation is defined as variation present in the germline, or the tissue involved
in forming sex cells. As a mutant sex cell may participate in fertilization, germline
variation may be passed on from parent to offspring44. In contrast, somatic variation
occurs in a single cell in developing somatic tissue. By definition, somatic cells are those
that are never transmitted from parent to progeny44. As cells are constantly dividing and
genetic material is continually replicated over the course of a lifespan, mistakes in
replication can accumulate in somatic cells through a lifetime45. Although many of these
variants do not have a phenotypic effect, some may alter key cellular functions by
affecting normal protein function and drive certain human diseases. Early somatic
variants – those occurring during embryogenesis – can also contribute to developmental
disorders, cancer or aging.

1.3.3

Inherited versus de novo variation

Variation can arise in the genome through two mechanisms. Inherited variation are DNA
changes transmitted from parent to offspring. Specifically, each egg and sperm cell
contribute half of the genetic information needed to produce an offspring. When the egg
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and sperm join during fertilization, a new cell is formed, composed of all the necessary
genetic information needed to form an individual. This leads to variation passed on from
parent to progeny.
On the other hand, de novo variation are DNA changes that are spontaneous (through
DNA replication errors or spontaneous lesions) or induced (caused by mutagens such as
radiation or chemical substances) in an offspring’s genome, not inherited from either
parent. These de novo genetic alterations may be acquired any time post-zygotically
(during the lifespan). This variation is de novo as the variation is not present in either
parental genome.
Both inherited and de novo variation may provide meaningful contributions to disease.
More specifically, diseases may be caused by inherited variation, or de novo variation.
An example of inherited variation causing disease is hemophilia A, where multiple
generations in a family inherit a variant in the coagulation factor VIII gene (F8) and
present with a severe bleeding disorder. In contrast, de novo variation is best exemplified
in severe early-onset pediatric diseases, where the causative mutations only arise postzygotically given that they are lethal in the germline and/or individuals with these
mutations do not reproduce46.

1.4

Human genetic diseases

Although there are diseases that occur through bacterial infection or exposure to viruses,
it is estimated that most human diseases have a genetic component. A genetic disease is
any disease attributed to abnormality in the human genome. These genetic diseases can
range from minor to severe and can be due to any of the aforementioned variation. In this
section, I describe the heritability of human genetic diseases.

1.4.1

Heritability of genetic diseases

Heritability refers to the ratio of genetic variation (VG) to phenotypic variation (VP); a
fundamental tool used in the study of the inheritance of human disease that is able to
partition the phenotypic variation into both genetic and environmental components47. Put
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simply, heritability is a statistic that is used to determine the proportion of variation in a
trait within a population that can be explained by genetics (rather than environment or
random chance). This is modelled through the following equation:
Phenotype (𝑃) = Genotype (𝐺) + Environment (𝐸)
There are two definitions of heritability48. The first, H2 or broad-sense, refers to the
genetic contributions to phenotypic variance through additive (phenotypic contributions
from more than one gene or alleles of a single gene, where the sum of the effects of both
alleles is equal to the sum of their effect individually), dominance (the relationship
between alleles of one gene where the effect of one allele masks the other, leading to a
phenotypic effect) and epistatic genetic effects (the phenomenon where one gene relies
on other modifier genes, where the sum of the effects in combination do not equal the
sum of the effects individually).
𝐻2 =

Var(𝐺)
Var(𝑃)

The second definition, h2 or narrow sense, captures the proportion of genetic variation
due to additive genetic effects (A; contributions from more than one gene or alleles of a
single gene acting synergistically).
ℎ2 =

Var(𝐴)
Var(𝑃)

Heritability of disease can also refer to the mode in which transmission occurs. Diseases
can be monogenic, digenic or polygenic, and involve variable penetrance, each defined in
the following sections.

1.4.1.1

Monogenic diseases

Monogenic diseases, or single gene disorders, are those caused by variants within a single
gene. These variants can be inherited in a family; can be dominant or recessive, and
autosomal or sex-linked. These modes of inheritance refer to the manner in which genetic
traits are passed from one generation to the next. The modes of inheritance include: 1)
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autosomal dominant; 2) autosomal recessive; 3) X-linked; 4) Y-linked; 5) codominant or;
6) mitochondrial. Their definitions are as follows:
1)

Autosomal dominant: when one copy of a gene in a cell harbours a variant. This
may be transmitted from one parent to an offspring or inherited de novo.

2)

Autosomal recessive: when both copies of a gene in a cell carry variants. One
copy is transmitted paternally and one copy is transmitted maternally to the
offspring.

3)

X-linked: when variants are harboured in genes on the X chromosome(s), one of
the two sex chromosomes that can be present in the genome. Note that normally
biological males have one X and one Y chromosome, and biological females have
two X chromosomes.

4)

Y-linked: when variants are harboured on the Y chromosome, with transmission
only possible from the paternal parent to a male offspring.

5)

Codominant: when two different alleles of a gene are expressed and each
influence the genetic trait.

6)

Mitochondrial: when genes in mitochondrial DNA carry variants and are
transmitted through maternal inheritance.

Monogenic diseases can also be considered Mendelian diseases, defined as diseases
where alternative genotypes fall into distinct phenotypic classes, according to Gregor
Mendel’s laws of inheritance49. One example of a monogenic disease is cystic fibrosis,
caused by a variant in the cystic fibrosis transmembrane conductance regulator gene
(CFTR) with an autosomal recessive mode of inheritance.

1.4.1.2

Digenic diseases

Digenic diseases are those where the disease phenotypes are caused by a combination of
variants in two genes, or two separate phenotypes caused by variants in two different
genes acting synergistically50. To cause disease, these genes may interact directly,
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indirectly, through a common pathway, through co-expression, or through similar
function. Due to the prevalence of digenic diseases, a common resource known as the
Digenic Diseases Database (DIDA) is accessible, containing information on over 40
digenic diseases and over 200 digenic combinations51. The first reported example of a
digenic disease was retinitis pigmentosa, where double heterozygotes with variants in the
peripherin 2 (RDS) and retinal outer segment membrane protein 1 (ROM1) loci displayed
the disorder52.

1.4.1.3

Polygenic diseases

Polygenic diseases are defined as genetic disorders caused by a combination of
abnormalities in more than one gene. Due to the fact that they are attributed to variants in
more than a single gene, they are inherited differently than monogenic disorders (as
described in Section 1.4.1.1). In humans, polygenic diseases are more frequent than
monogenic disorders, and have a greater economic burden. Due to the multiple gene
(multigenic) nature of these diseases, different methods have been developed to study
these diseases. These approaches include: 1) the use of a priori data or a set number of
genetic loci, or 2) the complete analysis of all available loci53. These may take the form
of case-control studies or genome-wide association studies (GWASs), respectively,
where case-control studies refer to the comparison of affected and healthy subgroups, and
GWASs refer the analysis and determination of similarities in genome-wide data of an
affected cohort. Association studies require the selection of several candidate genes in
order to carry out association analysis53. Illustrative examples of polygenic disease are
the familial dyslipidemias, such as coronary heart disease and diabetes. These are
polygenic as they are associated with multiple genes, and are not inherited as simply as
single gene disorders54.

1.4.1.4

Disease penetrance and expressivity

Disease penetrance and expressivity refer to factors that influence genetic changes.
Explicitly, penetrance refers to the proportion of individuals with a genetic change who
phenotypically exhibit a genetic disorder. When some individuals with the genetic variant
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do not display all or some of the features of a disorder, the condition is said to have
incomplete or reduced penetrance. Incomplete penetrance is demonstrated in cases of
breast cancer, where variants in the breast cancer, DNA repair associated 1 or 2 genes
(BRCA1 or BRCA2) may cause cancer in some individuals over the course of a lifetime,
but not others55.
On the other hand, expressivity is defined as the degree in which the expression of a trait
differs among individuals. This is exhibited when individuals with the same phenotype
display varying severity of a disease; or in other words, the disease exists on a spectrum.
For example, variable expressivity is seen in Marfan syndrome where some individuals
have mild symptoms (tall and thin features with slender fingers), while some experience
additional features such as life-threatening heart and blood vessel complications.
Although this disorder displays variable expressivity, most individuals with Marfan
syndrome carry variants in the fibrillin 1 gene (FBN1)56.

1.5

Genetic variation and rare diseases

For the rare genetic diseases described earlier – namely, lipodystrophy, extreme earlyonset obesity, brachydactyly, autosomal recessive cerebral atrophy, and those ascertained
from the CARE4RARE and FORGE Canada consortiums – although many cases of these
diseases have been genetically explained with causative variants identified, the genetic
etiology of many remain unknown. In this section, I describe the known genetics of these
diseases and unexplained cases in my laboratory.

1.5.1

The genetics of lipodystrophy

Over the years, many genetic variants have been associated with lipodystrophy. As the
defective gene often causes a distinct lipodystrophy phenotype, both CGL and FPLD
have been divided into subtypes.

23

1.5.1.1

Congenital generalized lipodystrophy

There are four subtypes of CGL based on previously identified genes; denoted as CGL1‒
4. CGL commonly follows an autosomal recessive mode of inheritance. Although each
subtype features the complete loss of adipose tissue, different subtypes present with
distinct characteristics57:
1)

CGL1: characterized by the absence of metabolically active adipose tissue from
birth, CGL1 is associated with variants in the 1-acylglycerol-3-phosphate Oacyltransferase 2 gene (AGPAT2), a gene encoding an enzyme required for
phospholipid and triglyceride biosynthesis.

2)

CGL2: featuring the lack of adipose tissue from birth, mild mental disability and
cardiomyopathy, CGL2 is associated with variants in the seipin lipid droplet
biogenesis associated gene (BSCL2) encoding seipin, a protein that may play a
role in adipocyte differentiation.

3)

CGL3: reported in a single patient, CGL3 features the absence of body fat,
shortened stature and vitamin D resistance. CGL3 is correlated with variants in
the caveolin 1 gene (CAV1) encoding the caveolin 1 protein, an integral
component of caveolae on adipocyte membranes.

4)

CGL4: featuring the absence of body fat with congenital myopathy and
cardiomyopathy, CGL4 is associated with variants in the polymerase I and
transcript release factor gene (PTRF; also referred to as cavin) associated with the
biogenesis of caveolae.

Lipid droplets are defined as organelles responsible for the storage of triglycerides.
Playing a fundamental role in metabolism, the reduction or lack of lipid droplets cause
the lipodystrophies58. With each form of CGL, although each are attributed to distinct
genes, all gene products are involved in adipocyte lipid droplet formation. Further, each
form of CGL is associated with low leptin (the hormone of energy balance) as a result of
the lack of adipose tissue. This results in excess triglycerides and high blood sugar.
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1.5.1.2

Familial partial lipodystrophy

As in the case of CGL, FPLD also exists in various forms (FPLD1–5) with subtypes
defined based on their associated gene(s). Generally, FPLD follows an autosomal
dominant mode of inheritance. Similar to CGL, each subtype features a similar pattern in
adipose tissue loss but various additional characteristics57:
1)

FPLD1: a genetically unexplained form of FPLD, characterized by the loss of
subcutaneous fat from the extremities.

2)

FPLD2: a form of FPLD featuring the loss of subcutaneous fat from the
extremities and truncal region from puberty. FPLD2, or Dunnigan variety, is
associated with variants in the lamin A gene (LMNA) encoding the lamin A
protein, where deleterious mutations result in the premature death of adipocytes.

3)

FPLD3: characterized by the loss of subcutaneous fat from the extremities,
principally from the distal regions. FPLD3 is associated with variants in the
peroxisome proliferator-activated receptor gamma gene (PPARɣ), encoding a
transcription factor required for adipogenesis.

4)

FPLD4: reported in a single family, FPLD4 features the loss of subcutaneous fat
from the extremities. This subtype of FPLD4 is associated with variants in the
AKT serine/threonine kinase 2 gene (AKT2) encoding protein kinase B, involved
in adipocyte differentiation and insulin receptor signaling.

5)

FPLD5: a subtype of FPLD featuring fibrosis of adipose tissue and the loss of
subcutaneous fat from the extremities. FPLD5 is attributed to variants in the
perilipin 1 gene (PLIN1) encoding an integral constituent of lipid droplet
membranes, involved in lipid storage. FPLD5 has also been associated with
homozygous variants the cell death inducing DFFA-like effector C gene
(CIDEC), encoding a protein required for lipid droplet formation and energy
storage in adipose tissue.
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1.5.1.3

Unexplained cases of lipodystrophy

With the familial lipodystrophies, although many causative gene mutations have been
identified in affected individuals as described (i.e. LMNA, PPARG, AGPAT2 and BSCL2
variants), many individuals remain genetically unexplained59,60. Over the years, the
Blackburn Cardiovascular Genetics Laboratory (Robarts Research Institute, London ON,
Canada) has been successful in identifying the genetic basis of 120 lipodystrophyaffected patients using Sanger sequencing. Although this resulted in 44% of 267
lipodystrophy patients characterized by mutations in lipodystrophy-causing genes, 56%
of patients remained genetically unexplained after Sanger sequencing.

1.5.2

The genetics of obesity

To date, there have been many genes identified that underlie monogenic and polygenic
obesity. The rare, monogenic forms of human obesity have been critical in the elucidation
of the pathogenic mechanisms causing obesity. These rare forms of monogenic obesity
are associated with the following genes: LEP, LEPR, POMC, PCSK1, MC4R, BDNF, and
NTRK2, where all aforementioned genes and protein products are involved in body
weight management (described in detail in Table 1.5.2)61-67. Further, all genes encode
either hormones or neurotransmitters/receptors belonging to the highly conserved leptinmelanocortin pathway, a critical pathway in the regulation of food intake and body
weight.
In contrast to the monogenic forms of obesity where obesity is the main feature, the
syndromic forms of early-onset obesity are Mendelian disorders with obesity as one
clinical feature. The additional clinical features may include intellectual disability,
dysmorphic countenances and developmental abnormalities, generally organ-specific. To
date, over 30 syndromes have been identified, with Prader-Willi, Bardet-Biedl, Cohen,
and Alström syndrome as classic examples68-71.
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Table 1.5.2. Genes involved in the pathophysiology of obesity.
Gene name

Symbol

Function

Leptin

LEP

Encoding the hormone leptin, this hormone is
involved in the regulation of body weight. Leptin
works by attaching to the leptin receptor on the
surface of organs and tissues, including the
hypothalamus. The hypothalamus controls states
including hunger and thirst, and the release of
hormones through the body. The binding of leptin
in the hypothalamus triggers a feeling of satiety.

Leptin receptor

LEPR

The leptin receptor is a Type I cytokine receptor
that binds with the hormone leptin. The leptin
receptor is responsible for the regulation of energy
metabolism and body weight through interactions
with gangliosides in the cell membrane.

Proopiomelanocortin

POMC

The POMC gene encodes the
proopiomelanocortin protein, which is cleaved
into small peptides in the body. These peptides
then bind to several proteins in the body to trigger
signaling pathways responsible for functions
including energy homeostasis, melanocyte
stimulation and immune modulation.

Prohormone convertase 1

PCSK1

Encoding a member of the subtilisin-like
proprotein convertase family, this protein is
involved in the secretory pathway. More
specifically, it functions in the proteolytic
activation of polypeptide hormones and
neuropeptide precursors.

Melanocortin 4 receptor

MC4R

Brain-derived
neurotrophic factor

BDNF

The MC4R gene encodes a membrane-bound
receptor belonging to the melanocortin receptor
family. This protein interacts with melanocytestimulating hormones and adrenocorticotrophic
hormones and plays a role in energy homeostasis
and somatic growth.
This gene encodes a protein found in the brain and
spinal cord that plays a role in growth,
differentiation, and maintenance of nerve cells.
The BDNF protein is localized in brain regions
responsible for controlling eating, drinking and
body weight.

Neurotrophic tyrosine
kinase receptor type 2

NTRK2

The NTRK2 gene encodes a membrane-bound
receptor kinase that phosphorylates both itself and
members of the mitogen-activated protein kinase
pathway. Signaling through NTRK2 results in cell
differentiation.
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1.5.2.1

Unexplained cases of early-onset obesity

As in the case of the lipodystrophy patients in the laboratory, the prevalence of
genetically unexplained cases is also reflected in the early-onset obesity cohort, where
known obesity-causing genes, POMC, LEP, LEPR, PCSK1 and MC4R, cannot explain
the phenotype of five patients and/or families with extreme early-onset obesity
ascertained in the Blackburn Cardiovascular Genetics Laboratory (Robarts Research
Institute, London ON, Canada)20. In some instances, these patients display variable comorbidities (i.e. hyperphagia, intellectual disability) in addition to extreme early-onset
obesity.

1.5.3

The genetics of brachydactyly

Most isolated brachydactyly syndromes display an autosomal dominant mode of
inheritance, with variable penetrance. To date, several gene mutations have been
designated as causative for each subtype (Table 1.5.3). Here, I describe subtype
brachydactyly type A.
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Table 1.5.3. The genetics of isolated brachydactyly.
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1.5.3.1

Brachydactyly type A

As described by Bell in 1951, the hallmark feature of brachydactyly type A is the
shortening of the middle phalanges72. Type A has been further divided into four subtypes,
A1 to A4, with each subtype further subdivided into types A to D.

1.5.3.1.1 Brachydactyly type A1 (BDA1)
In the early 1900s, Farabee and Drinkwater characterized the first disorder that could be
explained by Mendelian autosomal dominant inheritance – brachydactyly. In 1963, Haws
and McKusick continued the analysis on Farabee’s family and associated the condition to
BDA173. In BDA1, the middle phalanges of all the digits are absent or shortened, with
shortening of the thumb and big toe. In some instances, the middle and terminal
phalanges are fused (terminal symphalangism, or fusion of the terminal phalanges), with
shortening of the metacarpals. Drinkwater found that the shortened phalanges were due to
the absence of the epiphyses, which subsequently lead to overall shortened stature in
adulthood22,74,75. BDA1 has been attributed to mutations in the Indian Hedgehog gene
(IHH), where mutations affect endochondral ossification of the developing bones76-83.

1.5.3.1.2 Brachydactyly type A1, B (BDA1B)
Armour et al. described a family with a mild form of brachydactyly that did not fit the
clinical findings of other families with BDA184. In their family, Armour and colleagues
described shortened middle and terminal phalanges, with all the digits slightly shortened.
The feet of this family were also affected, with the children displaying multiple coned
epiphyses. From this research, Armour et al. highlighted the benefits of using a
metacarpophalangeal profile in designating clinical status. In 2002, Armour et al.
performed a linkage study, and mapped the condition to the cytogenetic bands 5p13.3p13.285. However, the causative gene and putative mutations have not yet been identified.

30

1.5.3.1.3 Brachydactyly type A1, C (BDA1C)
Type A1C was first described by Byrnes and colleagues in a consanguineous FrenchCanadian family86. In this subtype of BDA1, individuals displayed markedly shortened
middle phalanges of the second through fifth digits, and the first terminal phalanx. There
was also shortening in the first metacarpals resulting in the appearance of a shortened
thumb. The third to fifth metacarpals were slightly affected, and the feet were affected in
this family. BDA1C is attributed to a mutation in Growth Differentiation Factor 5
(GDF5), associated with a decreased effectiveness of chondrogenesis and abnormal
skeletal morphogenesis87. BDA1C is inherited in an autosomal recessive or dominant
manner, with recessive mutations causing a more severe phenotype86.

1.5.3.1.4 Brachydactyly type A1, D (BDA1D)
In 2015, Racacho et al. described patients with BDA1D, a “BDA1-like” brachydactyly88.
In the first proband, features included short second digits, curved fifth digits, and
shortened first and second toes. Upon radiographic analysis, it was found that there was
absence of the middle phalanges in the index fingers, with shortened middle phalanges in
the fifth digits. The terminal phalanges of the thumbs were also affected. In the second
proband, brachydactyly and clinodactyly of the fifth digits and right thumb were reported,
with abnormally-shaped middle phalanges of the second digit and fifth digit. This
condition was designated as BDA1-arachnodactyly. Type BDA1D has been associated
with mutations in Bone Morphogenetic Protein Receptor Type 1B (BMPR1B)88. Where
the p.K325N mutation acts in a dominant-negative manner. Mutations in BMPR1B result
in brachydactyly by affecting normal chondrogenesis.

1.5.3.1.5 Brachydactyly type A2 (BDA2)
BDA2 is characterized by the absence or shortening of the middle phalanx of the index
finger and second toe. Rarely, this feature can extend to the fifth digit. In severe cases,
the middle phalanx is a rhomboid or triangular shape causing the index finger to deviate
radially. BDA2 is inherited in an autosomal dominant manner, with mutations identified
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in Bone Morphogenetic Protein 2 (BMP2), BMPR1B, and GDF589-94. The reported
families are of German, Norwegian, Swiss, Chinese and Polish descent22.

1.5.3.1.6 Brachydactyly type A3 (BDA3)
In BDA3, the most common features include the shortening and slanting of the middle
phalanx of the fifth digit. Due to the characteristic rhomboid or triangular shape of the
middle phalanx, clinodactyly of the fifth finger is present22. The prevalence of BDA3 is
quite common, often seen in syndromic forms. The frequency of BDA3 can vary from
3.4% to 21% in various, isolated ethnic populations22. Although there are multiple
definitions of BDA3, Hertzog defined BDA3 as requiring the middle phalanx of the fifth
finger to be less than half the size of the middle phalanx of the fourth digit95. Williams et
al. also found that cone-shaped epiphyses in BDA3 are twice as likely in females than
males, suggesting a strong sex-bias in BDA3 inheritance96. Although there is no
candidate locus or gene identified to date, BDA3 is inherited in an autosomal dominant
manner with variable penetrance22.

1.5.3.1.7 Brachydactyly type A4 (BDA4)
In 1978, Temtamy and McKusick studied a family with four generations of BDA422. The
features of this family included the shortening of the second and fifth digits due to
brachymesophalangy – an abnormal shortening of the middle phalanges. Although the
fourth finger was not always affected, it displayed an irregularly shaped middle phalanx
resulting in radial deviation of the terminal phalanx when afflicted. The feet were also
affected22. BDA4 has been reported multiple times in the literature with added features
including nail dysplasia, clinodactyly, short stature, and a bifid appearance of the
thumb97-99. No causative locus or gene for this sub-phenotype has been identified.

1.5.3.1.8 Unexplained cases of brachydactyly
To date, various forms of brachydactyly have been characterized and numerous causative
genes have been found (Table 1.5.3). Although there is much known about
brachydactyly, many subtypes remain genetically undefined. We introduce a 31-year-old
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female from Ontario referred to Dr. Hegele’s Endocrinology Clinic (London Health
Sciences Centre, University Hospital, London ON, Canada) for medical consultation for a
lifelong history of short stature and shortening of all digits of the upper and lower
extremities. There was no history of other medical conditions, specifically no nystagmus,
musculoskeletal abnormalities, developmental delay, or scoliosis. Upon examination, all
digits of upper and lower extremities were noted to be short, with missing middle
phalanges and splayed fingers, similar to a brachydactyly type A phenotype. The
proband’s parents were both of short stature, but only her mother shared identical features
including very short fingers and toes. Eight maternal aunts and one uncle had all reported
abnormally shortened fingers of variable severity. One brother and her daughter had
similarly shortened digits (Figure 1.5.3.1.8).
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Figure 1.5.3.1.8. Pedigree of a Canadian autosomal dominant brachydactyly-affected family. The black arrow indicates the
proband. All shaded shapes represent those clinically affected. Biological females are represented by circles and biological males are
represented by squares.
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1.5.4

The genetics of autosomal recessive cerebral

atrophy
In 2013, our laboratory (Blackburn Cardiovascular Genetics Laboratory) elucidated the
genetic basis of a novel pediatric neurodegenerative disorder deemed, autosomal
recessive cerebral atrophy26. Using a combination of homozygosity mapping and exome
sequencing, Lahiry et al. identified four individuals with a c.995C>T (p.Thr332Met)
variant in the TMPRSS4 gene encoding transmembrane protease, serine 4, a protein
involved in numerous biological processes26.

1.5.4.1

Unexplained cerebral atrophy

Recently, a second family with a history of disease resembling autosomal recessive
cerebral atrophy was referred to the Blackburn Cardiovascular Genetics Laboratory from
India (Figure 1.5.4.1). In this case, the proband presented with microcephaly, severe
cortical atrophy and widened lateral ventricles. The parents were both clinically
unaffected with normal brain structure and function. The sister of the proband was also
affected but passed away prior to genetic testing.
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Figure 1.5.4.1. Pedigree of a family with cerebral atrophy. Biological males are
squares and biological females are circles. The arrow indicates the proband, whereas the
shaded shapes represent those affected by the cerebral atrophy, microcephaly and
widened lateral ventricles.
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1.5.5

Genetically unexplained consortium cases

The Blackburn Cardiovascular Genetics Laboratory is actively working on 11 FORGE
Canada and CARE4RARE Projects. The rare diseases in the 11 families previously listed
are all genetically unexplained and require a genetic diagnosis. By using NGS
technologies, I seek to identify genetic determinants underlying all the genetically
unexplained rare disease cases ascertained in the Blackburn Cardiovascular Genetics
Laboratory.

1.6

Next-generation sequencing and rare diseases

Since the 1970s, Sanger sequencing has been the gold standard in genetic studies with
several historical accomplishments, notably the sequencing of the first human genome29.
However, limitations including time requirements and high costs have led to the advent
of new and improved technologies, designating Sanger sequencing as first generation
sequencing100. Over the past five years, we have been in a new era of genomics, where
NGS methods have become mainstay in genomic research. NGS is an umbrella term used
to describe all the newer methods, capable of generating a colossal amount of data
rapidly and efficiently100. It includes three dominant methods used to identify genetic
variants, namely targeted resequencing, whole-exome sequencing (WES), and wholegenome sequencing (WGS).
Today, many platforms exist to perform NGS. Although each company offers a distinct
method, the general workflow is as follows: 1) template preparation, 2) sequencing and
imaging, 3) genome alignment and assembly, and 4) genome enrichment. Regardless of
the company chosen, each method provides a rapid and inexpensive genome-wide
sequence readout as an output, and allows for characterization of evolutionary
relationships and the elucidation of the DNA sequence for studies in health and
disease101.

37

1.6.1

Targeted resequencing

Targeted resequencing is a method of NGS that works by using NGS chemistry to isolate
and sequence any number of pre-selected genes from a sample library. With the ability to
rapidly sequence target genes, these targeted gene panels are able to identify causative
variants in genomic loci. Targeted resequencing is one of the fastest growing applications
for NGS technologies.

1.6.1.1

LipidSeq™

An excellent example of a NGS clinical resequencing panel is LipidSeq™, a targeted
gene panel designed by, and used in, the Blackburn Cardiovascular Genetics
Laboratory102. The objective of the pilot LipidSeq™ project was to develop a NGS-based
method to facilitate in the clinical diagnosis of dyslipidemias. Using Illumina
technologies, this pilot study on LipidSeq™ demonstrated a 95% concordance rate with
the gold standard, Sanger sequencing, highlighting its diagnostic utility in the clinic. To
date, over 3,000 DNA samples have been processed using LipidSeq™.
Currently, the LipidSeq™ panel targets ~73 genes and >180 SNPs associated with
monogenic dyslipidemias. The LipidSeq™ targets genes involved in lipid metabolism as
well as genes associated with lipodystrophy and its associated metabolic comorbidities
(Table 1.6.1.1).
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Table 1.6.1.1. Details regarding the genes targeted by the LipidSeq™ gene panel
relating to lipodystrophy and associated metabolic comorbidities.
Phenotype

Gene

Lipodystrophy

LMNA

Function

RefSeq
(NM_)

Chromosome:
Start-Stop/
Location

LMNA encodes lamin A and lamin
C proteins, which contribute to the
structural network of the inner
nuclear membrane of cells.

170707

1:156052369156109880/
1q22

PPARG

The PPARG gene encodes
peroxisome proliferator-activated
receptor-gamma (PPARɣ). This is a
nuclear receptor, which regulates
adipocyte differentiation.

015869

3:1232934912475855/
3p25.2

LMNB2

LMNB2 encodes lamin B, a
component of the structural network
of nuclear membranes in
vertebrates. It is important for
mitotic processes, nuclear stability,
chromatin structure, and gene
expression.

032737

19:24281632456966/
19p13.3

CIDEC

CIDEC is a DNA fragmentation
factor (DFF). In adipocytes, the
encoded protein contributes to lipid
droplet formation and plays a major
role in promoting apoptosis.

0011996
23

3:99083949921938/
3p25.3

AKT2

AKT2, an oncogene, encodes a
serine/threonine kinase with Src
Homology 2-like domains. It is
highly expressed in insulin-sensitive
tissues and regulates hepatic
metabolism during fasting.

001626

19:4073622440791443/
19q13.2

CAV1

CAV1 encodes caveolin-1, the main
component in the cavaolae plasma
membranes of most cell types.
Caveolin-1 is an integral membrane
protein, which links integrin
subunits to proto-oncogene tyrosine
kinase, FYN, promoting cell cycle
progression.

001753

7:116164839116201239/
7q31.2

AGPAT2

AGPAT2 encodes a 1-acylglycerol3-phosphate O-acyltransferase
protein, which converts
lysophosphatidic acid to
phosphatidic acid during
phospholipid biosynthesis. This
protein is localized to the ER.

006412

9:139567595139581911/
9q34.3
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BSCL2

BSCL2 encodes seipin, a
transmembrane protein that is
activated during pre-adipocyte
differentiation and contributes to
lipid droplet morphology. Seipin is
localized to the ER.

0011229
55

11:6245773462477091/
11q12.3

PTRF

PTRF encodes cavin, a protein that
regulates rRNA transcription and
plays an essential role in caveolae
biogenesis. Cavaolae, in turn, are
crucial for signal transduction and
lipid transport in many cell types.

012232

17:4055446740575506/
17q21.2

LIPE

LIPE encodes a hormone-sensitive
lipase, which exists in two forms,
depending on the translational start
codon. Present in steroidogenic
tissues, the longer form contributes
to cholesterol processing for steroid
hormone production. Expressed in
adipose, the shorter form hydrolyzes
TGs, thereby regulating the
mobilization of free fatty acids.

005357

19:4290566442931578/
19q13.2

Werner’s
Syndrome

WRN

The WRN gene encodes the Werner
protein, which shows dominant
nucleolar localization, possesses
DNA helicase activity (3’ to 5’) and
also acts as an exonuclease (3’ to
5’). This protein may also be
involved with DNA double strand
break repair.

000553

8:3089077831031277/
8p12

Mature Onset
Diabetes of the
Young (MODY)

HNF4A

Hepatocyte nuclear factor-4-alpha
(HNF4A) is a transcription factor
belonging to the nuclear receptor
family. HNF4A is the most
prominent DNA-binding protein in
the liver, where it is known to
regulate genes involved in lipid
metabolism. The encoded protein
also controls the expression of
genes including hepatocyte nuclear
factor 1 alpha. This gene may also
play a role in liver, kidney and
intestine development.

000457

20:4298444143061485/
20q13.12

GCK

GCK is expressed in the liver and
pancreatic islet beta cells and plays
a significant role in glucose
metabolism. Glucokinase (GCK) is
a unique member of the hexokinase
family where, in metabolic
pathways, hexokinases

033508

7:4418387044229022/
7p13
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phosphorylate glucose to produce
glucose-6-phosphate.
HNF1A

Hepatocyte nuclear factor-1-alpha
(HNF1A) or HNF1 homeobox A is
thought to aid in the orderly and
sequential activation of genes
during development at the level of
transcription. HNF1 protein is a
transcription factor that binds to a
variety of promoters in the liver and
is required for the expression of
several liver-specific genes.

000545

12:121415861121440315/
12q24.31

PDX1

Pancreatic and duodenal homeobox
1 (PDX1) acts as a transactivator
that binds the TAAT element in the
promoter region of target genes
involved in pancreas development.
The protein encoded by PDX1 is a
transcriptional activator of several
genes and plays a significant role in
glucose-dependent regulation of
insulin gene expression.

000209

13:2849416828500451/
13q12.2

HNF1B

Hepatocyte nuclear factor-1-beta
(HNF1B) is a transcription factor
(otherwise known as transcription
factor-2) that is a member of the
homeodomain-containing
superfamily of transcription factors.
This protein can bind as either a
homodimer or a heterodimer in
conjunction with HNF1A. This gene
has been shown to take part in
nephron development and regulates
the development of the embryonic
pancreas.

000458

17:3604643436105096/
17q12

NEUROD1

Neurogenic differentiation 1
(NEUROD1) is a basic helix-loophelix (bHLH) protein, which acts as
a transcription factor involved in
determining cell type during
development. NEUROD1 (after
heterodimerization with the
ubiquitous helix-loop-helix protein
E47, regulates insulin gene
expression by binding to a critical
E-box motif on the insulin
promoter.

002500

2:182540833182545392/
2q31.3

KLF11

Kruppel-like factor 11 (KFL11)
encodes a zinc finger transcription
factor that binds to specificity
protein 1-like sequences in both
epsilon- and gamma-globin gene

003597

2:1017077610194963/
2q25.1
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promoters. Their binding inhibits
cell growth and results in apoptosis.

Hypertriglyceridemia (HTG)

CEL

Carboxyl-ester lipase (CEL) is a
major component of pancreatic juice
and is in charge of the hydrolysis of
cholesterol and other dietary esters.
The protein encoded by CEL
promotes large chylomicron
production in the intestine and is
also thought to interact with
cholesterol and oxidized
lipoproteins to modulate the
progression of atherosclerosis.

001807

9:135936741135947250/
9q34.2

PAX4

Paired box gene 4 (PAX4) is a
member of the PAX family of
transcription factors. This gene
plays an important role during fetal
development and cancer growth. In
addition, it has been found that
PAX4 is essential for the
differentiation of insulin-producing
beta cells in the mammalian
pancreas.

006193

7:127250346127255982/
7q32.1

INS

Consisting of two dissimilar
polypeptide chains, A and B, and
linked by two disulfide bonds,
insulin is synthesized by beta cells
of the islets of Langerhans. Insulin
is under the control of a single gene
locus and binds the insulin receptor,
stimulating glucose uptake.

0011850
97

11:21810092182439/
11p15.5

BLK

B-lymphocyte specific kinase (BLK)
encodes a non-receptor tyrosine
kinase. These genes are typically
involved in cell proliferation and
differentiation. This protein
stimulates insulin synthesis and
secretion in response to glucose
levels and enhances expression
levels of several pancreatic beta-cell
transcription factors.

001715

8:1135152111422108/
8p23.1

LPL

LPL is responsible for the
breakdown of chylomicron
triglycerides into two fatty acids and
a monoacylglycerol along the
luminal surface of capillaries in the
heart, skeletal muscle, and adipose
tissue. It functions as a homodimer
and requires APOC2 as a cofactor.

000237

8:1979658219824770/
8p22
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APOC2

APOC2 is a lipid-binding protein
secreted in the plasma as a
component of chylomicrons and
VLDLs. It is essential for
lipoprotein lipase activation and TG
breakdown activity.

000483

19:4544923945452822/
19q13.2

APOC3

Apolipoprotein C-III is a component
of HDL and ApoB containing
lipoprotein particles. It impairs
hepatic uptake and catabolism of
ApoB-containing lipoproteins.

000040

11:116700624116703787/
11q23.3

APOA5

APOA5 is secreted in the plasma as
a component of HDL, and to a
lesser extent, VLDL and
chylomicrons. It is a strong
stimulator of LPL-mediated TG
hydrolysis and an activator of LPL.

052968

11:116660086116663136/
11q23

LMF1

The LMF1 protein resides in the ER
and is vital for LPL maturation and
transport through the secretory
pathway. It is therefore essential for
functioning circulating LPL in the
blood.

022773

16:9036341031318/
16q13.3

GPIHBP1

LPL and chylomicrons bind to
GPIHBP1 in the capillary
endothelial cells of the heart,
skeletal muscle and adipose tissue,
making it an important component
of chylomicron TG catabolism.

178172

8:144295068144299044/
8q24.3

GCKR

GCK is expressed in the liver and
pancreatic islet beta cells and plays
a significant role in glucose
metabolism. It is a unique member
of the hexokinase family where, in
metabolic pathways, hexokinases
phosphorylate glucose to produce
glucose-6-phosphate.

033508

7:4418387044229022/
7p13

CREB3L3

cAMP responsive element-binding
protein 3-like 3 (CREB3L3) is a
transcription factor specific to the
liver. The encoded protein is
localized to the ER and is activated
by cyclic AMP stimulation. The
encoded protein binds the cyclic
AMP response element (CRE) and
box-B element.

032607

19:41535984173051/
19p13.3

TRIB1

By controlling the differentiation of
tissue-resident M2-like
macrophages, TRIB1 is considered
critical for adipose tissue

025195

8:126442563126450647/
8q24.13
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maintenance and the suppression of
metabolic disorders.
GPD1

Low highdensity
lipoprotein
(LHDL)

GPD1 encodes an important protein
involved in lipid metabolism. The
encoded protein catalyzes the
conversion of dihydroxyacetone
phosphate (DHAP) and reduced
nicotine adenine dinucleotide
(NADH) to glycerol-3-phosphate
(G3P) and NAD+.

005276

12:5049760250505103/
12q13.12

GALNT2

GALNT2 encodes a membranebound glycosyltransferase protein
that catalyzes the first step of Oglycosylation of peptides in the
Golgi.

004481

1:230202956230417875/
1q42.13

MLXIPL

MLXIPL encodes a leucine zipper
transcription factor, which belongs
to the Myc/Max/Mad family. In a
glucose-dependent manner, it
activates the promoters of genes
coding for TG synthesis.

032951

7:7300752473038903/
7q11.23

ABCA1

ABCA1 is part of the ATP-binding
cassette (ABC) superfamily of
transporters. ABCA1 is a cholesterol
efflux pump, which removes
cholesterol from cells.

005502

9:107543283107690527/
9q31.1

APOA1

Apolipoprotein 1 is synthesized in
the liver and small intestines. It is
the main protein of plasma HDL,
promotes cholesterol efflux for
excretion and acts as a cofactor to
LCAT.

000039

11:116706467116708338/
11q23-q24

LCAT

Lecithin-cholesterol acyltransferase
(LCAT) esterifies cholesterol with a
lecithin molecule, reducing its
solubility and aiding in the
formation of pseudoHDL/LDL/VLDL. LCAT has a high
affinity for HDL and plays an
important role in the formation of
HDL cholesterol.

000229

16:6797378767978656/
16q22.1

ANGPTL3

Angiopoietin-like 3, expressed
predominantly in the liver, is in a
class of lipid metabolism
modulators that regulate VLDL
levels in the plasma. It acts as a dual
inhibitor of both lipoprotein lipase
and endothelial lipase.

014495

1:6306315863071976/
1p31.1-p22.3
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High lowdensity
lipoprotein
(HLDL)

ABCG1

ABCG1 encodes an ATP-binding
cassette transporter protein which
regulates macrophage cholesterol
and phospholipid transport. It also
contributes to cholesterol
homeostasis in several cell types.

004915

21:4361979943724497/
21q22.3

APOB

Apolipoprotein B is a hydrophilic
protein on chylomicrons, thereby
allowing for transport of LDL to the
tissues of the body. ApoB-48 is
synthesized in the intestines and
ApoB-100 is synthesized in the
liver.

000384

2:2122430121266945/
2p24-23

Abbreviations: HDL, high density lipoprotein; VLDL, very low density lipoprotein; LPL, lipoprotein lipase; TG,
triglyceride; ER, endoplasmic reticulum; LDL, low density lipoprotein; rRNA, ribosomal RNA.
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1.6.2

Whole-exome sequencing

WES is a method of NGS capable of sequencing all protein-coding regions of the genome
(approximately 1‒2%). Using a library preparation kit that captures all exonic content of
the genome (known as the exome); WES allows identification of all gene variants, rather
than the select few possible in the scaled-down approach of targeted resequencing. WES
is a feasible and rapid approach to sequencing a large amount of DNA, and a valuable
tool for rare disease research.

1.6.2.1

Whole-exome sequencing successes

WES has had momentous success as a tool for rare disease variant discovery. Although it
only targets a significantly small proportion of the human genome, it stands as the
method-of-choice for rare disease research because 85% of disease causing mutations
found-to-date have been harboured in exons103. Further, the use of WES has had much
success in identifying the genetic basis of rare diseases, with the identification of
causative genes for both Schinzel-Giedion syndrome and Miller syndrome as notable
examples of the first cases of WES success104,105. In sum, the genetic basis of >200
disorders have been identified using WES, making the success and efficiency of WES
preferred over WGS100,106. Moreover, due to the declining cost of WES, the high
diagnostic yield, and the general acceptance of WES in the health marketplace, it has
become the preferred diagnostic method for rare disease patients on the diagnostic
odyssey who have not been genetically explained using standard genetic techniques107.

1.6.3

Whole-genome sequencing

The third and most comprehensive form of NGS is WGS, a method reporting almost
every nucleotide (~85%) in the human genome. As WGS targets most nucleotides, it is
capable of determining variations in any part of the genome, including regulatory regions.
These variations detected through WGS have significant implications on an individual’s
phenotype, ranging from protective against disease, to causative of disease, to neutral or
benign. In recent years, WGS has become a widely used tool in cancer research and the
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analysis of somatically acquired variants in tumour tissues108. Despite the utility of WGS,
there are many caveats to the widespread implementation of WGS. For example, factors
including misdiagnosis, risk of incidental findings, and the gap in literature on nonexonic regions are all major considerations108. Because of these drawbacks, WES remains
the preferred sequencing method for rare disease research.

1.7

Thesis project outline

With a staggering number of rare diseases without a genetic explanation, there is a
substantial need to investigate these rare disorders and end the diagnostic odyssey for
these individuals and their families. In the Blackburn Cardiovascular Genetics
Laboratory, we have been referred patients with a variety of rare diseases including
lipodystrophy, extreme-early onset obesity, brachydactyly, cerebral atrophy, and those
through the FORGE Canada and CARE4RARE Projects. Generally, when familial
recurrence of a rare phenotype is present, the likelihood that the disease is monogenic is
high. Further, extreme severity of a disease with high penetrance also suggests the
possibility of a single gene explanation. Therefore, it is predicted that these rare diseases
are attributed to novel, single gene, genetic variations. Through NGS methods such as
LipidSeq™ and WES, I seek to identify the molecular basis of each rare disorder.

1.7.1

Project overview

Overall, we enrolled 153 patients with lipodystrophy, 5 patients with extreme early-onset
obesity, one family with brachydactyly, one family with cerebral atrophy, and 11 families
associated with FORGE Canada or CARE4RARE. To start, I began by using the
LipidSeq™ targeted gene panel for the lipodystrophy cohort, and Sanger sequencing for
all other rare disease samples to determine if known genes could explain these disorders.
In the cases where no mutations were found from Sanger sequencing or LipidSeq™, I
sought to determine the genetic basis of these unexplained diseases using WES and
subsequent bioinformatics analysis. In the event that candidate variants were identified, I
performed variant validation and co-segregation analysis. Further, when possible, I used
NGS data to identify novel CNVs.
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1.7.2

Project hypothesis

Given the evidence of a genetic basis for lipodystrophy, extreme early-onset obesity,
brachydactyly, autosomal recessive cerebral atrophy, and past CARE4RARE/ FORGE
Canada cases, I hypothesize that these aforementioned diseases are caused by rare genetic
variants with functional relevance, following monogenic inheritance. Furthermore, I
hypothesize that these variants will co-segregate with disease status in families, and be
absent from unaffected family members and control populations.

1.7.3

Project goal and aims

Using LipidSeq™ and WES, the overall goal was to utilize these NGS technologies to
identify a molecular basis for each patient/family disease of interest. In order to do this,
my aims were as follows:
1) To use NGS methods and bioinformatics processing, namely LipidSeq™ and
WES, to detect genetic variants or CNVs.
2) To identify rare or uncommon variants that are likely causative or associated with
the disease phenotype of interest.
3) To determine the functional relevance of these genetic variants using in silico
tools and literature reviews.
4) To perform variant validation studies to resolve whether these newly discovered
variants are co-segregating with the disease phenotype in the family or an
unaffected control population.
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Chapter 2 – Materials and Methods
2

Overview

The following section provides an overview of all the Materials used and Methods
performed in this study (Figure 2). Although the study relied on several external factors,
including clinical diagnoses, the processing of the LipidSeq™ targeted gene panel and
WES; I was involved in patient selection and developing eligibility criteria, and
responsible for all sample preparation, bioinformatics processing and data analysis,
variant validation and co-segregation analysis. Most importantly, I was responsible for all
variant prioritization, consisting of literature review and analysis of hundreds-tothousands of variants per case. Furthermore, I was responsible for performing all
analytics, reporting of the data, and manuscript preparation. For the CARE4RARE and
FORGE Canada cases, I was significantly involved in the microcephaly-ichthyosis and
widow’s peak cases (responsible for patient selection, bioinformatics processing and
analysis, variant validation, and co-segregation analysis). For the remaining
CARE4RARE and FORGE Canada cases, I was responsible for managing each case,
organizing and chairing meetings with CARE4RARE/FORGE Canada collaborators,
mentoring each student involved, and re-analyzing and confirming all results identified
by students in these cases.

2.1

Ethics approval

Ethics approval was obtained for all projects in accordance with the Ethics Review Board
at Western University (Certificate Number 07920E) in London, Ontario, Canada
(Appendix I). For each study, informed consent and ethical approval was obtained from
each participant, or in the event of a pediatric case, from a parent or guardian (the consent
form can be found in Appendix II).
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Figure 2. Flowchart of steps taken in order to identify the genetic bases of rare disorders. All steps shaded in blue represent steps
where I was involved.
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2.2

Study subjects

All study participants were recruited from Dr. Hegele’s Endocrinology Clinic (London
Health Sciences Centre, University Hospital, London, ON, Canada), the Blackburn
Cardiovascular Genetics Laboratory (Robarts Research Institute, London, ON, Canada),
the Medical Genetics Program of Southwestern Ontario (London Health Sciences Centre,
Victoria Hospital, London, ON, Canada), and the Children’s Hospital of Western Ontario
(London Health Sciences Centre, Victoria Hospital, London, ON, Canada). For the
CARE4RARE and FORGE Canada projects, patients were recruited from areas
throughout Canada.

2.2.1

Clinical information

For each study subject, clinical information was provided from Dr. Hegele or the
referring physician. For some CARE4RARE and FORGE Canada cases, clinical features
were obtained from the CARE4RARE and FORGE Canada Consortiums. In the event
that detailed clinical information was unavailable, the most common features and comorbidities of the diagnosed disease were assumed present.

2.3

DNA extraction and quality control

DNA was isolated from whole blood (3 mL) using the Puregene® Blood Extraction Kit
(Cat. No. 158389, Gentra Systems, Qiagen Inc., Mississauga, ON, Canada). Both the
quality and quantity of the DNA sample were measured using the NanoDrop 1000
spectrophotometer with target ratios of 260:280 and 260:230 of approximately 1.8
meeting the threshold for the study. DNA was purified and diluted to 5 ng/μL for both
targeted and WES.

2.4

SNP genotyping and autozygosity mapping

For certain CARE4RARE and FORGE cases, namely CARE4RARE 907 (Heterotaxy)
and FORGE 11 (Osteopetrosis), 122 (Dystonia, ataxia and intellectual disability) and 352
(Microcephaly-ichthyosis), genomic DNA (gDNA) was extracted and genotyped for
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SNPs using the Affymetrix® Genome-Wide Human SNP Array 6.0 (Santa Clara,
California, United States). With the data as input, GeneSpring GT v2.0 (Agilent
Technologies, Santa Clara, California, United States) software was used to identify areas
of homozygosity that were identical-by-descent within family members. The SNP allele
frequencies of healthy individuals were used to calculate a logarithm of the odds (LOD)
score for each SNP. Homozygous regions in affected individuals with high LOD scores
were prioritized when identifying candidate variants.

2.5

Next-generation sequencing

Two methods of NGS were used for the study. One technique used was targeted
sequencing, namely LipidSeq™, and the second was WES, discussed in Sections 2.5.1
and 2.5.2, respectively.

2.5.1

Patient selection for LipidSeq™

One-hundred-and-fifty-three patients referred to the Blackburn Cardiovascular Genetics
Laboratory with a clinical diagnosis of lipodystrophy were included in this portion of the
study. Patients were prioritized based on two criteria: 1) the absence of mutations in
known lipodystrophy-causing genes as previously determined from Sanger sequencing;
and 2) disease severity, where those with severe phenotypic characteristics (i.e. the partial
or complete absence of adipose tissue from the body) and metabolic comorbidities (i.e.
insulin resistance, diabetes, hypertriglyceridemia) were selected.

2.5.1.1

LipidSeq™ targeted sequencing

After dilution and purification to 5 ng/μL, all DNA samples were indexed and pooled
using the Nextera® Rapid Capture Custom Enrichment Kit, namely the “LipidSeq™”
targeted sequencing design. Using LipidSeq™, 73 genes and >180 SNPs associated with
lipid metabolism were sequenced for each sample. More specifically, all coding regions
and a ~150-base pair (bp) pad at intron-exon boundaries were sequenced. Following
indexing and pooling, library preparation was performed with the Nextera® Rapid
Capture Custom Enrichment Kit, and enriched DNA samples were sequenced on an
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Illumina MiSeq personal desktop sequencer (Illumina, San Diego, California, United
States) using 2×150-bp paired-end chemistry in accordance to manufacturer instructions.
DNA samples were sequenced in-house at the London Regional Genomics Centre
(LRGC; http://lrgc.ca/) in London, Ontario with an average of approximately 300× depthof-coverage.
Briefly, the extracted and purified DNA was first tagged with adapters. Reduced cycle
amplification added additional motifs including unique primer binding sites, indices, and
complementary regions to the oligonucleotides on the flow cell. The library was then
quantified and measured using the Agilent® 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, California, United States) prior to being processed on the Illumina MiSeq.
Once on the MiSeq, the DNA was immobilized onto a glass flow cell using the
oligonucleotide complementary adapters. Bridge amplification occurred where all the
strands were clonally amplified. This process occurred in parallel to millions of reactions,
and resulted in cluster generation and amplification of all the fragments. After bridge
amplification, sequencing was performed by way of sequencing-by-synthesis. More
specifically, each nucleotide base possessed a unique fluorescence and competed for
addition to the template strand, and the MiSeq instrument detected the fluorescent light
emitted during synthesis. This resulted in complete sequencing of the DNA in a base-bybase fashion109.

2.5.2

Patient selection for whole-exome sequencing

Twenty patients with lipodystrophy and five children with extreme early-onset obesity
from Dr. Hegele’s Endocrinology Clinic were selected for this portion of the study. These
patients were chosen based on the following criteria: 1) the absence of mutations in
known disease-associated genes as determined from Sanger sequencing or LipidSeq™,
and 2) disease severity, where those with severe characteristics (i.e. complete absence of
adipose tissue or extreme excess of adiposity) and several confounding conditions (i.e.
diabetes, insulin resistance or overgrowth) were prioritized. From the group of
lipodystrophy patients deemed mutation negative from Sanger sequencing or LipidSeq™,
patients of Dr. Hegele’s (rather than referrals from external physicians) were prioritized
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for WES to ensure consistent clinical diagnoses and tests were performed. The parents of
the children with extreme early-onset obesity were also approached for participation in
the study. This resulted in the recruitment of two sets of parents, or two sets of trios
(Mother, Father and proband) to the study.
Families with rare genetic diseases (namely brachydactyly, type A1 and cerebral atrophy)
referred to Dr. Hegele’s clinic or the Blackburn Cardiovascular Genetics Laboratory, and
cases ascertained through the CARE4RARE and FORGE Canada projects were also
selected for this portion of the study. These families were chosen based on similar
criteria: lack of mutations in known disease-associated genes, disease severity, and rarity.

2.5.2.1

Whole-exome sequencing

After DNA extraction, quality control and dilution as described previously in Section 2.3,
the DNA samples were indexed and pooled using the Illumina TruSeq Rapid Capture
Exome Library Prep Kit in preparation for WES. The patient samples were sequenced in
accordance to the WES protocol on the Illumina NextSeq 500 (Illumina, San Diego,
California, United States) benchtop sequencer with 2×100-bp paired-end chemistry in
accordance to the protocol used at the LRGC. Again, sequencing was performed using
the sequencing-by-synthesis method, as described previously in Section 2.5.1.1. The
average depth-of-coverage was approximately 100×.
The lipodystrophy samples, all early-onset obesity samples, the autosomal recessive
cerebral atrophy-like trio, and the brachydactyly proband were sequenced in-house at the
LRGC. For the remaining cases, WES was generously funded by the FORGE Canada and
CARE4RARE Research Programs, and performed at either the Genome Québec
Innovation Centre (http://gqinnovationcenter.com/) in Montreal, Québec or The Centre of
Applied Genomics (http://www.tcag.ca/) in Toronto, Ontario. At both locations, the
samples were run on an Illumina HiSeq 2000 (Illumina, San Diego, California, United
States) sequencer using an Agilent® SureSelect v5 Target Enrichment Kit.

54

2.6

Bioinformatics processing

Following sequencing, both the LipidSeq™ and WES raw data were returned in the form
of patient-specific, paired FASTQ files. FASTQ files contain FASTQ format, a textbased format with nucleotide sequence and corresponding quality scores. The paired
FASTQ files were input into CLC Bio Genomics Workbench v10 (CLC Bio, Aarhus,
Denmark) to align the data to the human reference genome (build Hg19). Sequence
alignment was performed using a custom automated workflow (Figure 2.6).
Succinctly, the workflow began by mapping the reads to the reference genome. From
there, the software performed local realignment, a “proofreading” step that used
alignment information of other nearby reads in order to re-align each given read. A
second “proofreading” step was then executed, where the tool effectively removed bias
by discarding duplicate reads that may have arose from PCR amplification during sample
preparation. Fixed ploidy variant detection was performed, using The Error Model
estimation in order to estimate the probability of having a certain base in a read, but
calling a different base. This tool allowed variants to be called or identified. The software
then performed two steps: 1) filtered based on overlap, or kept the reads overlapping with
the BED file (tab-delimited text file with information on the regions targeted using the
LipidSeq™ or WES kit); and 2) created statistics for target regions, which provided a
summary of the local and overall coverage. After the alignment and variant calling steps,
variant data were exported in the form of a variant calling format or VCF (.vcf) file (a
tab-delimited text file containing the variant information), and coverage statistics were
exported in the form of a BAM file (.bam), a binary version of a SAM file (a tabdelimited text file containing the sequence alignment data).
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Figure 2.6. Next-generation sequencing bioinformatics workflow. Custom workflow
designed in CLC Genomics Workbench v10. For each individual case, the workflow uses
two batched FASTQ files and generates a VCF and BAM file as output. Note that the
“Filter Based on Overlap” step utilizes the BED file for the LipidSeq™ or whole-exome
sequencing kit.
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2.7

Variant annotation

After variant calling, the VCF files were utilized as input for variant annotation. For the
LipidSeq™ data, ANNOVAR (http://annovar.openbioinformatics.org/), a software tool
that functionally annotates genetic variants, was used to annotate the variants within the
VCF files using a customized script. For the WES data, the Golden Helix VarSeq®
software (Golden Helix Inc., Bozeman, Massachusetts, United States), a variant
annotation and filtration software, was used to fully annotate the variants. ANNOVAR
and VarSeq® both annotated each variant with predictions from in silico tools including:
Polymorphism Phenotyping, v2 (PolyPhen-2; http://genetics.bwh.harvard.edu/pph2/)110,
Sorting Intolerant From Tolerant (SIFT) predictor (http://sift.jcvi.org/)111, MutationTaster
(http://www.mutationtaster.org/)112, and Combined Annotation Dependent Depletion
(CADD; http://cadd.gs.washington.edu/score)113. For splicing mutations, concordance
with in silico pathogenic predictions from the Human Splicing Finder
(http://www.umd.be/HSF3/HSF.shtml)114 and the Splicing Based Analysis of Variants
(SPANR; http://tools.genes.toronto.edu/)115 databases were used. For each variant, the
minor allelic frequency (MAF) was also extracted from the following databases: 1000
Genomes (http://www.internationalgenome.org/1000-genomes-browsers/)116, Exome
Sequencing Project (http://evs.gs.washington.edu/EVS/), Exome Aggregation
Consortium (ExAC) browser (http://exac.broadinstitute.org/)117, and Genome
Aggregation Database (gnomAD) (http://gnomad.broadinstitute.org/)117. Annotated
variants harboured within genes associated with the disease of interest were prioritized.

2.8

Variant prioritization

Once annotated, variants were prioritized based on several criteria for causality. These
stringent criteria were used to ensure the candidate variants identified for each case had a
high likelihood of being disease-causing (Table 2.8). Note that given the complexities of,
and differences between each case, some variant prioritization criteria varied between
patient sample or family (i.e. autosomal dominant versus recessive mode of inheritance,
minor allele frequency [MAF] of >1% versus 0%, etc.), and these criteria were
customized for each case.
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Table 2.8. Criteria used to prioritize candidate variants and infer them as disease
causing.
Criteria considered to predict a variant as disease-causing:
I.

II.
III.
IV.
*

The variant is predicted to be pathogenic by the following analyses:
A. Multiple in silico prediction tools agree that the variant has a high likelihood of being
disease-causing
B. Gene function, expression, and pathway analyses are in line or associated with the phenotype
of interest
Using the following databases, but not limited to: GeneCards (http://www.genecards.org/)118,
OMIM (https://www.omim.org/), NCBI Gene (https://www.ncbi.nlm.nih.gov/gene), UniProt
(http://www.uniprot.org/)119, Reactome Pathway Database (http://reactome.org/)120, Human
Protein Atlas (http://www.proteinatlas.org/)121, KEGG (http://www.genome.jp/kegg/)122
C. Disease databases show a relation between the gene or variant and the disorder of interest
Using the following databases, but not limited to: HGMD
(http://www.hgmd.cf.ac.uk/ac/all.php)123, NCBI ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/), Orphanet (http://www.orpha.net/consor/cgibin/index.php)124, DECIPHER (https://decipher.sanger.ac.uk/)125
D. Literature searches and guidelines suggest the variant has a high likelihood of being diseasecausing
Using PubMed, Web of Science, and the ACMG standards and guidelines 126
Genotype analysis shows the mutation is rare (at least <1%) or absent from a large population*
The mutation co-segregates in the family in accordance with the predetermined mode of inheritance,
and can be validated through an independent method
Functional assessment – including ex vivo, in vitro and in vivo bench studies – show the mutant gene
product is dysfunctional

Note that the control databases (1000 Genomes, ExAC, ESP, gnomAD) were first checked to ensure their control cohorts did not include the
phenotype of interest. In the event that the phenotype of interest was part of the control cohort in the database, the frequency was used with
caution.
The database abbreviations are as follows: OMIM, Online Mendelian Inheritance in Man; KEGG, Kyoto Encyclopaedia of Genes and
Genomes; HGMD, Human Gene Mutation Database; ACMG, The American College of Medical Genetics and Genomics.
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2.8.1

Zygosity

Given the predicted mode of inheritance of the disease from the family history, zygosity
was used to prioritize specific variants. More specifically, if the disease was expected to
follow an autosomal dominant mode of inheritance, heterozygous variants were
prioritized; if the disease was expected to follow an autosomal recessive mode of
inheritance, either homozygous variants or compound heterozygous variants were
prioritized. In the event that there was no family history available, the predicted zygosity
of the disease of interest was used (i.e. all known cases of congenital general
lipodystrophy are associated with an autosomal recessive inheritance pattern, therefore
homozygous variants were prioritized).

2.8.2

Read depth

The read depth represents the number of unique reads that include a given nucleotide in a
sequence. In order to discard sequencing artifacts or Mendelian errors, variants are
prioritized based on read depth. A read depth criterion of 30 was used for quality
control. Note that the read depth is indicated as a quality control measurement and this
step is capable of removing ~95% of Mendelian errors127.

2.8.3

Sequence ontology

Sequence ontology refers to the structured vocabulary used for genomic annotation. More
specifically, it offers a common, universal set of terms and definitions for genomic data.
In this project, the sequence ontology terms – disruptive inframe insertion/deletion,
frameshift variant, inframe insertion/deletion, initiator codon variant, missense variant,
splice acceptor/donor/region variant, stop gain/loss/retained variant – were prioritized.
These non-synonymous and splicing variants were prioritized as they are more likely to
be pathogenic, destabilize the protein structure, and result in dysfunctional interactions
between interacting molecules128-131.

59

2.8.4

Minor allele frequency

Minor allele frequency refers to the frequency at which the second most prevalent allele
occurs in a population. In this case, the MAFs were extracted from 1000 Genomes,
Exome Sequencing Project, ExAC and gnomAD, as mentioned in Section 2.7. A MAF of
0.01 was used for all rare diseases with an autosomal recessive mode of inheritance, and
a MAF of zero was used for rare diseases with a suspected autosomal dominant mode of
inheritance.

2.8.5

In silico analyses

As specified in Section 2.7, in silico tools were used to predict the biological effect or
functional relevance of the variants on protein function. Variants were prioritized if the
tools predicted that the variant has a high-likelihood of being disease causing.

2.8.6

Gene and protein analysis and literature review

To narrow down the list of candidate variants, analysis into gene function, expression and
pathway were performed, and disease databases were analyzed to determine a
relationship between the variant and disease of interest. A comprehensive literature
review was performed for each variant, and the American College of Medical Genetics
(ACMG) standards and guidelines were implemented and considered. See Table 2.8 for
more details on the prioritization method.

2.8.7

Association with the disease phenotype

In the event that a variant was identified in a known gene previously associated with the
disorder, that variant was prioritized if it satisfied all aforementioned criteria. With regard
to the LipidSeq™ data, the lipodystrophy-associated genes were selectively analyzed for
potentially causative variants.

60

2.9

Copy-number variation detection

All patients processed using LipidSeq™ or with WES performed in-house were subject
to CNV detection. The CNV Caller tool, an application within the VarSeq® software,
was used to call CNVs with sequencing depth-of-coverage data from the previously
generated BAM file. The VCF file and BED file (tab-delimited text file with information
on the targeted chromosomal regions) for either LipidSeq™ or WES were also input to
VarSeq®, as the program uses a set of matched control samples prepared using the same
library-preparation chemistry or sequencing method (i.e. LipidSeq™ or WES kit). The
CNV Caller tool is capable of identifying four CNV states: 1) wild-type diploid state; 2)
heterozygous deletion; 3) homozygous deletion; and 4) duplication.
In short, the CNV calling algorithm relied on the coverage information computed from
the BAM files. The algorithm inspected for a change in coverage compared to a set of
reference samples as evidence of a CNV event. More specifically, the program selected
the top 30 reference samples with the least percent-difference (<20%) in coverage data
compared to the sample of interest. These reference samples were used to identify
differences in coverage, and correct for GC-content bias and regions that were
unamenable to mapping. Using the reference samples, the algorithm computed two
evidence metrics: Z-score and ratio threshold value. The Z-score is a measurement
referring to the number of standard deviations from the reference sample mean, whereas
the ratio refers to the normalized mean for the sample divided by the average normalized
mean of all the reference samples. Using these two metrics, the algorithm was able to
assign a CNV state (deletion or duplication) to each target region. In addition to these
metrics, a third metric, the Variant Allele Frequency (VAF), was calculated to be used as
evidence for a CNV. Any VAF value other than zero or one were evidence against
deletions, whereas VAF values of 1/3 and 2/3 represented supporting evidence for
duplications.
In addition to evidence metrics, quality control flagging was also performed by the
software. These flags indicated whether a CNV event was unreliable, specifically if there
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was a low reference sample read depth or high variation between reference samples in the
region of interest. These flags were used to filter out unlikely CNV events.

2.9.1

Copy-number variation prioritization

After CNV calling in VarSeq®, CNV events were prioritized based on both ratiothreshold value (≤0.7 for heterozygous deletions, ≥1.3 for duplications) and Z-score (≤3.0 for heterozygous deletions, ≥3.0 for duplications). The VAF value was considered as
secondary validation of evidence. In the event that a CNV event was flagged with a
quality control flag, the CNV was no longer considered a candidate CNV associated with
the disease of interest.

2.10

Variant validation and co-segregation analysis

In the event that candidate variants were identified, validation and co-segregation
analyses were performed using an independent method (i.e. Sanger sequencing or
microarray analysis).

2.10.1

PCR

Genomic DNA was ascertained from the proband and all other family members (if
available) and amplified using polymerase chain reaction (PCR) and a custom set of
primers (see Appendix III for primer sequences). Unique primers were designed for each
variant of interest.

2.10.2

PCR imaging and purification

After PCR, the PCR products were loaded onto a 1.5% agarose gel with RedSafe™
Nucleic Acid Staining Solution (iNtRON Biotechnology Inc., Gyeonggi Province, South
Korea) and run with a 100-bp DNA Ladder (ThermoFisher Scientific, Waltham,
Massachusetts, United States). The gel was run for 45 minutes at 145 volts using a Gibco
BRL Horizontal 11-4 Gel Electrophoresis Apparatus (Life Technologies, Carlsbad,
California, United States). The gel was subsequently imaged using the Azure Biosystems
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c150 Gel Documentation Platform (ThermoFisher Scientific, Waltham, Massachusetts,
United States). If the PCR products were of expected size when compared to the ladder
fragment size, the PCR products were purified using calf intestinal alkaline phosphatase
(CIAP) and exonuclease I (ThermoFisher Scientific, Waltham, Massachusetts, United
States).

2.10.3

Sanger sequencing and analysis

After PCR, the cleaned and purified DNA product was sent for Sanger sequencing at the
LRGC using an Applied Biosystems (ABI) 3730 Automated DNA Sequencer (Applied
Biosystems, Foster City, California, United States). Electropherograms were generated
and analyzed using the ABI SeqScape® Software v2.6 (Life Technologies, Carlsbad,
California, United States) where it was aligned to the corresponding reference gene
sequence from the National Centre for Biotechnology Information (NCBI) GenBank. If
the variants were present in other clinically affected individuals in the family (when
available) following the same mode of inheritance, they were considered to co-segregate
with disease status in the family. In the event that the variant was absent from affected
family members, the candidate variant was deemed not causative of the disease of
interest.

2.11

Validation of copy-number variation events

For the validation of candidate CNVs, either Sanger sequencing as described or the
CytoScan™ HD Array Kit and Reagent Kit Bundle (ThermoFisher Scientific, Waltham,
Massachusetts, United States) were used. Briefly, the CytoScan™ HD Solution provides
the broadest coverage for detecting human chromosomal aberrations; the CytoScan™ HD
Array can reliably detect over 750,000 SNPs and 2.6 million copy-number probes (with
25-50 kilo-base copy-number changes). Due to the high SNP coverage, the CytoScan™
HD Array allows a user to accurately estimate breakpoint locations, a necessary feat in
validating CNV events. The CytoScan™ HD Array was performed according to
manufacturer’s instructions at Victoria Hospital in London, Ontario (London Health
Sciences Centre, Victoria Hospital, London, ON, Canada). Following sequencing, the

63

data were analyzed using the Chromosome Analysis Suite (ChAS) v3.2 (ThermoFisher
Scientific, Waltham, Massachusetts, United States). The regions lying between probes
differing in copy-number state were used to predict the approximate size of the copynumber variant and were predicted to harbour the breakpoint of the candidate CNV.

2.12

Gene enrichment analysis

For patients with lipodystrophy or extreme early-onset obesity in which no candidate
variant or multiple candidate variants were identified, PANTHER (protein annotation
through evolutionary relationship) classification system (http://www.pantherdb.org/) was
used to determine if any protein families (and their genes) were under-or-overrepresented
using Fisher’s Exact Test in comparison to a reference database132. Put simply,
PANTHER was used to determine whether certain genes or pathways were affected
more-or-less often than expected by chance. For the cases in which PANTHER was run,
the candidate variant list used as input was the list of variants remaining after filtering
based on zygosity, ontology, and minor allele frequency. Note that proteins were
classified according to family and subfamily, molecular function, biological process, and
pathway.

2.13

Statistical analysis: Brachydactyly case

Statistical analysis and comparison of the anthropometric data between IHH mutation
positive and IHH mutation negative individuals in the brachydactyly case was done using
the Wilcoxon-Mann-Whitney test on SAS v.9.4 (SAS Institute, Cary, North Carolina,
United States). The Wilcoxon-Mann-Whitney test is used when sample size is small, and
data are not normally distributed133. For statistical analysis in the brachydactyly case,
eighteen family members were assessed. Fourteen of these 18 family members were
clinically affected, and four were clinically unaffected.

2.14

Box plot generation: Brachydactyly case

Box plots for the brachydactyly case were generated using R: The R Project for Statistical
Computing software and the ggPlot2 package134.
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Chapter 3 – Results
3

Overview

One-hundred-and-fifty-three patients with lipodystrophy, five children with extreme
early-onset obesity, one family with a history of brachydactyly, one family with a history
of cerebral atrophy, and 11 families with several rare diseases (as ascertained from
FORGE Canada and CARE4RARE) participated in this study. Here, I discuss all the
results and outcomes of NGS.

3.1

Study subjects and clinical features

For all cases studied – namely the lipodystrophy, early-onset obesity, brachydactyly,
cerebral atrophy, CARE4RARE and FORGE Canada projects – patient files, clinical
notes, and/or hospital records were thoroughly reviewed to develop accurate clinical
descriptions and select appropriate patients for sequencing. All cases were chosen based
on disease severity. In the event that limited information about the phenotype was
available, the phenotype described in the OMIM database was used.

3.2

LipidSeq™ variant detection

After sequencing using the LipidSeq™ targeted gene panel, the data for all 153 patients
with lipodystrophy were analyzed for potential disease-causing variants. These variants
were prioritized based on zygosity, read depth, sequence ontology and minor allele
frequency as discussed in Chapter 2, Section 2.8. Of the 153 total patients, 81 variants
were identified within 14 lipodystrophy-associated genes: LMNA, PPARG, PLIN1,
CIDEC, LIPE, LPIN1, AGPAT2, BSCL2, CAV1, AKT2, PTRF, DYRK1B, POLD1 and
WRN (Figure 3.2). These variants explain the clinical phenotype or secondary
complications of 58 patients (38% of the patient cohort) processed using the LipidSeq™
gene panel, as all genes are either associated with lipodystrophy or with common features
often implicated in lipodystrophy (i.e. high triglycerides, high cholesterol). The 95
patients classified as mutation negative after LipidSeq™ became candidates for the WES
portion of the study.
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Figure 3.2. Variant breakdown for patients with lipodystrophy sequenced using the
LipidSeq™ targeted gene panel. The DNA samples of Dr. Hegele’s patients with
lipodystrophy were ascertained and sequenced using LipidSeq™. Fifty-eight mutationpositive patients were classified according to lipodystrophy-causing gene. Each region in
the graph represents the gene implicated, and the number of patients with a variant in the
gene. Note that some patients harboured multiple variants in more than one gene, which
likely contributed to their phenotype.
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3.3

Sanger sequencing of TMPRSS4

For the proband featuring a cerebral atrophy-like phenotype, Sanger sequencing of the
expected TMPRSS4 variant region using a custom set of primers (see Appendix III) was
performed to determine whether the case shared the same molecular etiology as the
previous case in the Blackburn Cardiovascular Genetics Laboratory (as described in
Chapter 1, Section 1.5.4). From Sanger sequencing, no variants were identified in the
TMPRSS4 region of interest designating the proband eligible for the WES part of the
study.

3.4

Whole-exome sequencing

Twenty patients with lipodystrophy, five children with extreme early-onset obesity, one
proband with brachydactyly, one proband with a cerebral atrophy-like phenotype, and 11
CARE4RARE and FORGE Canada cases were selected for the whole-exome portion of
the study. To start, patient data were collected in order to fully understand the patient
phenotype. The clinical features of the lipodystrophy and extreme early-onset obesity
cases are described in Table 3.4A and Table 3.4B, respectively. The clinical description
of the brachydactyly, cerebral atrophy-like, CARE4RARE and FORGE Canada cases are
listed in Chapter 1 (Sections 1.5.3.1.8, 1.5.4.1 and Table 1.2.5.3, sequentially). After
WES, bioinformatics processing and in silico analyses were performed on the WES data
to identify potential disease-causing variants. Variants were prioritized if they satisfied
criteria I-III in Table 2.8 (Chapter 2).
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Table 3.4A. Features of all patients with lipodystrophy in which whole-exome
sequencing was performedA.
Patient IDB

Biological SexC

Classification

Additional Clinical Features (if present)

1804

Female

Total lipodystrophy

T2D, insulin resistance, hyperlipidemia, exercise
intolerance

8615

Female

Total lipodystrophy

T2D, iron-deficient anemia, diabetic neuropathy,
history of bronchitis, class 3 obesity, CAD

1088

Female

FPLD

N/A

3458

Female

FPLD

Hypothyroidism, diabetes

3969

Female

FPLD

Peripheral neuropathy (motor/axonal), Charcot
Marie Tooth, T2D, constant migraines, NASH

4116

Female

FPLD

Hypertension, T2D, chronic renal failure,
hypothyroidism

4665

Female

FPLD

Neuropathy, T2D, Behçet syndrome, pyoderma
gangrenosum, hidradenitis

5662

Female

FPLD

N/A

2025

Female

FPLD

Profound insulin resistance, decreased creatinine
levels, proteinuria, dermatomyositis

3011

Female

FPLD

Insulin resistance, dyslipidemia, hirsutism, high
triglycerides

11618

Female

FPLD

Hypertension, T2D, hypercholesterolemia,
obesity

14318

Female

FPLD

Severe insulin resistance

794

Female

FPLD

Hepatosplenomegaly, cirrhosis and NASH, high
triglycerides, high cholesterol, insulin-requiring
T2D, liver failure

14106

Female

FPLD

N/A

1120

Male

FPLD

N/A

4162

Female

Acquired lipodystrophy

Hypercholesterolemia, lower motor neuron
weakness, hair loss, osteoarthritis

4164

Female

Acquired lipodystrophy

Insulin-requiring T2D

4194

Female

Acquired lipodystrophy

T2D, diabetic neuropathy, osteoarthritis

4226

Female

Acquired lipodystrophy

N/A

12395

Female

PCOS/FPLD

T2D, neuropathy, hypertension

The abbreviations are as follows: ID, identification; N/A, not applicable; T2D, Diabetes mellitus, Type 2; CAD, coronary artery disease; FPLD, familial partial
lipodystrophy; NASH, non-alcoholic steatohepatitis; PCOS, polycystic ovary syndrome.
A
Patients were selected based on their diagnosis with a rare metabolic disorder, poor lipid profile, and lack of mutations in known disease-related genes (as
determined through Sanger sequencing). Patients of Dr. Hegele’s (London Health Sciences Centre) were prioritized to ensure consistent diagnosis, high sample
quality, and detailed, accurate patient information. After whole-exome sequencing, the data were run through CLC Bio Genome Workbench v10 and annotated using
the curation and annotation program, Golden Helix VarSeq®.
B
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
C
Referring to the biological sex assigned at birth.
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Table 3.4B. Features of all patients with extreme early-onset obesity in which wholeexome sequencing was performedA.
Patient IDB

Biological SexC

Classification

Additional Clinical Features (if present)

12340

Male

Early-onset obesity

Insulin resistance, hyperphagia

15544

Male

Early-onset obesity

15858D

Female

Early-onset obesity

Autism spectrum disorder and developmental
delay, overgrowth
Hyperphagia, overgrowth, intellectual disability

12424

Male

Early-onset obesity

N/A

14504D

Female

Early-onset obesity

N/A

The abbreviations are as follows: ID, identification; N/A, not applicable.
A
Patients were selected based on their diagnosis with a rare metabolic disorder, poor lipid profile, and lack of mutations in known disease-related genes (as
determined through Sanger sequencing). After whole-exome sequencing, the data was run through CLC Bio Genome Workbench v10 and annotated using the
curation and annotation program, Golden Helix VarSeq®.
B
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
C
Referring to the biological sex assigned at birth.
D
Trio sequencing and analysis was performed with this patient and their unrelated parents.
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3.4.1

Lipodystrophy

From WES and bioinformatics analysis, over one-million variants were identified among
the 20 patients with lipodystrophy. After variant prioritization, candidate variants were
identified for 13 of the 20 patients with lipodystrophy within the following genes: ISCU,
HSPG2, LDLR, PDRM16, ZMPSTE24, FLNC, GALC, ABCA4, WRN, ABCG8, FHL1,
ANLN, LPL, FN1, PAPSS2, NEUROD1, BSCL2, APOB, PCSK9, and PYGM (Table
3.4.1). These variants partially explain the lipodystrophy phenotype or associated
comorbidities displayed by these patients.

3.4.2

Extreme early-onset obesity

After WES, data processing and bioinformatics analysis, over 100,000 variants were
called in the exomes of five children with extreme early-onset obesity. After variant
prioritization, candidate variants were identified in two of the probands (Table 3.4.2).
These variants are predicted to explain the extreme early-onset obesity phenotype or the
associated conditions (i.e. intellectual disability) described in these patients.
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Table 3.4.1. Candidate variants identified in patients with lipodystrophy using
whole-exome sequencingA.
Patient
IDB
1804
(CGL)
8615
(CGL)
1088
(FPLD)
3458
(FPLD)
3969
(FPLD)
4116
(FPLD)

4665
(FPLD)

Gene

Chromosome:
Position

DNA change

Amino acid
change

Zygosity/Effect

Frequency

ISCU

12:108956417

c.19_20delinsGG

p.Phe7Gly

Homo/Missense

0

HSPG2

1:22200454

c.3707C>A

p.Ala1236Glu

Homo/Missense

1×10-3

LDLR

19:11221435

c.1048C>T

p.Arg350Ter

Het/Nonsense

8×10-6

PRDM16

1:3329229

c.2468G>C

p.Arg823Pro

Het/Missense

7×10-4

ZMPSTE24

1:40756665

c.1199A>G

p.Asn400Ser

Het/Missense

0

FLNC

7:128494727

c.6988G>A

p.Gly2330Ser

Het/Missense

7×10-4

GALC
LDLR

14:88452941
19:11233961

c.334A>G
c.2252G>A

p.Thr112Ala
p.Arg751Gln

Het/Missense
Het/Missense

2×10-3
8×10-5

19:11233940

p.Arg744Gln

Het/Missense

0

1:94528818

c.2231_2232delins
AG
c.1610G>A

p.Arg537His

Het/Missense

1×10-3

ABCG8

1:94510250
8:30998961
8:30938692
2:44101538

c.2969G>A
c.2983G>A
c.1149G>T
c.1412-8delinsTT

p.Gly990Glu
p.Ala995Thr
p.Leu383Phe
N/A

Het/Missense
Het/Missense
Het/Missense
Homo/Splicing

0
7×10-4
4×10-4
0

FHL1

X:135288637

c.46G>T

p.Gly16Trp

Het/Missense

0

ANLN
LPL

7:36450231
8:19811864

c.1205C>T
c.775G>A

p.Pro402Leu
p.Asp259Asn

Het/Missense
Het/Missense

0
0

PAPSS2
NEUROD1

10:89501019
2:182543418

c.1114G>T
c.170G>A

p.Val372Phe
p.Gly57Glu

Het/Missense
Het/Missense

8×10-6
0

BSCL2
APOB

11:62457948
2:21232803

p.Leu427Pro
p.Ile2313Val

Het/Missense
Homo/Missense

2×10-3
0

PCSK9
PYGM
WRN

1:55505647
11:64527223
8:30921838

c.1280T>C
c.6936_6937delins
TG
c.137G>T
c.148C>T
c.243T>G

p.Arg46Leu
p.Arg50Ter
p.Phe81Leu

Het/Missense
Het/Nonsense
Het/Missense

8×10-3
1×10-4
0

ABCA4

WRN
5662
(FPLD)
2025
(FPLD)
3011
(FPLD)
14318
(FPLD)

4194
(ALD)

Abbreviations are as follows: CGL, congenital generalized lipodystrophy; FPLD, familial partial lipodystrophy; ALD, acquired lipodystrophy; Het, heterozygous;
Homo, homozygous.
A
The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype,
and support from numerous papers in the literature. frequency listed for each candidate variant is the frequency from gnomAD, also confirmed from the databases:
1000 Genomes, Exome Aggregation Consortium, and the Exome Sequencing Project.
B
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
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Table 3.4.2. Candidate variants identified in patients with extreme early-onset
obesity using whole-exome sequencingA.
Patient IDB

Gene

Chromosome:
Position

DNA change

Amino acid
change

Zygosity/Effect

Frequency

15544

BLK

8:11405609

c.244G>C

p.Gly82Arg

Het/Missense

1×10-5

MC4R

18:58038832

c.751A>C

p.Ile251Leu

Het/Missense

6×10-3

BBS10

c.424G>A

p.Asp142Asn

Het/Missense

0

SETD8

c.995T>C

p.Leu332Pro

Het/Missense

0

c.713G>C

p.Arg238Pro

Het/Missense

0

c.2645T>C

p.Ile882Thr

Het/Missense

0

15858

KMT2C

Abbreviations are as follows: Het, heterozygous; Homo, homozygous; Hemi, hemizygous.
A
The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype,
and support from numerous papers in the literature. frequency listed for each candidate variant is the frequency from gnomAD, also confirmed from the databases:
1000 Genomes, Exome Aggregation Consortium, and the Exome Sequencing Project.
B
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
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3.4.3

BrachydactylyA

From WES and bioinformatics processing of the DNA sample from the proband, over
37,000 variants were identified in the proband’s exome. After a non-synonymous rare
variant prioritization approach and literature review, I was left with one candidate variant
correlating with the brachydactyly phenotype. This variant, a heterozygous disruptive
inframe insertion (c.285_287dupGAA, p.Glu95_Asn96insLys), was detected in the
Indian hedgehog gene (IHH). This IHH variant is predicted to exert a damaging effect on
protein function from multiple in silico prediction tools, is considered novel in multiple
control population databases, and has not been previously reported in the literature.
Dominant variants in the IHH gene are associated with brachydactyly type A1,
correlating with the phenotype and inheritance pattern seen in this family83.

3.4.4

Cerebral atrophy-like

Due to the absence of the expected variant in TMPRSS4, WES and bioinformatics
analysis was performed on the DNA of the proband featuring a cerebral atrophy-like
phenotype and his parents in order to perform trio analysis and identify causative genetic
factors. From this analysis, one homozygous candidate variant (from 52,958 total
variants) in the Kinetochore Scaffold 1 or CASC5 gene was identified (c.6485A>G,
p.Glu2162Gly), associated with primary microcephaly-4. This gene variant is predicted
to cause a pathogenic effect on protein function from in silico tools and is present at a
minor allele frequency of 6×10-6 in control population databases. Note that the frequency
in the normal population is associated with heterozygotes.

AA

version of this section has been submitted for publication83.
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3.4.5

CARE for RARE and FORGE Canada

From WES and bioinformatics processing on the exomes of the affected probands,
candidate variants were identified in eight of the 11 CARE4RARE or FORGE Canada
cases, namely microcephaly-ichthyosis, autosomal dominant isolated cryptophthalmos,
widow’s peak syndrome, amyoplasia, metaphyseal chondrodysplasia, craniosynostosis,
heterotaxy disorder, and craniorachischisis (Table 3.4.5).
Here, I focus on the microcephaly-ichthyosis and widow’s peak cases. With the
microcephaly-ichthyosis case, the DNA from two affected infants were subject to WES.
From WES and data processing, a total of 121,280 variants were identified in both
exomes. After prioritization, this was narrowed down to one candidate variant in the
vacuolar protein sorting-52 gene (VPS52; c.57delG, p.Thr20fs). The VPS52 gene is
associated with pluripotent differentiation for ectodermal cell interactions. Further,
mutations in the VPS52 complex are associated with microcephaly, a clinical feature of
the affected probands.
For the widow’s peak case, two affected individuals had their DNA extracted and WES
performed. From WES and bioinformatics analysis, a total of 1,873,928 variants were
identified in the two exomes. After prioritizing based on variants on the X chromosome
(due to the predicted X-linked dominant inheritance), frequency, read depth and sequence
ontology, one candidate variant in the lysine-specific demethylase 6a gene (KDM6A)
(c.2703-6_2703-5delTT) remained. Variation in the KDM6A gene is associated with
Kabuki Syndrome-2, matching the phenotype of the proband.

74

Table 3.4.5. Status of all CARE for RARE and FORGE Canada cases.
Case

Status

FORGE 214, Angelman-like syndrome




Nothing significant found with the functional studies
Input into MatchMaker Exchange

FORGE 122, Dystonia, ataxia and
intellectual disability*



Compound heterozygous variants previously found in the NudC
Domain Containing 2 (NUDCD2)
Variants Sanger sequenced again, and are found to not cosegregate in the family
Rainfall plots generated to determine mutational burden; gene
enrichment analysis performed



FORGE 11, Osteopetrosis




Exome analysis phase – looking for candidate variants
Waiting for DNA on an additional case

FORGE 352, Microcephaly-ichthyosis*



Candidate variant (p.Thr20fs) found in the vacuolar protein
sorting 52 (VPS52) gene co-segregates in the pedigree
Waiting on DNA for additional affected family members


C4R 572, Autosomal dominant isolated
cryptophthalmos



Investigating a candidate variant in the Diacylglycerol Kinase
Delta (DGKD) gene

C4R 573, Widow’s peak syndrome*



Candidate variant (c.2703-6_2703-5delTT) identified in Lysine
Demethylase 6A (KDM6A)
RNA extraction performed on the samples of both affected
individuals
RT-PCR to be performed to confirm the variant



C4R 575, Amyoplasia




C4R 592, Metaphyseal chondrodysplasia




New mutations identified in affected patients and not in parents:
heparin sulfate proteoglycan 2 (HSPG2; p.Val3507Leu) in
affected male, TEA Domain Transcription Factor 4 (TEAD4;
p.Val212Met) in affected female
Currently looking to recruit additional patients
Candidate variant identified in the Dishevelled Segment Polarity
Protein 3 (DVL3) gene (p.Gln301Ter)
Currently investigating other variants and considering functional
studies

C4R 664, Craniosynostosis*



Candidate variant identified in the TNF Receptor Associated
Factor 7 (TRAF7) gene (c.1673C>T, p.S558F)

C4R 907, Heterotaxy disorder



Candidate variant identified in the Interferon Related
Developmental Regulator 1 (IFRD1) gene (c.568-4_568-3delTT)
Waiting on DNA to confirm the variant of interest


C4R 924, Craniorachischisis*





Variants of interest identified in the Zinc Finger And BTB
Domain Containing 33 (ZBTB33; p.Asp189_Asp190insAla) and
the LFNG O-Fucosylpeptide 3-Beta-NAcetylglucosaminyltransferase (LFNG; p.Trp49Argfs) genes
Confirmed to co-segregate with disease status in the pedigree

Abbreviations are as follows: FORGE, Finding of Rare Disease Genes Canada project.
Results listed are those up until July 1, 2018.
*The red asterisk represents the projects I was directly involved in or working with undergraduate students on. The remaining cases without an asterisk were those in
which I assumed an administrative role.
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3.5

Shared sequence variation

From over one million total variants across the 25 rare metabolic disease (lipodystrophy
and early-onset obesity) exomes, six ultra-rare androgen receptor (AR) variants were
identified in four patients with partial lipodystrophy and one with extreme early-onset
obesity (Table 3.5). Of these six identified variants, three have never been reported in the
literature or in any database. For the variants that are not novel, note that a frequency
greater than zero-percent was prioritized to account for heterozygotes in the normal
control population.
The markedly high prevalence of rare AR variants in this small patient cohort is
unexpected; furthermore, AR variants have never been described in either of these two
disorders characterized by abnormal tissue distribution. All variants detected were
harboured within the N-terminal domain of the AR protein product (Figure 3.5)
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Table 3.5. Candidate variants identified in the androgen receptor gene.
Patient ID
(Phenotype)A

Amino Acid Change

Sequence Ontology

Zygosity/Effect

Frequency

2025 (FPLD)

Gly470_Gly473del

In-frame deletion

Homozygous

5 × 10-3

3011 (FPLD)

Gln80_Glu81insGlnGlnGln

In-frame insertion

Heterozygous

0

4116 (FPLD)

His384Gln

Missense

Heterozygous

0

14318 (FPLD)

Gly470_Gly473del

In-frame deletion

Homozygous

5 × 10-3

Gln62Leu

Missense

Heterozygous

4 × 10-5

Gln69fs

Frameshift

Hemizygous

0

15544 (Obesity)

The candidate genes and variants were selected based on: low frequency in multiple databases, deleterious in silico predictions, relevance to the disease phenotype,
and support from numerous papers in the literature.
The frequencies listed for each candidate variant were extracted from gnomAD and verified using independent databases, ExAC, 1000 Genomes and ESP.
Abbreviations are as follows: FPLD, familial partial lipodystrophy.
A
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
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Figure 3.5. Androgen receptor gene and protein structure. Amino acid changes of interest in the androgen receptor (AR) protein
structure are represented by the yellow stars.
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3.6

Copy-number variation discovery

All patients processed using LipidSeq™ (individuals with lipodystrophy) or with WES
performed in-house (lipodystrophy and obesity cases) were subject to CNV detection. To
call CNVs, the CNV Caller tool within the VarSeq® software was used. CNVs were
called using sequencing depth-of-coverage data from each BAM file. As discussed in
Chapter 2, CNVs were prioritized based on both ratio-threshold value (≤0.7 for
heterozygous deletions, ≥1.3 for duplications) and Z-score (≤-3.0 for heterozygous
deletions, ≥3.0 for duplications).

3.6.1

LipidSeq™ copy-number variation detection

For each patient with lipodystrophy processed on the LipidSeq™, the CNV Caller tool
within VarSeq™ was used to call CNVs. After CNV calling and prioritization, seven
candidate CNVs were identified within seven patients and predicted to be causative of the
lipodystrophy phenotypes (Table 3.6.1).
In total, three heterozygous deletions and four duplications were detected and prioritized
as causative. The deletions were present in AGPAT2, PLIN1 and CIDEC, where AGPAT2
is associated with CGL1, and both PLIN1 and CIDEC are associated with FPLD5. Each
deletion is expected to cause or be associated with the lipodystrophy phenotype of these
patients. The duplications identified in four patients were present in PLIN1, MFN2,
APOA5/APOA4 and CREB3L3 associated with FPLD5, neuropathy, high triglycerides,
and hyperlipidemia/hypertriglyceridemia, respectively. While the PLIN1 variant is
expected to cause the lipodystrophy phenotype, the MFN2, APOA5/APOA4 and
CREB3L3 duplication CNVs are thought to be associated with the secondary
complications of lipodystrophy (i.e. high triglycerides).
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Table 3.6.1. Candidate copy-number variants identified in patients with
lipodystrophy using the LipidSeq™ targeted gene panel.
Patient IDA

Region (affected probes)

Gene(s), Exon(s)B

CNV State

1120C

19:4153347-4173301

CREB3L3, 5’UTR – 3’UTR

Duplication

4192

11:116659835-116694261

APOA5, APOA4, 5’UTR – 3’UTR

Duplication

14557

1:12052361-12057728

MFN2, exons 4 – 6

Duplication

15678

15:90207349-90216895

PLIN1, exon 3 – 3’UTR

Duplication

1099D

15:90220425-90220484

PLIN1, exon 2

Deletion/Heterozygous

15529

3:9921657-9922188

CIDEC, alternative non-coding exon 1

Deletion/Heterozygous

2108

9:139581377-139582161

AGPAT2, 5’UTR – exon 1

Deletion/Heterozygous

After sequencing using the LipidSeq™ panel, the data was run through CLC Bio Genome Workbench v10 and annotated using the curation and annotation program,
Golden Helix VarSeq®. Copy-number variation was called using the depth of coverage and the CNV caller algorithm embedded in the Golden Helix VarSeq®
software.
Abbreviations are as follows: ID, identification; CNV, copy-number variation; UTR, untranslated region.
A
The sample ID number represents a random, integral laboratory number assigned upon the receipt of the patient sample to allow for the privacy and respect of the
patient.
B
All known genes and exons/regions affected.
C
Copy-number alteration confirmed using the independent method, CytoScan™ HD.
D
Copy-number alteration confirmed using Sanger sequencing.
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3.6.2

Exome copy-number variation detection

For the 25 lipodystrophy and obesity exomes, the CNV Caller tool in VarSeq® was
utilized to call CNVs. After prioritization based on ratio threshold value and Z-score, no
CNVs were predicted to be causative from WES data.

3.7

Validation of candidate variants and copy-number

variations
When a candidate variant or CNV is discovered, it is imperative to ensure the variant or
CNV is not a sequencing artifact, and to determine whether the variant or CNV cosegregates with disease status in the family (if available). For select cases, variants were
confirmed through Sanger sequencing, and CNVs were confirmed through Sanger
sequencing, WES, or the CytoScan™ HD microarray.

3.7.1

IHH validation (brachydactyly)A

The IHH p.Glu95_Asp96insLys variant was validated using PCR and Sanger sequencing.
Primers were designed (see Appendix III) for the region of interest (c.285_287dupGAA,
p.Glu95_Asn96insLys) and genomic DNA from the family was genotyped to confirm the
presence of the mutation. Seventeen family members were genotyped for the mutation
using direct Sanger sequencing, and the variant was determined to co-segregate with
disease status in the family. Figure 3.7.1A shows the same family pedigree as Chapter 1,
Figure 1.5.3.1.8 with additional genotyping information, Figure 3.7.1B illustrates the
results from Sanger sequencing.

AA

version of this section has been submitted for publication83.
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Figure 3.7.1A. Pedigree and IHH genotype information for a Canadian autosomal dominant brachydactyly type A1-affected
family.
The proband, as indicated by the black arrow, was the first patient ascertained. All red and blue shaded individuals represent those
whose DNA samples were Sanger sequenced for the IHH variant (exon 1, c.285_287dupGAA, p.Glu95_Asn96insLys). The reddened
squares (males) and circles (females) represent affected individuals with brachydactyly type A1 who carry the IHH variant. The blue
coloured squares and circles indicate those who are unaffected by brachydactyly and do not carry the IHH variant. The green coloured
squares and circles represent the individuals clinically diagnosed with brachydactyly whose DNA was not obtained or sequenced.
Diagonal lines indicate deceased individuals.
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Figure 3.7.1B. Chromosome location, gene structure, sequence analysis and protein structure of Indian Hedgehog. A shows
chromosome 2 and the location of the IHH gene drawn to scale. B shows the genomic DNA for the IHH gene. C shows the mRNA for
IHH with the mutation indicated. Electrophoretic tracings for the IHH variant for both unaffected and affected family members are
also shown. D shows the IHH protein structure with key domains, regions, and the mutation indicated.
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3.7.2

VPS52 validation (microcephaly-ichthyosis)

Using PCR followed by Sanger sequencing, the VPS52 (c.57delG, p.Thr20fs) variant was
validated in the two affected individuals. Additionally, the DNA of an available,
unaffected sibling was Sanger sequenced to confirm the absence of the variant. The
VPS52 variant was found to co-segregate with disease status in the pedigree (Figure
3.7.2).

3.7.3

KDM6A validation (widow’s peak)

The KDM6A variant (c.2703-6_2703-5delTT) was subjected to PCR and Sanger
sequencing to confirm the validity of the candidate variant. The variant was present in
both affected individuals, and absent in an unaffected family member, confirming cosegregation with disease status in the family (Figure 3.7.3).

3.7.4

AR validation (lipodystrophy and obesity)

All six AR gene variants (p.Gly470_Gly473del, p.Gln80_Glu81insGlnGlnGln,
p.His384Gln, p.Gly470_Gly473del, p.Gln62Leu, p.Gln69fs) were subject to PCR and
Sanger sequencing for validation. Due to the high GC-content of the AR gene, the
sequencing results were inconclusive and validation of the AR variants is ongoing.
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Figure 3.7.2. Sanger sequencing confirmation of the VPS52 gene variant in a family with a history of microcephaly-ichthyosis.
From whole-exome sequencing, one candidate variant (c.57delG) in the vacuolar protein sorting-52 gene (VPS52) was predicted to be
causative of the microcephaly-ichthyosis phenotype in the family. The arrows indicate the probands. After whole-exome sequencing,
Sanger sequencing was utilized to confirm the variant in the two affected probands and confirm the absence of the variant in an
available unaffected family member. Squares indicate biological males, circles indicate biological females, and diagonal lines
represent individuals who are deceased.
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Figure 3.7.3. Sanger sequencing confirmation of the KDM6A gene variant in a
family with a history of widow’s peak syndrome. From whole-exome sequencing, one
candidate variant (c.2703-6_2705-5delTT) in the lysine-specific demethylase 6a gene
(KDM6A) was predicted to be causative of the widow’s peak syndrome phenotype in the
family. After whole-exome sequencing, Sanger sequencing was utilized to confirm the
variant in the two affected probands and confirm the absence of the variant in an
available unaffected family member. Squares indicate biological males, and circles
indicate biological females. Horizontal lines over the squares represent the samples
subjected to whole-exome sequencing.
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3.7.5

Copy-number variation validation

After CNV detection, validation was necessary to ensure that the CNV events called were
not artifacts or false positives. In order to validate the CNVs, three independent methods
were used, namely Sanger sequencing, WES and the CytoScan™ HD array. To date, two
CNVs in patients 1099 and 1120 have been confirmed while five are ongoing.

3.7.5.1

Patient 1099: PLIN1 exon 2 deletion

From the VarSeq® CNV Caller tool and LipidSeq™ data, an exon 2 deletion was
identified in the PLIN1 gene. This CNV event was validated using PCR, gel
electrophoresis and Sanger sequencing on the patient and normal control samples (no
lipodystrophy) with primers flanking exons 1 and 3 (Figure 3.7.5.1; see Appendix III for
primer details).
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Figure 3.7.5.1. Validation of a PLIN1 exon 2 deletion in a patient with familial partial lipodystrophy. Panel A: Sanger
sequencing results showing the deletion of exon 2. Panel B: PCR and agarose gel electrophoresis across the breakpoints to confirm a
PLIN1 exon 2 deletion in a patient with familial partial lipodystrophy. Lane 1 shows a 1-kb ladder, lane 2 shows a normal control, and
lane 3 shows the patient sample. The patient is heterozygous for both the wild type sequence and a 1646-bp deletion.
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3.7.5.2

Patient 1120: CREB3L3 duplication

From the VarSeq® CNV Caller tool and LipidSeq™ data, a full gene deletion of
CREB3L3 was detected. To confirm this CNV event and determine whether the
neighbouring genes were affected, WES was performed. From WES, it was determined
that several neighbouring genes were also duplicated (Figure 3.7.5.2). More specifically,
the PIAS4, ZBTB7A, MAP2K2, CREB3L3, SIRT6, and ANKRD24 genes were fully
duplicated (5’UTR–3’UTR). Notably, the SIRT6 gene encodes the sirtuin-6 protein, a
nuclear protein that catalyzes deacylation and mono-ADP ribosylation. Deficiency of
SIRT6 results in accelerated aging, suggesting a link between lamin A and SIRT6, as
lamin A defects are associated with progeroid features and lipodystrophy. Lamin A
deficiency is the main cause of FPLD2, matching the phenotype of the patient.
To further validate the CNV event detected from WES, the DNA of the patient was
subjected to genotyping using the CytoScan™ HD array. The microarray demonstrated
the same results as the WES data, confirming the validity of the multi-gene duplication.
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Figure 3.7.5.2. Detection of a duplication event from LipidSeq™ versus whole-exome sequencing data. Panel A shows the CNV
event called by the VarSeq® CNV Caller tool using LipidSeq™ data. Panel B illustrates the CNV event called by the VarSeq® CNV
Caller tool using exome data. In each panel, the top region shows the CNV state as determined from both ratio and Z-score metrics,
and the bottom region shows the exon map of the affected gene(s). The regions highlighted in blue as “duplicate” are the regions
where a duplication event occurred.
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3.8 Gene enrichment analysis
In the event that multiple candidate variants, no candidate variants or no candidate CNVs
were identified, PANTHER was used to analyze gene lists and determine whether there
was overrepresentation of certain protein families, molecular functions, biological
processes, or cellular components and pathways. The list of genes remaining after initial
rare non-synonymous filtering (non-synonymous sequence ontology, Read Depth ≥ 30,
Minor Allele Frequency ≤ 1%) were used as input. From analysis on the gene lists of
patients with lipodystrophy and early-onset obesity, two partial lipodystrophy patients
were found to harbour variants with significant overrepresentation in specific biological
pathways. More specifically, for patient 14318, gene overrepresentation was identified in
the biological pathways of O-glycan processing and tissue homeostasis. For patient
11618, overrepresentation was significant in the interferon-gamma-mediated signaling
pathway.

3.9

Statistical analysis: Brachydactyly case

To strengthen the association of the IHH variant with the brachydactyly phenotype
displayed in the family, family-based association analyses were performed using the
Wilcoxon-Mann-Whitney test and anthropometric measurements. From these tests, the
IHH variant was associated with shortened length of middle phalanges by 21.1%
(P<0.001), of palms by 13.8% (P<0.01), of middle digit to palm ratio by 6.8% (P<0.03)
and of stature by 9.5% (P<0.001), consistent with the relative mild clinical phenotype
displayed by the patient (Figure 3.9).
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Figure 3.9. Comparison of anthropometric measures between those positive for the
IHH mutation and those negative for the IHH mutation. Physical measurements were
taken for all available family members with brachydactyly. Validation of the IHH
mutation was performed using Sanger sequencing. Statistical analysis was performed
using the Wilcoxon-Mann-Whitney test on SAS v9.4. Box plots were generated using the
ggPlot2 package in R project v3.4.3. Panel A represents the digit length (cm) for IHH
mutation positive and mutation negative individuals taken from the base of the third
finger to the tip. B shows the palm length (cm) for IHH mutation positive and negative
individuals taken from the base of the palm to the top of the palm. C displays the height
in inches for mutation positive and negative individuals. D shows the digit-palm ratio for
mutation positive and negative individuals, where the digit and palm lengths were taken
as described previously.
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Chapter 4 – Discussion
4

Summary of findings

In this MSc Thesis, I have identified genetic variants underlying several rare diseases
using NGS technologies. More specifically, each case was subjected to either LipidSeq™
targeted sequencing or WES. Bioinformatics processing and in silico analyses were then
utilized to identify potential disease-causing variants from the LipidSeq™ and WES data.
From LipidSeq™ targeted sequencing of 153 patients clinically diagnosed with
lipodystrophy, 58 patients were found to harbour 81 variants within 14 lipodystrophyassociated genes. Furthermore, seven patients were found to harbour CNVs in
lipodystrophy-associated genes. This is the first report of systematically screening for
CNVs in patients with lipodystrophy, and these are the first CNVs reported in
lipodystrophy patients in the literature.
From WES and bioinformatics analysis, candidate variants were identified in 13 of the 20
patients with lipodystrophy, and two of the five patients with extreme early-onset obesity.
For the rare disease cases ascertained through the Blackburn Cardiovascular Genetics
Laboratory, namely the brachydactyly and autosomal recessive cerebral atrophy-like,
candidate variants were identified in both cases. Last, for the rare disease cases
ascertained through the CARE4RARE and FORGE Canada Consortiums, eight out of the
11 cases had candidate variants identified.
Of the candidate variants found, several were validated using Sanger sequencing and
many were found to co-segregate with disease status in the pedigrees. These variants
have been prioritized and will be considered for future functional studies. Of the
candidate CNVs identified, the CNV in patient 1120 (CREB3L3 and surrounding genes)
was confirmed using the independent methods of WES and CytoScan™ HD. Secondary
validation (through Sanger sequencing) of the PLIN1 CNV was also performed using
Sanger sequencing.
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The context of these findings are discussed within the subsequent sections in this
Chapter. Additionally, I discuss the implications, limitations, and future directions for
this study, and the benefits and caveats of using NGS for identifying the genetic basis of
rare diseases.

4.1

LipidSeq™

LipidSeq™, the custom-designed targeted NGS panel, was utilized for the sequencing of
lipodystrophy-associated genes in patients with various forms of lipodystrophy. From the
DNA of 153 patients with lipodystrophy, LipidSeq™ targeted sequencing, bioinformatics
processing and variant curation were performed, and 81 variants harboured within 14
genes were identified among the 58 patients. Furthermore, from CNV calling and
prioritization, seven novel CNVs were identified within seven patients.

4.1.1

Unexpected variation in POLD1

From the LipidSeq™ data, despite the fact that many of the causative genetic variants
were harboured within common lipodystrophy-associated genes (i.e. LMNA, PPARG,
PLIN1, etc.); an unexpected 14 variants were detected within POLD1. The POLD1 gene,
encoding polymerase (DNA-directed), 1, is a catalytic and proofreading subunit of DNA
polymerase  (Pol), involved in lagging strand DNA synthesis during replication135,136.
In order to aid in high fidelity DNA replication, synthesis and repair, POLD1 works with
accessory proteins POLD2, POLD3 and POLD4. Together with these subunits, the
heterotetramer interacts with Proliferating Nuclear Cell Antigen (PCNA) and the clamp
loader, Replication Factor C (RFC) to form the polymerase holoenzyme. In addition to its
role in lagging strand synthesis, Pol plays a role in proofreading (through exonuclease
activity), and lesion repair resulting from mutagenic exposure. Furthermore, Pol is
important in DNA repair mechanisms including base excision repair, mismatch repair,
double strand break repair, and nucleotide excision repair. Mutations in Pol have been
associated with genomic instability and tumourigenesis. Variants have also been
identified in the developmental disorders mandibular hypoplasia, deafness, progeroid
features and lipodystrophy (MDPL), and Werner’s syndrome137.
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MDPL is an extremely rare, heterogeneous, multi-system disorder featuring premature
aging of the tissues and organs. Most importantly, MDPL features variable lipodystrophy.
In 2013, Weedon et al. reported POLD1 variants in four individuals featuring a
prominent, atypical lipodystrophy phenotype136. Using deletion mutants, they showed
that POLD1 variants abolished polymerase activity while maintaining exonuclease
activity.
Due to the similar adipose tissue distribution of MDPL and the lipodystrophy seen in our
patient cohort, I encourage LipidSeq™ targeted sequencing to differentiate lipodystrophy
associated with POLD1 versus lipodystrophy caused by genes such as LMNA, PPARG
and PLIN1. Differentiation may change treatment, thereby altering patient prognosis.
Moreover, due to the higher than expected prevalence of POLD1 variants in our cohort, I
suggest that lipodystrophy associated with POLD1 variants may be underestimated,
further encouraging investigation of POLD1 in addition to classic lipodystrophyassociated genes in the future.

4.1.2

Copy-number variation findings

The advent of LipidSeq™ targeted sequencing has shown numerous benefits for patients
with metabolic disease and clinical medicine, notably for the clarification of disease
phenotypes caused by pathogenic variants. Understudied however, was the contribution
of CNVs to lipodystrophy phenotypes. Using LipidSeq™ data and the CNV Caller Tool
in VarSeq®, I detected CNVs by analysing depth of coverage readings from nextgeneration sequencing results. From the 153 uncharacterized lipodystrophy patients who
were evaluated for potential CNVs, I identified seven novel CNVs that have never been
reported in the literature or in any control database. Three individuals carried
heterozygous deletions (patients 1099, 2108 and 15529), while four carried heterozygous
duplications (patients 1120, 4192, 14557 and 15678).

4.1.2.1

Patient 1099

In a biological male with FPLD, a PLIN1 heterozygous deletion of exon 2 was identified.
Using Sanger sequencing, this PLIN1 deletion was confirmed to be a 1646-bp deletion.
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Perilipin-1, encoded by the PLIN1 gene, is a lipid droplet coat protein expressed in
adipocytes, involved in the facilitation of lipolysis. Loss-of-function variants in PLIN1
are associated with autosomal dominant FPLD4, a subtype of partial lipodystrophy
featuring variable loss of adipose tissue from the extremities138. As mutant PLIN1
proteins have an increased propensity for degradation and heterozygous knockout mice
display significantly reduced fat mass, I suggest that the PLIN1 exon 2 deletion is causing
the lipodystrophy in this patient139.

4.1.2.2

Patient 2108

In patient 2108 – a biological female clinically diagnosed with autosomal dominant
Dunnigan-Köbberling syndrome – a heterozygous deletion of the 5’UTR–exon 1 region
of AGPAT2 was identified. Dunnigan-Köbberling syndrome is a form of lipodystrophy
characterized by the loss of adipose tissue from the body, sparing the face140. As
homozygous variants of AGPAT2 are associated with CGL (a more severe, recessive
form of complete lipodystrophy), I suggest that this heterozygous CNV event may be
causing the milder, partial lipodystrophy phenotype in this patient.

4.1.2.3

Patient 15529

In a biological female featuring FPLD, a heterozygous deletion of alternative non-coding
exon 1 in CIDEC was detected. Generally, recessive variants in CIDEC are associated
with FPLD5. As this is a heterozygous deletion, it is predicted that this CIDEC CNV is
contributing to the FPLD phenotype rather than causing it. As alternative non-coding
exons play a large role in alternative splicing, I suggest that this CNV affects the splicing
of the CIDEC gene. Further, as a candidate variant (c.T53G, p.V18G) was identified in
the AGPAT2 gene through LipidSeq™ sequencing, I propose that the CIDEC CNV and
AGPAT2 variant are acting synergistically to cause the partial lipodystrophy phenotype.

4.1.2.4

Patient 4192

In another biological female with FPLD, I detected a duplication of the entire APOA5 and
APOA4 genes. APOA5 encodes apolipoprotein A-V, a low abundance plasma protein that
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plays a role in triacylglycerol homeostasis141. APOA4 encodes apolipoprotein A-IV, a
component of chylomicrons and high-density lipoproteins that plays a protective role in
reverse-cholesterol transport142. GWASs have identified multiple SNPs in APOA5 that
are associated with elevated TGs. Furthermore, studies on mutant Apoa5-/- mice
demonstrate aberrant lipoprotein binding and TG modulation functions143. Due to the
duplication of the entire APOA5 coding gene, I suggest that the duplication may be
contributing towards the lipodystrophy phenotype in this patient. Furthermore, I suggest
the duplication may be synergistically working with the APOA4 duplication and an
additional aberrant gene product in order to cause the lipodystrophy present in this
patient. In the future, I suggest WES to determine added genetic factors causing the
lipodystrophy phenotype.

4.1.2.5

Patient 14557

In a patient (14557) with FPLD, I identified a novel duplication event in the MFN2 gene.
The MFN2 gene encodes the mitofusin 2 protein, involved in the morphology of
mitochondria. As the mitochondria require flexibility in morphology to maintain
mitochondrial function, the mitofusin 2 protein is generated in many tissues and cells
including muscle, the spinal cord, nerves, and peripheral nerves. Variants in MFN2 are
the primary cause of autosomal dominant Charcot-Marie-Tooth (CMT) disease, type
2A144. CMT is a heterogeneous disorder, characterized by peripheral neuropathy145. An
additional clinical disease associated with MFN2 mutations is multiple symmetric
lipomatosis (MSL), a mitochondrial disorder associated with abnormal brown fat
metabolism. Patients with MSL feature lipomatosis (multiple lipomas or benign fat tissue
tumours on the body) as well as lipodystrophy. MSL has been attributed to a p.R707W
(c.2119C>T) mutation146. As our patient was found to carry a heterozygous p.R707W
mutation in MFN2 in addition to a heterozygous duplication, I suggest this variant and
CNV are cooperatively contributing to the lipodystrophy phenotype. Additionally, due to
the overlap between FPLD and MSL in terms of lipoatrophy, I suggest that the CNV
duplication and variant in MFN2 are causing an atypical form of lipodystrophy. Followup studies are required to confirm the pathogenicity of the CNV event and the effects of
the CNV combined with the p.R707W variant.
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4.1.2.6

Patient 15678

From CNV detection, a biological female with FPLD was found to harbour a
heterozygous duplication of PLIN1 (exon 3 – 3’UTR). As in the case with patient 1099, I
propose that the FPLD phenotype in this patient can be explained by the PLIN1
duplication. As both excess and insufficient lipid storage in white adipose tissue lipid
droplets can result in dyslipidemia, insulin resistance and diabetes, I suggest the PLIN1
duplication is contributing to the lipodystrophic phenotype of this patient147. Furthermore,
as a novel heterozygous AGPAT2 variant (c.T53G, p.V168G) was also detected in this
patient’s genome from LipidSeq™, I suggest this AGPAT2 variant and PLIN1 duplication
are both contributing to the patient’s lipodystrophy.

4.1.2.7

Patient 1120

In a biological male clinically diagnosed with FPLD, a duplication of the CREB3L3 gene
was identified. The cyclic AMP-responsive element-binding protein 3-like protein 3
(CREB3L3) gene encodes a transcription factor that activates unfolded protein response
target genes during endoplasmic reticulum stress. Activated by cAMP stimulation,
CREB3L3 binds the cAMP response element (CRE) and box-B element to activate
transcription. In addition, CREB3L3 is involved in fatty acid oxidation and ketogenesis,
and induced during fasted or insulin-resistant states148. Variations in CREB3L3 cause
hypertriglyceridemia, where Creb3l3-/- mice have elucidated the mechanism as due to
inefficient catalysis of triglyceride clearance149. As the entire CREB3L3 gene was
duplicated, I speculated that neighbouring genes (such as the SIRT6 gene associated with
lipid metabolism) were also affected. To confirm this prediction, I pursued WES. The
results of the CNV detection from WES data are further discussed in Section 4.2.13.
In addition to the CREB3L3 CNV, patient 1120 also harbours two missense mutations,
each in PLIN1 (c.G814A, p.V272M) and PTRF (c.C168A, p.S56R) predicted as
deleterious from in silico prediction tools. Moreover, PLIN1 and PTRF are associated
with FPLD5 and CGL4, respectively, each associated with lipodystrophy. All together, I
suggest that the CREB3L3 duplication, along with the variants in PLIN1 and PTRF, are
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modulating or causing the lipodystrophy phenotype and abnormal lipid profile present in
this patient.

4.1.3

Benefits of LipidSeq™

The use of LipidSeq™ targeted sequencing offers several benefits. First, LipidSeq™ is a
targeted panel, with the flexibility to adapt with the growing body of literature. As novel
lipodystrophy genes are continually being discovered (i.e. adrenoceptor alpha 2A
[ADRA2A] mutations in FPLD150), the LipidSeq™ has the ability to stay current and
include all known genes associated with dyslipidemia. Second, as LipidSeq™ is
restricted to specific genes, it lessens the probability of incidental findings associated
with other disorders. With concerns regarding the proper disclosure of incidental
findings, the use of LipidSeq™ decreases the possibility of these findings and the
potential for genetic discrimination in the workplace or from insurers. Third, in
comparison to Sanger sequencing, LipidSeq™ can rapidly provide a higher diagnostic
yield at a cost-effective rate. With LipidSeq™ data generation taking less than a week,
LipidSeq™ offers a quick turnaround from bench-to-bedside. Last and most importantly,
LipidSeq™ allows for the genetic diagnosis of several metabolic disorders. Notably in
the 153-person lipodystrophy cohort, LipidSeq™ sequencing led to the genetic diagnosis
of 40% of patients through variants or CNVs, speaking to the utility of LipidSeq™ in the
clinic. For these patients, the results may have actionable consequences in the realms of
treatment, management or predictive recurrence risks, altogether improving patient
outcome and prognosis.

4.1.4

Limitations of LipidSeq™

Although I was able to use the LipidSeq™ targeted gene panel to identify the genetic
basis (variants and CNVs) of 40% of patients with lipodystrophy, 60% of cases remain
genetically unexplained, speaking to the limitations of LipidSeq™. This gap in variant
and/or CNV discovery is due to the inherited constraints of LipidSeq™ targeted
sequencing. First, with LipidSeq™ there is low-to-no coverage of the untranslated and
non-coding regions, making the identification of candidate variants in those regions
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impossible. This is a drawback of LipidSeq™ as disease-associated variants have been
known to be harboured in the UTR. For example, in 2017 Wang et al. identified a TBX5
3’UTR variant driving congenital heart disease in a Han Chinese population151. Second,
with targeted NGS-based approaches, although there can be identification of CNV
events, many CNVs can be missed depending on the location of the event. More
specifically, numerous CNV events occur in highly repetitive regions through genomic
instability, non-allelic HR or NHEJ152. Due to these areas being relatively unamenable to
mapping (i.e. due to guanine-cytosine rich regions), these areas are either missed or not
targeted through LipidSeq™ sequencing. Last, despite the fact that the LipidSeq™ is
flexible and can be modified to incorporate any gene of interest, variant discovery from
LipidSeq™ is restricted to a priori knowledge. Therefore, it is impossible for LipidSeq™
sequencing to allow for the identification of novel disease-associated genes. Albeit the
utility of LipidSeq™ in identifying variants in known lipodystrophy-associated genes, it
is necessary to use broader methods such as WES in order to identify novel pathogenic
genes and variants, not previously implicated in lipodystrophy.

4.2

Whole-exome sequencing of patients with rare

metabolic diseases
In patients with prior Sanger sequencing or LipidSeq™ sequencing in which no candidate
variants were found, WES was pursued in order to identify novel disease-causing
variants. Rare metabolic disease patients – namely 20 patients with lipodystrophy and
five with extreme early-onset obesity – were subjected to the WES process. Following
WES, data processing and bioinformatics analysis were performed to identify and
prioritize putative disease-causing variants. After individual analysis, the exomes of
individuals with lipodystrophy and extreme early-onset obesity were evaluated for shared
variation. From these analyses, 13 of the 20 patients with lipodystrophy and two of five
patients with extreme early-onset obesity had candidate variants identified. Furthermore,
variation in the AR gene was detected in four patients with partial lipodystrophy and one
patient with extreme early-onset obesity, creating a connection between the two opposite
phenotypes.
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4.2.1

Lipodystrophy

WES was performed for 20 patients with variable forms of lipodystrophy. WES
identified variants within 13 patients discussed herein.

4.2.1.1

Patient 1804

In a biological female clinically diagnosed with CGL, a homozygous variant in the ironsulfur cluster assembly enzyme (ISCU, c.19_20delinsGG, p.Phe7Gly) was identified. The
ISCU protein is a scaffold protein required for the de novo synthesis of iron-sulfur
clusters (Fe-S) in mitochondria. Specifically, ISCU is responsible for the maturation of
mitochondrial and cytoplasmic proteins153. These Fe-S clusters are required for the
function of numerous proteins, including those required for iron regulation and DNA
repair. Proteins with these Fe-S clusters are also required for energy production in the
mitochondria154. As Fe-S clusters are required cofactors for proteins involved in several
biological processes, it is likely that dysfunction of the iron-sulfur cluster biogenesis
pathway underlies several human diseases.
Mutations in ISCU are causative of iron-sulfur deficiency myopathy, or myopathy with
exercise intolerance. This disease features severe, progressive muscle weakness, severe
exercise intolerance and cardiomyopathy155,156. As patient 1804 exhibits exercise
intolerance, specifically exertion-related chest complications, I suggest that this novel
ISCU variant is contributing towards the phenotype present in this patient. As a
candidate variant has not been identified as causative of her lipodystrophy, I suggest
further analysis of the exome data using less stringent criteria (i.e. lower read depth) to
determine the genetic basis of the lipodystrophy in this patient. I also suggest considering
other genetic factors (discussed in Section 4.8) as causing the lipodystrophy in this
patient.

4.2.1.2

Patient 8615

From WES, patient 8615 – a biological female featuring general lipodystrophy, diabetes,
iron-deficient anemia, diabetic neuropathy, central obesity and coronary artery disease –
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was found to harbour a homozygous variant in the heparin sulfate proteoglycan 2 gene or
HSPG2 (c.3707C>A, p.Ala1236Glu) encoding for the perlecan protein. The perlecan
protein belongs to the extracellular matrix basement membrane, where it supports cells in
many tissues. Additionally, perlecan is found in cartilage and plays a role in cell
signaling, angiogenesis and muscle contraction157. Perlecan also plays a large role in the
cardiovascular system, where it plays a role in lipid metabolism by interacting with
lipoprotein lipase and apolipoprotein B. Variants in HSPG2 have been linked to coronary
artery disease, insulin sensitivity, adipose tissue defects and metabolic syndrome, all
secondary features of the proband158,159. Therefore, I predict that the HSPG2 variants are
contributing towards the lipodystrophy phenotype of this patient. As the definitive cause
of the lipodystrophy present in this patient has not been elucidated, I suggest further
analysis of the exome of this patient using less stringent criteria, as discussed prior.

4.2.1.3

Patient 1088

In patient 1088, a biological female featuring FPLD, high cholesterol, diabetes and high
blood pressure, two candidate variants were detected and are predicted to cause the
phenotype of the patient. The first is a missense variant (c.2468G>C, p.Arg823Pro) in
PRDM16 encoding the PR domain containing 16 protein, a transcription co-regulator that
binds and activates PPARɣ to develop brown adipocytes from brown adipose tissue
(BAT). When functioning normally, BAT oxidizes chemical energy to produce heat in
protection against obesity. An association between PRDM16 variants and a metabolic
syndrome phenotype in a Uygur Chinese population has been reported, which suggests it
may be involved in the development of lipodystrophy, as lipodystrophy is classified as a
metabolic disorder160. The second candidate variant (c.1048C>T, p.Arg250Ter) is a
classified pathogenic variant within LDLR, encoding the low-density lipoprotein receptor.
LDL receptors are cell surface proteins involved in the receptor-mediated endocytosis of
LDL cholesterol. Under normal circumstances, LDL is transported into the cell through
receptor binding, and carried to the lysosome where it is subsequently degraded.
Mutations in LDLR cause familial hypercholesterolemia (FH), an autosomal dominant
disorder characterized by elevation of serum cholesterol bound to LDL, promoting the
deposit of cholesterol in the arteries, tendons, and skin161.
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In sum, these findings suggest that patient 1088 is not only affected with FPLD but may
also have FH, explaining the high cholesterol levels. Considering the chance of
developing familial partial lipodystrophy is approximately one in 50,000 and the
prevalence of FH is one in 300, this makes the phenotype of patient 1088 one in 15
million. This illustrates the power of WES in the clinic, as it would be difficult for a
clinician to diagnose a disorder with such low and improbable statistical odds.

4.2.1.4

Patient 3458

In patient 3458, a female clinically diagnosed with FPLD, a novel, heterozygous variant
in the ZMPSTE24 gene was detected (c.1199A>G, p.Asn400Ser). The ZMPSTE24
protein is a zinc metalloproteinase STE24 with a role in processing farnesylated
proteins162. ZMPSTE24 also ensures the correct processing and maturation of lamin A.
Mutations in ZMPSTE24 are known to cause mandibuloacral dysplasia with type B
lipodystrophy (MADB). This condition features bone abnormalities, patchy skin
colouring, and loss of fat tissue across the body163. Mutations in ZMPSTE24 are also
associated with severe progeria and restrictive dermopathy (thin, easily eroded skin and
joint contracture). Complete loss-of-function alleles are associated with restrictive
dermopathy, whereas residual or partial activity of ZMPSTE24 correlates with increased
disease severity and MADB or progeroid features164. We suggest that this ZMPSTE24
variant is contributing towards the lipodystrophy phenotype of this patient. As a note,
Sanger sequencing performed 12 years ago missed the variant in ZMPSTE24. The recent
identification of this variant using WES highlights the power of NGS in variant
identification.

4.2.1.5

Patient 3969

In patient 3969, a biological female featuring FPLD, candidate variants were identified in
FLNC (c.6988G>A, p.Gly2330Ser) and GALC (c.334A>G, p.Thr112Ala). FLNC encodes
gamma filamin, a protein that aids in the crosslinking of actin filaments in the cortical
cytoplasm, involved in the anchoring of membrane proteins for the actin cytoskeleton. As
gamma filamin is muscle-specific, dominant mutations in FLNC cause myofibrillar
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myopathy, a myopathy characterized by muscle weakness and the atrophy of the upper
and lower extremities165. GALC encodes galacosylceramidase, an enzyme involved in
breaking down galactolipid fats in the nervous system, epithelial cells of the small
intestine and colon, and kidneys166. Defects in GALC are associated with Krabbe disease,
a disease featuring mobility restrictions due to damage to myelin-forming cells in the
nervous system. Due to the loss of myelin, nerves in the brain cannot properly transmit
signals, leading to Krabbe disease167,168. As the primary health concern of patient 3969 is
peripheral neuropathy, I suggest that the variants in FLNC and GALC are contributing
towards the neuropathy phenotype. Additional analysis should be done to determine
whether these genetic variants interact to amplify the neuropathy in this patient.
Furthermore, future directions for this patient should include continued analysis of her
exome data using less stringent criteria to determine the genetic basis of her
lipodystrophy.

4.2.1.6

Patient 4116

After WES and bioinformatics analysis, patient 4116 – a biological female clinically
diagnosed with FPLD – had two LDLR candidate variants (c.2252G>A, p.Arg751Gln;
c.2231_2232delinsAG, p.Arg744Gln) identified in her exome. Similar to patient 1088 as
discussed in Section 4.2.1.3, the LDLR variants are likely contributing to the high
cholesterol levels in this patient. In addition to the LDLR variants, a novel variant in the
AR gene was also detected (c.1152C>G, p.His384Gln) in the patient’s exome (discussed
in Section 4.2.3). Together, the LDLR and AR variants are likely contributing to the
abnormal lipid profile of the patient. Future work should focus on identifying the genetic
basis of the lipodystrophy phenotype of the patient. This can be done by using less
stringent criteria when analysing the exome data or considering alternative genetic factors
(as discussed in Section 4.8).

4.2.1.7

Patient 4665

In a biological female with FPLD (patient 4665), four candidate variants were identified
from WES. Two variants were detected in ABCA4 (c.1610G>A, p.Arg537His;
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c.2969G>A, p.Gly990Glu) and two in WRN (c.2983G>A, p.Ala995Thr; c.1149G<T,
p.Leu383Phe). ABCA4 encodes a member of the ATP binding cassette transporters.
Involved in lipid transport, ABCA4 is associated with the import of lipid substrates such
as vitamins, phospholipids, glycolipids, fatty acids, cholesterol and bile salts169. On the
other hand, WRN encodes the Werner protein, where variants in WRN cause an aging
disease known as Werner syndrome, featuring abnormal fat deposition including the loss
of adipose from the distal limbs170. As Werner syndrome is caused by pathogenic
recessive variants in the WRN gene and this patient harbours two heterozygous variants in
WRN, I suggest that patient 4665 may feature an atypical form of Werner syndrome. I
also propose that the ABCA4 gene variants are contributing to the lipodystrophy
phenotype of the patient. Additional studies should be done to confirm the pathogenicity
of the variants and their role in the lipodystrophy phenotype (see Section 4.8 for details).

4.2.1.8

Patient 5662

The DNA of patient 5662, a female featuring FPLD was subjected to WES and
bioinformatics processing. After analysis, a homozygous splicing variant was identified
in ABCG8 (c.1412-8delinsTT). This ABCG8 splicing variant is predicted to alter the wild
type splice acceptor site from multiple in silico splicing prediction tools, is considered
novel in multiple control databases, and has not been previously reported in the literature.
The ABCG8 gene encodes sterolin-2, half of the protein, sterolin. In the body, sterolin is
involved in eliminating fatty components of plant-based foods that cannot be used in
human cells171. Mutations in ABCG8 have been identified in individuals with
sitosterolemia, a condition characterized by the accumulation of plant sterols and the
impaired ability to remove cholesterol from the body. Furthermore, individuals with
sitosterolemia feature atherosclerosis, xanthomas, and blood abnormalities172. I propose
that the ABCG8 gene is contributing to the abnormal lipid profile of the patient; however,
further analysis of the exome data is required to determine the genetic cause of the
patient’s lipodystrophy.
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4.2.1.9

Patient 2025

Patient 2025 is a biological female that was clinically diagnosed with lipodystrophy.
Upon review of the patient’s clinical data, it was discovered that the patient also has
dermatomyositis – a rare genetic inflammatory disease causing severe myopathy, painful
skin rashes, sensitivity to light and calcinosis (calcium deposits in the muscle).
Furthermore, the patient suffers from severe insulin resistance and proteinuria. Due to the
fact that this patient has dermatomyositis in addition to lipodystrophy, variants associated
with dermatomyositis were also prioritized during exome analysis.
In this patient, three candidate variants were identified within three candidate genes:
FHL1 (c.46G>T, p.Gly16Trp), ANLN (c.1205C>T, p.Pro402Leu) and AR
(c.1369_1380delGGCGGCGGCGGC, p.Gly470_Gly473del). The FHL1 gene (four and a
half LIM domains 1) encodes three isoforms that play critical roles in skeletal muscle and
cardiac muscle movement. More specifically, FHL1A plays a key role in sarcomere
assembly, FHL1B plays a role in the nuclear envelope, and FLH1C is thought to play a
role in the function of skeletal and cardiac muscles173. Dominant mutations in FHL1 have
been linked to reducing-body myopathy (RBM), a rare myopathy featuring the
progressive weakness of the muscles, a rigid spine, and a progressive disease course174.
The ANLN gene encodes anillin, an actin binding protein with a role in cell growth and
migration. Variants in ANLN are causative of focal segmental glomerulosclerosis-8, a
renal disease featuring proteinuria and the progressive decline in renal function175. The
AR variant is discussed in Section 4.2.3.
Due to the association with myopathy, proteinuria and renal function and the severe
myopathy and renal dysfunction in the patient, I suggest that the novel FHL1 and ANLN
variants are contributing towards the disease phenotype of the patient. Furthermore, I
suggest that the AR gene variant is contributing to the metabolic profile of patient 2025.

4.2.1.10 Patient 3011
Patient 3011 is a biological female featuring FPLD, insulin resistance, dyslipidemia,
hirsutism (overgrowth of hair) and hypertriglyceridemia. From WES, I identified three
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candidate gene variants contributing to the phenotype of the patient: LPL (c.775G>A,
p.Asp259Asn), PAPSS2 (c.1114G>T, p.Val372Phe), and AR
(c.170_171insGCAGCAGCA, p.Gln80_Glu81insGlnGlnGln). The LPL gene encodes
lipoprotein lipase, an enzyme found within cells that line capillaries in muscles and
adipose tissue. LPL plays a key role in breaking down fat into triglycerides, which are
then transferred from organs to the blood through lipoproteins. Mutations in LPL have
been associated with many conditions, including atherosclerosis, insulin resistance, and
dyslipidemia associated with diabetes176. The PAPSS2 gene encodes 3'-phosphoadenosine
5'-phosphosulfate synthase 2, a sulfate donor co-substrate required for sulfotransferase
(SULT) enzymes. These SULT enzymes catalyze many endogenous and exogenous
compounds, such as drugs and xenobiotics177. Mutations in PAPSS2 are associated with
brachyolmia type 4 with mild epiphyseal changes (BCYM4). Furthermore, variants in
PAPSS4 have been associated with hirsutism, androgen excess and polycystic ovary
syndrome, all clinical features of patient 3011178. The AR variant is discussed in detail in
Section 4.2.3.
All together, I predict that the LPL, PAPPS2 and AR gene variants are all contributing to
the patient’s phenotype. More specifically, it is likely that the LPL variant is contributing
to the insulin resistance, dyslipidemia and hypertriglyceridemia, whereas the PAPSS2
variant is contributing to the polycystic ovary syndrome and hirsutism. The AR variant is
likely also contributing to the hirsutism and involved in the metabolic profile of the
patient. Further analysis is required to confirm the pathogenicity of the novel variants and
identify the genetic basis of the patient’s lipodystrophy (as discussed in Section 4.8).

4.2.1.11 Patient 14318
Patient 14318 is a biological female in her teens, clinically diagnosed with FPLD. From
WES and bioinformatics analysis, several candidate variants were detected. These
include variants in NEUROD1 (c.170G>A, p.Gly57Glu), BSCL2 (c.1280T>C,
p.Leu427Pro), APOB (c.6936_6937delinsTG, p.Ile2313Val), PCSK9 (c.137G>T,
p.Arg46Leu), and PYGM (c.148C>T, p.Arg50Ter) and AR (c.185A>T, p.Gln62Leu;
c.1369_1380delGGCGGCGGCGGC, p.Gly470_Gly473del).
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NEUROD1, encoding the neurogenic differentiation 1 protein, is a transcription factor
involved in cell type determination during development. NEUROD1 is also important in
the regulating insulin gene expression. Mutations in NEUROD1 are associated with
mature-onset diabetes of the young 6 (MODY6) and autosomal dominant diabetes
mellitus179. The BSCL2 gene encodes seipin, an endoplasmic reticulum protein involved
in late pre-adipocyte differentiation and lipid droplet formation180. Mutations in BSCL2
are associated with CGL2, as discussed in Chapter 1. APOB encodes apolipoprotein B,
the main apolipoprotein on low density lipoproteins (LDLs) and chylomicrons181. Defects
in APOB are associated with autosomal dominant hypercholesterolemia. The prohormone
convertase 9 (PCSK9) gene encodes a serine protease involved in the elevation of plasma
LDL cholesterol and reduction of hepatic and extrahepatic LDL receptor levels182.
Mutations in PCSK9 are causative of autosomal dominant hypercholesterolemia, 3,
featuring significantly high cholesterol levels. The glycogen phosphorylase, muscle
associated (PYGM) gene or the muscle isoform of glycogen phosphorylase is involved in
the breakdown of glycogen during glycogenolysis183. Mutations in PYGM are associated
with glycogen storage disease type V (GSDV), a disease caused by the impaired
breakdown of glycogen. Due to this defective enzyme being unable to break down
glycogen, muscle cells cannot produce energy and become easily fatigued184. The AR
variant is further discussed in Section 4.2.3.
Together, I suggest that the variants within NEUROD1, BSCL2, APOB, PCSK9, PYGM
and AR are all contributing to the severe lipodystrophy phenotype of this young patient.
Further research is required to determine the pathogenicity of the novel variants and
determine whether these variants work synergistically (see Section 4.8 for details).

4.2.1.12 Patient 4194
In patient 4194, a female clinically diagnosed with acquired lipodystrophy, a variant in
the WRN gene (c.243T>G, p.Phe81Leu) was detected from WES. Variants in the WRN
gene are associated with Werner syndrome or adult progeria, characterized by dramatic
aging, abnormal fat deposition, diabetes mellitus, diminished infertility and
atherosclerosis185. More specifically, patients with Werner syndrome experience fat loss
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from the extremities with excess fat in the truncal region, similar to patients with
FPLD170. As Werner syndrome is generally caused by homozygous variants, I suggest
that this heterozygous variant is causing the milder phenotype seen in this patient.
As patient 4194 has a form of acquired lipodystrophy generally caused by environmental
effects, I also propose the possibility that this heterozygous variant in WRN could have
been activated by environmental factors, leading to the onset of lipodystrophy in this
patient. Note that this patient was not processed on the LipidSeq™ gene panel prior to
WES.

4.2.1.13 Patient 1120
After identifying a CREB3L3 duplication from LipidSeq™ targeted sequencing, the DNA
of patient 1120 was subjected to WES to investigate whether additional neighbouring
genes were also duplicated. From WES data and CNV analysis, the duplication in patient
1120 was found to span six genes: protein inhibitor of activated STAT 4 (PIAS4), zinc
finger and BTB domain containing 7A (ZBTB7A), mitogen-activated protein kinase
kinase 2 (MAP2K2), CREB3L3, SIRT6, and ankyrin repeat domain 24 (ANKRD24).
Interestingly, one of the duplicated genes is the SIRT6 gene, encoding the sirtuin-6
protein.
The sirtuin-6 or SIRT6 protein is a protein deacetylase and mono-ADP ribosyltransferase
enzyme activated under stress conditions186. SIRT6 is a major player in many pathways
associated with aging, such as glycolysis, lipid metabolism, inflammation and DNA
repair187. Mutations in SIRT6 are a major cause of progeroid diseases, which feature
lipodystrophy, kyphosis (excessive convex curvature of the spine), neurodegeneration,
immune deficiency, and metabolic defects188. Specific to metabolism, the SIRT6 protein
is considered the epigenetic gatekeeper of glucose metabolism, playing a key role in
glucose homeostasis. This role was demonstrated in SIRT6 knockout mice, where the
complete loss of subcutaneous fat and insulin hypersensitivity led to early mortality189,190.
As our patient harbours a duplication of SIRT6 in addition to CREB3L3, I propose that
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the lipodystrophy phenotype and metabolic abnormalities featured by this patient are
caused by this large CNV event.

4.2.2

Extreme early-onset obesity

The DNA of five children with extreme early-onset obesity were subjected to WES.
Candidate variants were identified in two patients from WES and bioinformatics
processing.

4.2.2.1

Patient 15544

In a male child with early-onset obesity, features of autism spectrum disorder,
developmental delay and overgrowth, candidate variants were detected in three genes:
BLK (c.244G>C, p.Gly82Arg), MC4R (c.751A>C) and AR (c.204_205insA, p.Gln69fs).
Further discussion on the AR gene is in Section 4.2.3.
The BLK gene encodes a non-receptor tyrosine kinase involved in cell proliferation and
differentiation. Playing a role in B-cell receptor signaling and development, this protein is
also known to stimulate insulin synthesis and secretion191. Mutations in BLK are
associated with mature-onset diabetes of the young (MODY11), characterized by
autosomal dominant diabetes and insulin-dependence192. As discussed in Chapter 1, the
MC4R gene is a member of the melanocortin receptor family that interacts with
adrenocorticotrophic hormones. Defects in this gene are known to cause autosomal
dominant obesity. The AR variant is discussed further in Section 4.2.3. Together, I
suggest that the defects in BLK, MC4R and AR are contributing to the extreme early-onset
obesity phenotype of this patient by modulating normal lipid metabolism.

4.2.2.2

Patient 15858

In a female child featuring extreme early-onset obesity, hyperphagia and intellectual
disability, a novel heterozygous missense variant (c.2645T>C, p.Ile882Thr) was
identified within the KMT2C gene. KMT2C encodes the lysine-specific methyltransferase
2C, a histone methyltransferase that regulates gene transcription through modification of
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chromatin structure. Particularly, KMT2C mediates the mono- and tri-methylation of
histone H3 at lysine 4193. In 2012, Kleefstra et al. discovered a dominant mutation in
KMT2C as causative for Kleefstra syndrome-2, a neurodevelopmental disease
characterized by delayed development, intellectual disability, childhood obesity, and
prominent facial features194. As the description of intellectual disability, obesity, and
facial features (hypertelorism, synophrys, carp mouth with macroglossia) of Kleefstra
syndrome matches the phenotype of the patient, I suggest that this child has a form of
Kleefstra syndrome-2195.
In addition to the dominant KMT2C variant, additional variants were identified in the
Bardet-Biedl Syndrome 10 (BBS10) and SET domain containing (lysine
methyltransferase) 8 (SETD8) gene. As variants in BBS10 are associated with BardetBiedl syndrome and variants in SETD8 are associated with adipogenesis and rodent
obesity, I suggest that these gene variants are also modulating the phenotype and causing
the extreme overgrowth and obesity features of this patient196,197. Further studies (such as
those outlined in Section 4.8) are necessary to confirm the pathogenicity of the KMT2C
variant and determine whether the SETD8 or BBS10 variants are involved in the disease
phenotype of this patient.

4.2.3

Lipodystrophy-obesity connection

With lipodystrophy and obesity, despite the fact that they sit on opposite ends of the
spectrum (excess versus absent adiposity), they share many metabolic complications
including diabetes mellitus, hypertriglyceridemia and hepatic steatosis. Furthermore,
although both disorders are widely heterogeneous in terms of underlying genes and
pathways, the diseases both feature severe insulin resistance, suggesting a commonality
between the two disorders and the potential for shared genetic variation198. To determine
whether there was a connection between lipodystrophy and obesity, I analyzed all
exomes for shared variation.
Altogether, over one million variants were identified in the 25 rare metabolic disease
exomes of interest. From the 25 exomes, ultra-rare androgen receptor gene (AR)

111

mutations were detected in 20%. These variants include missense mutations in two
familial partial lipodystrophy females, small deletions in three insulin resistant partial
lipodystrophy females, and a frameshift in a male child with extreme early-onset obesity.
Of these identified variants, four have never been recorded in the literature. Due to the
burden of ultra-rare AR mutations in these rare metabolic phenotypes, I suggest that the
AR gene may be the common link between lipodystrophy and extreme early-onset
obesity.
The AR gene encodes a DNA-binding transcription factor involved in the regulation of
gene expression. Activated by androgens, these androgen receptors allow the body to
appropriately respond to these hormones, playing critical roles in the reproductive,
muscular, skeletal, cardiovascular and central nervous systems. In the literature,
dysfunctional androgen levels have been known to predispose individuals to metabolic
abnormalities. More specifically, hyperandrogenism in women has shown to predispose
to T2D, and hypoandrogenism in men has been linked to insulin resistance and metabolic
syndrome199,200. Furthermore, androgen receptor-deficient mice have been shown to
develop obesity and metabolic dysfunction, further demonstrating the association
between aberrant AR and metabolic disease features201. Due to the high frequency of AR
variants in this cohort, I suggest that AR mutations are contributing to these metabolic
phenotypes by modulating the metabolic dysfunction in these patients.
Although these effects on metabolic syndrome are well established, our study is the first
to suggest a direct association between AR mutations, lipodystrophy and obesity. In
addition, because the burden of ultra-rare AR variants is specific to the N-terminal
domain (NTD), I suggest an important role of the NTD in metabolic function. Identifying
a common genetic factor for both lipodystrophy and extreme early-onset obesity can
allow for the understanding of the pathways controlling insulin sensitivity and glucose
uptake and allow for the development of therapeutic interventions for adipose tissue
disorders. In the future, I suggest assessing all lipodystrophy and obesity patients for AR
gene variation, and functional studies on the AR protein (additional details in Section
4.8).
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4.3

Whole-exome sequencing of rare disease families

For families with a history of rare disease referred to the Blackburn Cardiovascular
Genetics Laboratory (namely, BDA1 and cerebral atrophy-like), WES was performed on
the DNA of the proband followed by bioinformatics processing and variant curation.
From thousands of variants, one candidate variant was identified for each case. The
successful identification of candidate variants for both cases highlights the capability of
WES in identifying novel variants. Notably, the BDA1 case demonstrates the ability of
WES to clarify the genetic basis of “cold cases”.

4.3.1

Brachydactyly type A1A

Fifteen years ago, a 31-year-old female from Ontario was referred for medical
consultation at Dr. Hegele’s clinic for a lifelong history of short stature and shortening of
all digits of the upper and lower extremities. After discussion regarding her family
history, it was discovered that the brachydactyly phenotype co-segregated in her family.
After Sanger sequencing of all known brachydactyly-associated genes was performed at
the Blackburn Cardiovascular Laboratory, the family remained genetically unexplained
and the case was left untouched for 15 years. One patient sample was recently processed
using WES and analyzed for variants of interest. In this family, we report autosomal
dominant BDA1, characterized by short stature and shortened digits. Affected family
members carry a heterozygous in-frame insertion in IHH, designated c.285_287dupGAA,
p.Glu95_Asn96insLys, explaining their brachydactyly phenotype. This IHH variant is
predicted to exert a damaging effect on protein function from multiple in silico prediction
tools, co-segregates with disease status in the family, is considered novel in multiple
control population databases, and has not been previously reported in the literature.
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version of this section has been submitted for publication83.
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4.3.1.1

IHH and brachydactyly type A1

Previously, a genetic basis of BDA1 had been identified, with causative mutations
harboured in IHH77,202. Located at the chromosomal position 2q35-36, IHH encodes the
IHH protein, a member of the hedgehog family of proteins. Along with sonic and desert
hedgehog, IHH acts as a signaling molecule that regulates patterning processes in both
vertebrate and invertebrate development203. In vertebrates, the family is involved in limb
polarity and chondrogenesis, with IHH playing a critical role in human skeletal
development. IHH mutants show decreased chondrocyte maturation and proliferation,
and the failure of osteoblast development in endochondral bones, highlighting the role
that IHH plays in bone formation and cartilage differentiation204. The connection between
skeletogenesis and BDA1 has been solidified in Ihh-/- mice studies, where the loss of IHH
signaling leads to reduction defects in the forelimbs and digits205.
Several mutations have been identified in the IHH gene. Dominant mutations in IHH are
causative of BDA1, whereas recessive mutations in IHH have been linked to an extended
phenotype, acrocapitofemoral dysplasia, which features short stature, short limbs and
cone-shaped epiphyses206. All mutations responsible for BDA1 have been limited to the
N-terminal active fragment of IHH79. These mutations have been restricted to codon
positions 95, 100, 131 and 154, with ours as no exception. The prevalence of BDA1
mutations at these codon positions suggests they are mutation hotspots, with high
conservation of these amino acid positions existing between humans and species
including mice, chicken, frog and zebrafish207. This feature solidifies the importance of
the N-terminal region in bone development and differentiation, especially since mutations
causing acrocapitofemoral dysplasia differ and are exclusively at the distal N and C
terminal regions.
The IHH protein works through a feedback control mechanism. IHH binds to the
PTC1/patched receptor, which in turn, binds to SMO/smoothened to activate the Gli
complex of transcription factors. From there, these transcription factors continue to signal
and regulate downstream genes affecting patterning. Because IHH acts later in
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endochondral bone formation, mutations in IHH lead to the delay in bone growth and
subsequent digit abnormality. Studies on IHH-null mice uncovered the association
between IHH mutations and BDA1, as loss of IHH signaling leads to shortened forelimbs
and abnormal digits. We propose that our novel variant is acting in the same manner,
leading to digit reduction and shortened stature. More specifically, although our variant is
the first insertion identified in BDA1, we suggest that our variant acts similar to the
p.Glu95Lys missense mutation identified by Ma et al., where the mutation results in the
conversion of a negatively charged area to a positive area in a critical calcium-binding
groove207. In turn, this leads to instability of the N-terminal fragment, and the potential
increased intracellular degradation through the lysosome.

4.3.2

Cerebral atrophy-like

In 2013, our laboratory used homozygosity mapping and WES to identify the genetic
basis of a novel pediatric neurodegenerative disorder, autosomal recessive cerebral
atrophy. This phenotype is caused by a missense variant (c.995C>T, p.Thr332Met) in the
TMPRSS4 gene. Recently, our laboratory was referred a second case from India with a
high resemblance to the initial autosomal recessive cerebral atrophy case. More
specifically, the patient displayed microcephaly and cerebral atrophy. Using Sanger
sequencing of the region containing the previously identified TMPRSS4 variant, I sought
to determine whether this phenotype shared the same genetic basis. When no variants
were identified from Sanger sequencing, I pursued WES to identify novel diseaseassociated variants. From WES and bioinformatics processing of the proband’s exome, I
identified a variant in the kinetochore scaffold 1 gene (CASC5; c.6485A>G,
p.Glu2162Gly) matching the phenotype of the proband.

4.3.2.1

CASC5 and primary microcephaly-4

During cell division, genetic material must be accurately transmitted from parent to
daughter cells. To ensure this, eukaryotes couple the movement of spindle microtubules
to replicated chromosomes through a multi-protein attachment complex termed the
kinetochore. The kinetochore is a disc-shaped protein that holds the sister chromatids
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together during cell division. In total, kinetochores perform four functions: 1) create a
sturdy interface with centromeric chromatin, 2) contribute a microtubule-binding
interface, 3) generate the spindle assembly checkpoint, and 4) correct improper
attachments208. Even the simplest kinetochores consist of over 19 proteins, with all
proteins highly conserved among eukaryotes. One such protein that localizes to the
kinetochore is the kinetochore scaffold 1 protein, encoded by the CASC5 gene. This
protein is pertinent for two events: the accurate attachment of centromeres to the
microtubules, and spindle-assembly checkpoint signaling209.
Microcephaly, Primary Hereditary (MCPH) is a neurodevelopmental disorder featuring
intellectual disability coupled with microcephaly from birth, where the microcephaly is
caused by the reduction of the cerebral cortex. To date, several causative genes have been
identified, including: microcephalin, CDK5 Regulatory Subunit Associated Protein 2
(CDK5RAP2), Abnormal Spindle Microtubule Assembly (ASPM), Centrosomal Protein
135 (CEP135), Centrosomal Protein 152 (CEP152) and CASC5210. Although each of
these genes play a unique role in the pathogenesis of MCPH, each is predicted to cause
MCPH by disturbing mitotic spindle orientation, causing premature chromosomal
condensation, or affecting microtubule dynamics211.
Specifically, variants in the CASC5 gene cause microcephaly 4, primary, autosomal
recessive – a form of MCPH featuring brain reduction and mental handicap209. Although
the pathophysiological mechanism has not been resolved, it is thought that variants in
CASC5 affect the ability for CASC5 to bind the mitotic spindle checkpoint protein,
BUBR1, an essential component of the mitotic checkpoint212. Variants in BUBR1 are
associated with Mosaic Variegated Aneuploidy (MVA) Syndrome 1, a phenotype
attributed to a mitotic chromosomal segregation defect leading to aneuploidy213. Due to
the required direct interaction between CASC5 and BUBR1, it is suggested that defects in
CASC5 are pathogenic by way of a common mechanism involving chromosome
missegregation. As our variant is in the same exon as known, classified microcephaly-4
variants, I suggest that our variant acts in a similar fashion, causing chromosome
missegregation, and allowing premature entry into mitosis.
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4.4

Whole-exome sequencing for CARE for RARE

and FORGE Canada projects
For families ascertained through clinicians as part of the CARE4RARE and FORGE
Canada projects, WES was performed on the DNA of the probands followed by
bioinformatics processing and variant curation. From thousands of variants, candidate
variants were narrowed down for eight of the 11 total cases. The successful identification
of candidate variants for these rare disease cases demonstrates the utility of WES in
identifying novel variants. Furthermore, as this was the effort of numerous clinicians and
scientists, it emphasizes the importance of collaboration in the discovery of the genetic
basis of rare diseases. Herein, I discuss two cases, microcephaly-ichthyosis and widow’s
peak syndrome, and briefly summarize the project.

4.4.1

Microcephaly-ichthyosis in the Old Order Amish

The Old Order Amish are a North American religious group from Anabaptist origins. In
Canada, the majority of the Old Order settlements are within Ontario, mainly in the
Norfolk and Bruce counties. Due to social isolation, the founder effect (loss of genetic
variation in an area established by a small number of individuals), and the many genetic
bottleneck events in Amish history, there is a high incidence of particular genetic
disorders among the Old Order Amish214. This is due to the autozygosity – chromosomal
segments or alleles that are identical-by-descent due to consanguineous mating – often
present in the Old Order Amish population.
In an Old Order Amish family with a history of microcephaly and ichthyosis, WES,
bioinformatics processing and variant detection was performed. From WES on the DNA
of the proband, a novel frameshift insertion was identified in the VPS52 gene (c.57delG,
p.Thr20fs). This variant results in a premature stop codon 30 amino acids from the start
site, ultimately leading to deletion of 90% of the protein. Furthermore, this frameshift
variant co-segregates with disease status in the pedigree, is predicted to be pathogenic
from in silico prediction tools, is not present in any disease database, and has not been
reported previously in the literature. This variant is also harboured within an autozygous
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block in the family, 6p22.2p21.2. Due to the severity of the frameshift and the association
of the gene defects with the phenotype, I propose that the VPS52 variant is causing the
recurring microcephaly-ichthyosis phenotype in this family.
The VPS52 gene encodes the vacuolar protein sorting-52 protein, a component of the
Golgi associated retrograde protein (GARP) complex. The GARP complex is a large
complex involved in the retrograde transport of proteins from endosomes to the transGolgi network215. Moreover, the GARP complex is a tetrameric complex consisting of
four proteins, VPS51, VPS52, VPS53 and VPS54. These four proteins tether together to
fulfil retrograde vesicle trafficking.
Vps52 acts to support the growth and pluripotent differentiation of the embryonic
ectoderm through cell-cell interactions in extraembryonic tissues. Null mutations in
Vps52 have been shown to cause early embryonic lethality, ectoderm death, and
gastrulation defects in murine models216. Furthermore, Vps52 knockouts result in the
complete loss of GARP function215. Due to the similarity between the consequences of
null Vps52 and the microcephaly-ichthyosis phenotype in this family, I predict that the
variants in VPS52 are causative of the disease. More specifically, as the ectoderm is
responsible for skin formation and there is embryonic lethality in the affected individuals,
I suggest that the VPS52 frameshift variant is causative of the microcephaly-ichthyosis
lethal phenotype. Functional studies are required to confirm that the variant is indeed
causing the microcephaly-ichthyosis phenotype in this family.

4.4.2

Widow’s peak syndrome

Widow’s peak syndrome is an ultra-rare X-linked dominant disease featuring a prominent
widow’s peak (pointed frontal hairline), facial abnormalities and skeletal anomalies.
Described by Kapur et al. in 1989, widow’s peak syndrome has only been reported once
previously in the literature217. Through CARE4RARE, we report a second case of
widow’s peak syndrome with matching features, namely, a pointed frontal hairline,
epiphyseal dysplasia (disorder of bone and cartilage development affecting the long
bones or epiphyses in the arms and legs), rotated ears, bilateral ptosis (drooping of both
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eyelids) and knee joint issues. From WES, bioinformatics processing and variant
detection, I report a novel splicing variant in KDM6A (c.2703-6_2703-5delTT), predicted
to be pathogenic from in silico prediction tools. Using Sanger sequencing, this variant
was found to co-segregate with disease status in the family.
Mutations in KDM6A are causative of Kabuki syndrome-2, a congenital syndrome
featuring intellectual disability, facial anomalies (long palpebral fissures and eversion of
the eyelids), prominent ears, scoliosis, and radiographic abnormalities218,219. Due to the
overlapping clinical features of widow’s peak syndrome and Kabuki syndrome-2, I
suggest that this family features a novel disease overlapping with these syndromes.
Furthermore, I propose a potential link between these exclusive disorders. Due to the
presence of the variant in a polyT region, it is necessary to quantitatively confirm the
KDM6A variant. SNaPshot Multiplex sequencing was unsuccessful in confirming the
variant, therefore, it is necessary to perform reverse transcription polymerase chain
reaction (RT-PCR) in the future. To date, RNA extraction has been done and RT-PCR is
ongoing.

4.4.3

CARE for RARE and FORGE summary

In summary, eight of 11 CARE4RARE and FORGE Canada Cases in the Blackburn
Cardiovascular Genetics Laboratory were solved using WES and bioinformatics analysis,
highlighting the utility of WES in gene discovery. The cases with candidate variants
identified are microcephaly-ichthyosis, autosomal dominant isolated cryptophthalmos,
widow’s peak syndrome, amyoplasia, metaphyseal chondrodysplasia, craniosynostosis,
heterotaxy disorder, and craniorachischisis. Each aforementioned case requires functional
assessment in order to confirm the pathogenicity of the variants of interest. For the
remaining cases, namely, Angelman-like syndrome, dystonia, ataxia and intellectual
disability, and osteopetrosis, it is necessary to consider factors beyond the exome.

4.5

Gene enrichment analysis

From PANTHER computing and analysis on data from patients with lipodystrophy and
extreme early-onset obesity, two patients with partial lipodystrophy were found to
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harbour variants with significant overrepresentation in specific biological pathways.
Namely, patient 14318 had overrepresentation of genes involved in O-glycan processing
and tissue homeostasis, and patient 11618 had overrepresentation of genes involved in
interferon-gamma-mediated signaling (PANTHER outputs in Appendix IV).
The O-glycan processing pathway is involved in adding a carbohydrate or carbohydrate
derivative to an O-linked residue to form a core O-glycan structure. As these genes are
fundamental, defects in this pathway often result in severe metabolic perturbations or
embryonic lethality220. For patient 14318, there was a 5.11-fold enrichment of genes
involved in this biological process. Therefore, variants in genes involved in O-glycan
processing were considered for association with lipodystrophy. From this gene list
associated with O-glycan processing, most of the genes involved were those belonging to
the mucin gene family. As mucin genes are highly polymorphic with variable number
tandem repeat (VNTR) length polymorphisms, these variants were excluded as they are
likely unassociated with the lipodystrophy in this patient221,222.
Genes involved in maintaining tissue homeostasis are those that regulate somatic stem
cell activity223. In patient 14318 there was a 3.35-fold enrichment of genes involved in
this biological process. For the list of overrepresented genes in patient 14318 involved in
tissue homeostasis, each gene was examined for association with lipodystrophy. As there
was no literature supporting an association between each gene and/or variant with
lipodystrophy, these genes were not prioritized as candidates. Although there is no
available literature supporting these genes now, future work should continue to
investigate the variants within these genes for their potential contribution to
lipodystrophy.
For patient 11618, genes involved in interferon-gamma mediated signaling were
overrepresented. More specifically, there was 6.54-fold enrichment of the genes in this
pathway. As most of these genes were human leukocyte antigen (HLA) genes with a high
degree of polymorphism, they were deemed unassociated with the lipodystrophy in this
patient.
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In sum, although PANTHER was helpful in identifying overrepresented biological
processes in these patients, no gene lists generated from PANTHER are predicted to
contribute to the partial lipodystrophy phenotypes of these patients.

4.6

Clinical utility of LipidSeq™ and whole-exome

sequencing
From the utilization of the LipidSeq™ resequencing gene panel, 40% of a 153-person
lipodystrophy cohort was, at least partially, genetically explained. From WES, 65% of
lipodystrophy patients, 40% of extreme early-onset obesity patients, two rare disease
cases (brachydactyly type A1 and cerebral atrophy-like), and 73% of
CARE4RARE/FORGE Canada cases had candidate variants identified. Together, these
statistics indicate the clinical utility of NGS, especially in the context of variant discovery
in rare disease research.

4.6.1

Comparison of LipidSeq™ and whole-exome

sequencing to whole-genome sequencing
As some cases remained genetically unexplained following the implementation of
LipidSeq™ and WES, it begs the question whether WGS would have been preferred.
Here, I argue that although WGS is capable of sequencing almost all three-billion base
pairs of the human genome, compared to 2% with WES and even less with targeted
sequencing, LipidSeq™ and WES are still superior to WGS for rare disease research.
With WGS, there are several implications affecting clinicians, researchers and patients.
These implications refer to data yield, interpretation and ethics.
Although the diagnostic yield is greater with WGS, there are several issues concerning
amassing such a wealth of data. In terms of computational storage, it is impractical for
most laboratories to store such data. Furthermore, the processing of the data require high
computational and statistical power, often unavailable at a cost-efficient rate. As large
cohorts would need to be processed and screened to result in a clinical outcome, it is
unfeasible for most laboratories to advance towards the sole use of WGS. In addition, the
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body of literature regarding intergenic regions and their role in disease is sparse. Without
an abundance of information on these regions or a universal standard for their
interpretation, it is difficult for providers to assess risk without creating false reassurance
or needless worry. Last, there are several ethical implications regarding the availability of
such data. Without distinct laws in place on genetic discrimination, issues may arise
when patients with WES data try to obtain insurance. Additionally, with an almost
guaranteed likelihood of incidental findings, there is apprehension to progress towards
WGS. As WGS has shown to only offer limited clinical utility compared to WES (only
3% increased detection in a recent study), WES is recommended over WGS224.

4.7

Limitations of the project

Although I demonstrated the clinical utility of NGS in solving or clarifying the molecular
basis of rare disorders, there are limitations and study caveats to consider. These caveats
are divided to those specific to this project, and those specific to the use of targeted
panels and WES technology.

4.7.1
1)

Study considerations
Acquired lipodystrophy cases

In this study, I relied on an assumption that all the lipodystrophy cases were genetic. For
many patients in our lipodystrophy cohort, it is likely that some of these lipodystrophy
cases are acquired with no inherited component. The presence of acquired lipodystrophy
cases was demonstrated when it was determined that four patients subjected to WES had
acquired lipodystrophy. Acquired lipodystrophy refers to lipodystrophy that sporadically
appears during a random point in life. As up to 70% of human immunodeficiency virus
(HIV)-infected individuals on highly active antiretroviral therapy (HAART) therapy
report to have HIV-associated lipodystrophy, it is likely that some forms of lipodystrophy
are drug-related or environmental225. The study of these cases may have caused an
underestimation of the clinical utility of LipidSeq™ and WES. In the future, it is
necessary to consider these cases separately in order to refrain from any bias in the
results.
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2)

Limited clinical information

For some of the cases listed in this MSc Thesis, clinical information was limited.
Moreover, some of the cases were referred from external physicians to the laboratory
leading to inconsistencies in clinical diagnosis. As additional clinical information would
have streamlined the variant prioritization process (i.e. if information was available on
mode of inheritance, secondary complications, etc.) and potentially changed the outcome
of cases, this was an inherent limitation of the study.
3)

Lack of trios and families

For many of the pediatric cases and those affecting multiple members in a family, one
frequent challenge was the inaccessibility of patient samples. Regardless of whether it
was due to lack of proximity of the patients or lack of willingness to participate in genetic
research, the inaccessibility of patient samples made it difficult to confirm variants, cosegregation and pathogenicity. To account for the unavailable DNA samples, I used
numerous databases; however, it would have been beneficial to ascertain these samples to
perform trio and family analysis.
Furthermore, as rare diseases are so uncommon it can often be more challenging to study
these diseases due to small sample size. In this study, some cases were limited to a single
affected individual. This n-of-1 problem also contributed to the difficulty in confirming
variants and pathogenicity.

4.7.2

General methodological limitations

In general, there are numerous limitations with targeted sequencing and WES. With these
methods, several genetic factors are not considered. These include large rearrangements,
mitochondrial gene mutations, epigenetic factors, uniparental disomy, environmental
effects, and mutations in repetitive and GC-rich regions. As these were not investigated, I
may be lacking all the information necessary to genetically explain each patient or rare
disease case.
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4.8

Future directions

From this MSc Thesis, there are several considerations in terms of future directions.
These include those specific to this project and those necessary for the rare disease
research field. These are separated into their respective categories below.
Future work for the project
From here, future work for this project will require focus on confirming the WES results
and ensuring the disease-causing criteria for candidate variants are fulfilled. For cases
with a candidate variant or multiple variants identified, validation and co-segregation
analyses should be performed if not done so already. For all candidate CNVs identified,
secondary validation using an independent method (i.e. Sanger sequencing or
CytoScan™ HD) should be done. Ultimately, functional studies are required to confirm
the pathogenicity of each CNV in causing the disease of interest. These studies are
recommended for all novel variants, particularly the CARE4RARE and FORGE Canada
cases, and are listed in the following sub-section. For those cases in which a candidate
variant (or multiple candidate variants) was not identified, the exome data should be
revisited and re-evaluated using less stringent criteria (i.e. higher minor allele frequencies
and lower read depth stringency) and other factors, as discussed in the following section,
should be considered.
Functional assessments to be considered for this project
For those cases in which a candidate variant was identified using NGS – namely the
lipodystrophy, extreme early-onset obesity, brachydactyly, cerebral atrophy-like and
solved CARE4RARE/FORGE Canada cases – it is suggested that functional assessments
be undertaken to confirm the validity and pathogenicity of the candidate variants. These
experiments may include, but are not limited to the following:
1)

Western blotting

A Western blot is an analytic method used in molecular biology to identify specific
protein molecules from a mixture of proteins extracted from cells. By separating based on
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size, transferring to a solid support, and using a primary and secondary antibody to
visualize a target protein, Western blotting can elucidate the molecular weight of a
protein of interest226.
For this project, Western blotting can be used as a first tier assessment of whether a
protein product is present or absent. More specifically, Western blotting can allude to
whether the defective gene results in abnormal protein expression. If Western blotting
demonstrates a change in expression, additional studies may be pursued to determine if
the protein product is dysfunctional.
2)

mRNA quantification (RT-qPCR)

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) is a technology
used to analyze RNA expression. By converting labile RNA to more stable
complementary DNA (cDNA) using a reverse transcriptase and using real-time
fluorescence to quantify the quantity of DNA present at each cycle during PCR, RTqPCR can be used for measuring gene expression and copy-number variation227. In this
study, RT-qPCR can be used to determine differences in mRNA expression between
patients with genetic variants and control samples. Additionally, this technique can allow
for independent confirmation of NGS results228.
3)

Co-immunoprecipitation

In a cell, two or more proteins can interact and lead to biological effects. Coimmunoprecipitation (co-IP) is a common method used to analyze protein-protein
interactions. Briefly, in co-IP the protein of interest is isolated using a specific antibody,
and interacting partners are identified by subsequent Western blotting229. In this project,
co-IP may be a useful technique in determining AR protein interactions. Furthermore,
with the lipodystrophy patients harbouring variants in multiple genes, co-IP may be
useful in elucidating protein interactions.
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4)

Molecular studies

In molecular biology, molecular studies and model systems are common methods used to
study the biological consequences of the genetic variation underlying human diseases.
These studies may include in vitro assays, ex vivo studies, or in vivo models.
In vitro assays are those used to determine whether gene products are defective and/or
disrupt downstream pathways. These assays typically introduce the variant into the DNA
of an artificial system to assess the biological effects on protein function and connecting
pathways. Ex vivo studies are those that are generally performed on extracted patient
tissues. Experiments to determine gene expression or protein interactions are pursued
with patient-derived cells to investigate the pathogenicity of a candidate variant. In vivo
experiments are those done within a model system. Common model organisms include
Drosophila melanogaster (fruit flies), Caenorhabditis elegans (roundworms), Danio
rerio (zebrafish) and mus musculus (mice). Model organisms are an efficient and
effective strategy, as you can manipulate the genome of the animal and investigate the
resultant phenotype.
In this project, molecular studies would be useful to confirm that the novel candidate
variants discovered are indeed pathogenic.
Further considerations for the project
For those cases in which a candidate variant was not identified – namely Angelman-like
syndrome; osteopetrosis; dystonia, ataxia and intellectual disability; remaining
lipodystrophy cases; and the remaining extreme early-onset obesity cases – it is necessary
to consider other genetic factors or determinants of disease. Here I list some avenues that
are being pursued, and others that are options for the future:
1)

Mosaicism

Mosaicism describes a situation where different cells in an individual carry a distinct
number of chromosomes or chromosomal arrangements. This is demonstrated as the
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presence of two genotypes in a single individual from a single egg230. Mosaicism is often
the cause of sporadic disease in affected individuals with unaffected parents231.
In one study, I took mosaicism into account when analysing the LipidSeq™ results of a
child with prenatal hypoglycemia. This child could not be explained solely by a
heterozygous mutation in KCNJ11. After consideration of mosaicism, it was determined
through surgery and DNA testing that the child harboured somatic ABCC8 mutations in
her pancreas. Together, the KCNJ11 and ABCC8 variants explained her phenotype.
2)

Splicing

Splice variants play a central role in the diversification of genomes and in cellular
function. Furthermore, splice sites are associated with disease states and may drive
disease phenotypes232. As exonic regions were prioritized more in this study, it is
necessary to retroactively consider splicing variants, especially those more distal to the
exons.
Recently, my laboratory began a collaboration with Dr. Brendan Frey of the University of
Toronto in order to classify splice variants and use algorithms to predict the pathogenicity
of each splice variant. Continued work on understanding these splice region variants and
their contribution to disease will be pursued in the future.
3)

Chromosomal rearrangements

Chromosomal rearrangements involve large structural changes including deletions,
duplications, inversions and translocations. As the DNA is sheared prior to WES and the
WES kit only captures ~150-bp reads, it is necessary to consider cytogenetic techniques
to determine whether chromosomal rearrangements may be involved.
4)

Regulatory regions

Regulatory regions are one of the mechanisms through which protein levels are
controlled. Regulatory regions include promoters, enhancers, silencers and insulators233.
As much of the regulatory content is harboured within intergenic DNA not sequenced
through WES, it is imperative that the sequence of these regions be considered.
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5)

Digenic disorders

Digenic disorders refer to those diseases where mutations on two genes interact to cause
the phenotype234. In this MSc Thesis, I consistently use knowledge of candidate genes
and protein-protein interactions in order to consider the possibility of digenic inheritance.
Future work will continue to explore the prospect of digenic inheritance by keeping up
with current literature and continually checking for newly elucidated interactions between
candidate genes.
6)

Polygenic disorders

Polygenic diseases are those caused by the contribution of numerous distinct or
interacting genes53. Generally, in these disorders each variant contributes a small-tomoderate effect on the phenotype, cumulatively causing the disease. To determine
whether the genetic basis of any of the unsolved cases are polygenic, it would be
necessary to perform a GWAS to identify genetic loci associated with the disease. From
there, it would be possible to develop a polygenic risk score – a metric that summarizes
all genome-wide genotype data to predict the genetic risk of a disorder – to determine
risk for disease235.
7)

Matchmaker Exchange

Due to the scarcity of rare diseases and the small datasets in each laboratory for each rare
disease case, it is necessary for data sharing in the research community. The Matchmaker
Exchange (MME) platform was designed to provide a robust approach to gene discovery
through the creation of a network connecting databases of rare phenotypes and genotypes
using a programming interface236. Put simply, MME is a platform allowing clinicians,
physicians and patients to connect with the hope for serendipitous occasions where two
investigators learn that they share similar rare disease cases (i.e. cases with similar
features or symptoms). So far, the Angelman-like syndrome case has been input into
MME, with other CARE4RARE and FORGE Canada cases to follow if necessary.
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8)

Epigenetics

The term “epigenetics” refers to a change in gene expression without a change in DNA
sequence. These modifications in gene expression may be through changes in
methylation or acetylation. As epigenetics has been shown to play a large role in
phenotypic traits and disease, it is necessary to consider epigenetic mechanisms of
disease. In the future, it may be necessary to explore epigenetic changes. For example,
future work could include the use of bisulfite genomic sequencing – a method to detect
changes in DNA methylation through the conversion of genomic DNA with sodium
bisulfite – to evaluate the epigenetic landscape of each unsolved disease.
Future directions for the rare disease research field
For the rare disease research field, there is an ample amount of work that needs to be
done. Three main points that should be focused on are: 1) the standardization of variant
interpretation and analysis; 2) the conversion of all data to open-source; and 3) the
increase in awareness of rare diseases. With candidate variant interpretation, it is
necessary for all clinicians and researchers to conform to a standard set of guidelines to
ease communication and promote collaboration. In this study, I considered the ACMG
standards and guidelines for variant interpretation126. I suggest the adoption of these
guidelines across the field to 1) promote a universal standard of variant interpretation and
2) reduce any possible contradictions regarding variant interpretation. I also encourage
that all data be open-source and accessible. As rare diseases are extremely difficult to
study due to small sample sizes and low statistical power, it is necessary that all
investigators make their data publically available to allow for further and faster
advancements within the field. Last, I advocate for increased awareness of rare diseases.
As individuals with rare diseases face a diagnostic odyssey, it is necessary to increase the
awareness of these diseases to pave the way towards the end of the diagnostic odyssey for
these patients. By raising awareness with policy makers, researchers, physicians and the
public, it may translate to greater research funding and research interest, more robust
diagnoses in the clinic, and ultimately, the elucidation of molecular mechanisms and
potentially, novel treatments or cures in the future.
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4.9

Conclusions

NGS technologies, including targeted resequencing panels and WES, are highly robust,
efficient and cost-effective approaches in the diagnosis of rare disorders. In this MSc
Thesis, I have effectively achieved my goal: to demonstrate the utility of NGS in rare
disease research, the laboratory and the clinic, and identify a molecular basis for rare
disease patients and families of interest. More specifically, I have fulfilled my aims to
apply NGS technologies to detect genetic variants and CNVs, identify rare variants
underlying disease phenotypes, determine the functional relevance of these variants using
in silico tools, and perform variant validation studies to determine whether the variants
co-segregate with disease status in families.
More specifically, by processing 153 patients clinically diagnosed with lipodystrophy
through the LipidSeq™, a custom gene panel used for the clinical diagnosis of
monogenic dyslipidemias, 81 variants in 14 lipodystrophy-associated genes (LMNA,
PPARG, PLIN1, CIDEC, LIPE, LPIN1, AGPAT2, BSCL2, CAV1, AKT2, PTRF,
DYRK1B, POLD1 and WRN) were identified within 58 patients. Furthermore, an
additional seven CNV events were detected in seven patients with lipodystrophy, namely
duplications in PLIN1, MFN2, APOA5/APOA4, CREB3L3 and deletions in AGPAT2,
PLIN1 and CIDEC. This is the first report of systematically screening for CNV events,
and these represent the first CNVs identified in patients with lipodystrophy.
Twenty patients with lipodystrophy and five patients with extreme early-onset obesity
were subjected to WES and bioinformatics analysis. From WES, candidate variants were
discovered in 13 patients with lipodystrophy and two with extreme early-onset obesity in
the following genes: ISCU, HSPG2, LDLR, PDRM16, ZMPSTE24, FLNC, GALC, AR,
ABCA4, WRN, ABCG8, FHL1, ANLN, LPL, FN1, PAPSS2, NEUROD1, BSCL2, APOB,
PCSK9, PYGM, BLK, MC4R, BBS10, SETD8, and KMT2C. Furthermore, two of two rare
disease cases (brachydactyly type A1, IHH; cerebral atrophy-like, CASC5) and eight of
11 CARE4RARE/FORGE Canada had candidate variants identified from WES data and
bioinformatics processing. The successful identification of candidate genes and the
clarification of the genetic determinants underlying many of these rare disease cases
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demonstrate the power of WES in rare disease research. Additionally, as many of these
genetic variants have never been reported, these results highlight the effectiveness of
NGS in detecting novel genetic variation.
In sum, in my MSc Thesis project I have identified novel disease-associated genes,
characterized novel variants, and demonstrated the utility of targeted sequencing and
WES in clarifying the genetic basis of rare genetic diseases. Furthermore, I have provided
instructions on how to perform NGS and bioinformatics in a robust, efficient manner, and
effectively ended the diagnostic odyssey for some patients through the identification of
candidate variants. Understanding these genetic variants and their association with each
will lead to many positive implications, most importantly, benefits to families, changes in
treatment options for genetically explained patients, and added knowledge for the field.

4.10

Project significance

Broadly, many significant outcomes may result from this MSc Thesis. These outcomes
take three forms: benefits to the family, therapeutic benefits, and scientific benefits. On
the family level, identifying the molecular basis of these rare diseases can allow for
several positive outcomes. First, it can allow the physician to assign a definitive name of
the condition. Although this may not lead to altered management, this may allow the
individual or the family to find support in community groups or the scientific literature.
Second, it marks the end of the diagnostic odyssey. As a tumultuous journey for
individuals, the end of the diagnostic odyssey may prevent unnecessary tests,
prescriptions or consultations. Third, it may open the door for preventative medicine. For
example, one clinical story describes a lipodystrophy patient whose LMNA mutation
discovery encouraged physicians to approach her case differently. This enabled the
detection of a severe cardiac rhythm disorder, and allowed subsequent life-saving
treatment237. Last, it may provide recurrence risk for future pregnancies. The
understanding of recurrence may allow for advanced family planning and preparation on
the psychosocial level.

131

The second significant outcome of this research is the effect that these results have on
treatment options for an affected individual. Through a genetic diagnosis, a physician
may be able to offer a change in surveillance, or modification in medication. These
alterations may provide an improved prognosis for an individual.
The third outcome of genetic variant discovery are the benefits that these results have on
the rare disease research field. By identifying a genetic basis of a rare disorder, the results
may provide insight on both normal and disease pathways and pave the way towards the
development of novel therapeutic interventions.
In addition to the positive implications on rare disease research, the application of NGS
technologies in rare disease research also has significant implications on the field. More
specifically, by demonstrating the clinical utility of LipidSeq™ and WES for rare disease
cases, we can encourage other researchers or clinicians to use these methods when
investigating the genetic basis of rare disease phenotypes.
In sum, identifying the molecular bases of rare disorders using NGS technologies
demonstrated the power of NGS as a clinical diagnostic tool, and contributed the first
step towards the long-term goal – to develop novel treatments and end the diagnostic
odyssey for these rare disease patients.
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Appendix III: Primer List
Gene

Primer Names

Primer Sequence (5’-3’)

IHH

Forward
Reverse

CTCGCCTACAAGCAGTTCAGC
AAAATGTGCCAGGGGGTGGGTAG

TMPRSS4

Forward
Reverse

CCGGGAAAGGCTGAGTAACAAAAC
GATAGTCTTAGCCCAGGTTTCTC

AR*

AR1-F1
AR1-F2
AR1-R5
AR1-F3
AR1-R4
AR1-F4
AR1-R3
AR1-F5
AR1-R2
AR1-R1
AR2-FWD
AR2-REV
AR3-FWD
AR3-REV
AR4-FWD
AR4-REV
AR5-FWD
AR5-REV
AR6-FWD
AR6-REV
AR7-FWD
AR7-REV
AR8-FWD
AR8-REV
Forward
Reverse

GTTGAACTCTTCTGAGCAAGAG
GGATGAGGAACAGCAACCTTCAC
GTGAAGGTTGCTGTTCCTCATCC
CCAAGGACAATTACTTAGGGG
CCCCTAAGTAATTGTCCTTGG
CAAAGGGCTAGAAGGCGAGAGCC
GGCTCTCGCCTTCTAGCCCTTTG
GAAGAAGGCCAGTTGTATGG
CCATACAACTGGCCTTCTTC
GAACACAGAGTGACTCTGCCCTG
GACCTGAGACTTCACTTGCC
CCCTGAAAGGTTAGTGTCTCTC
CCCGAAGAAAGAGACTCTGGAAAC
GACTAGAAAATGAGGGAGAAGGGG
CTATGTCACCCAGGCTAGAGC
GGATTTCACCAGGCAAAGGTG
CTCAACCCGTCAGTACCCAG
CCATCACCACCAACCAGGTCTG
GAGGGATGGCAATCAGAGAC
GTCCTCTCTGAATCTCTGTGC
CTAATGCTCCTTCGTGGGCATG
CATTGGCTCTATCAGGCTGTTC
GAAGAGGCTAGCAGAGGCCAC
CAGGCAGAAGACATCTGAAAGG
CTTCAGCTCTGCCACCTACC
AAGAGGAGCCTGTTGTGTGG

VPS52

Forward
Reverse

GCTAAGAGAACAGCGAAGGTTCCG
CAGCTCAGGTCTTTCTGAAGCTAGG

KDM6A

Forward
Reverse

CATCTCATGGACTTGTGCAAATGCC
GTGGTCTTGGAGGTGGACATTTATC

PLIN1

*AR primer naming method: geneexon-Forward/Reverse(number if necessary)
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Appendix IV: PANTHER gene lists
Patient 14318, O-glycan processing

158

Patient 14318, tissue homeostasis

159

Patient 11618, interferon-gamma-mediated signaling
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Presented at the Robarts Research Retreat at Kings University College, London ON
Determining the genetic basis of rare diseases using whole-exome sequencing:
Brachydactyly type A1 (April 23, 2017)  Presented at the Canadian Human and
Statistical Genetics Meeting at Le Chateau Frontenac, Quebec City QC
Ultra rare androgen receptor mutations in metabolic phenotypes (March 28, 2017)
 Presented at London Health Research Day 2017 at the Convention Centre, London
ON
Determining the molecular basis of rare disorders using whole-exome sequencing
(January 20, 2017)  Presented at the Harold B. Stewart Memorial Lecture at Western
University, London ON
Absence of Protective APOC3 Mutations in Dyslipidemic Patients (August 2014) 
Presented at Western University’s Biochemistry Undergraduate Summer Research
Program (BUSRP) Presentation Day
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ORAL PRESENTATIONS
Novel CNVs in patients with inherited lipodystrophy (June 13, 2018)  Presented at
the Department of Biochemistry Graduate Student Spring Symposium at Western
University, London ON
The identification of novel CNVs in patients with inherited lipodystrophy (June 11,
2018)  Presented at the International Symposium on Atherosclerosis at the Toronto
Metro Convention Centre, Toronto ON
The identification of novel CNVs in patients with inherited lipodystrophy (June 1,
2018)  Presented at the Robarts Research Retreat at King’s University College, London
ON
* Won a monetary award ($100) and my name engraved on a plaque
Connecting extreme ends of the spectrum: obesity and lipodystrophy (January 10,
2018)  Presented at the Molecular Data Club at Robarts Research Institute, London ON
Genetic testing: finding the needle in a haystack (September 29, 2017)  Presented
with Strong Brains, Strong Minds, Strong Muscles at the Kiwanis Senior’s Centre,
London ON
Determining the genetic basis of rare diseases using whole-exome sequencing:
Brachydactyly type A1 (June 20, 2017)  Presented at the Robarts Research Retreat at
King’s University College, London ON
Determining the genetic basis of rare diseases using whole-exome sequencing (May
31, 2017)  Presented at the Molecular Data Club at Robarts Research Institute, London
ON
Determining the genetic basis of rare diseases using whole-exome sequencing:
Brachydactyly type A1 (April 22-25, 2017)  Selected to present at the Canadian
Human and Statistical Genetics Meeting at Le Chateau Frontenac, Quebec City QC
Gene hunting: determining the molecular basis of lipodystrophy using whole-exome
sequencing (March 21-22, 2015)  Presented at Ontario Biology Day at Carleton
University, Ottawa ON
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CONFERENCES/EDUCATIONAL EVENTS
American Society of Human Genetics 2017 Annual Conference (presented)
October 2017
Hosted by the American Society of Human Genetics at the Orange County Convention
Centre, Orlando USA
Robarts Research Retreat (presented)
June 2017
Hosted by Robarts Research Institute at King’s University College, London ON
Sixth Annual Canadian Human and Statistical Genetics Meeting (presented)
April 2017
Hosted by the Canadian Institute of Health Research, Le Chateau Frontenac, Quebec City
QC
London Health Research Day (presented)
March 2017
Hosted by Schulich School of Medicine and Dentistry, at the Convention Centre, London
ON
Harold B. Stewart Memorial Lecture (presented)
January 2017
Schulich School of Medicine and Dentistry, Western University, London ON
Genetics in Your Practice Education Day (participated)
November 2016
Hosted by the Medical Genetics Program of Southwestern Ontario, at the Sheraton,
London ON
Ontario Biology Day (presented)
March 2015
Carleton University, Ottawa ON
Biology and Environmental Sciences Research Day (presented)
March 2015
Department of Biology, Western University, London ON
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VOLUNTEERING
Schulich Graduate Student Council Representative
July 2017 – present
LHSC University Hospital, London ON
 Representative for the Biochemistry Department in the council
 The council is responsible for meeting every month, informing every department
of the changes happening within Schulich School of Medicine and Dentistry, and
representing all departmental graduate students during voting and decisionmaking
 The Representative is responsible for relaying all information to the Department
and responding to student inquires
Crisis and Support Line (Counselling)
September 2014 – present
ANOVA, formerly known as the Sexual Assault Centre London and Women’s
Community House, London ON
 Volunteer on the Crisis and Support Line providing non-directive, nonjudgmental support and information to anyone who has been directly or indirectly
impacted by sexual violence or domestic violence
Big Bike Participant/Volunteer
June 20, 2017
Western University, London ON
 Raised funds and participated in the annual Big Bike event, where all proceeds go
to the Heart and Stroke Foundation
 Also assisted at the Waffle Breakfast event hosted by Robarts Research Institute
to raise additional funds
Discovery Day 2018 Host
May 4, 2018
Western University, London ON
 Helped run the Biochemistry Laboratory Workshop for high school students at
Discovery Day at Western University
Medical Genetics Sponsored Studentship
November 2017 – April 2018
Medical Genetics, LHSC Victoria Hospital, London ON
 Responsibilities include: assisting genetic counsellors with generating pedigrees,
assessing lifetime risks of cancer using IBIS and BOADICEA, and prioritizing
patients for appointments
 Opportunities also include shadowing the Genetic Counsellors during new clinic
appointments and follow-ups
 Currently involved in updating the website content
Food Services: Menu Pick Up/Patient Visiting
January 2017 – November 2017
LHSC University Hospital, London ON
 Duties included: picking up menus from all inpatient floors in the hospital, going
room-to-room to visit patients and pick up outstanding menus, delivering cards,
and helping patients complete their daily menus
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Panel Interviewee
June 19, 2017
London Central Secondary School, London ON
 Attended Grade 12 English classes to answer any questions about life beyond
high school
 Sat on a panel with other volunteers and provided guidance and support
Big Bike Participant/Volunteer
June 14, 2017
Western University, London ON
 Raised funds and participated in the annual Big Bike event, where all proceeds go
to the Heart and Stroke Foundation
 Also assisted at the Waffle Breakfast event hosted by Robarts Research Institute
to raise additional funds
Magic Wand Planning Committee
January 2017 – June 2017
Ronald McDonald House of Southwestern Ontario, London ON
 On the organizing committee for the 2nd biennial Storybook Ball, a night of dinner
and dancing and magical fun to raise money for the Ronald McDonald House
 Responsibilities included: obtaining sponsorships and donations, planning and
setting up the event, and running the event
Discovery Day 2017 Host
May 12, 2017
Western University, London ON
 Helped run the Biochemistry Laboratory Workshop for high school students at
Discovery Day at Western University
President
September 2016 – April 2017
Western Aikido Club, Western University, London ON
 As the Sport Western Aikido Club’s President, I planned, organized and carried
out daily presidential responsibilities such as financial accounting, email
communication to other executive members, and weekly communication with the
Western Rec Centre
 I also assisted in planning club events, and attended Rec Centre Presidential
Meetings
Unit Support (Surgical Outpatients)
April 2012 – January 2017
LHSC University Hospital, London ON
 As a unit support volunteer in surgical outpatients, I assisted with greeting and
welcoming patients, visitors and staff
 I also provided assistance to surgeons, residents, nurses, and occupational
therapists by putting together operation room kits, wound kits and breast surgery
care kits
LAMP Presenter (Graduate Student Meet and Greet)
November 2016
Western University, London ON
 For the LAMP meet and greet, I sat on the panel and answered questions from
undergraduate students pertaining to research and graduate school
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Registration Volunteer (Genetics in Your Practice Education Day)
November 2016
Hosted by the Medical Genetics Program of Southwestern Ontario, at the Sheraton,
London ON
 For the Medical Genetics Education Day, I was in charge of registration for all
health care professionals and attendees, and organizing event handouts and CME
certificates
Vice President/Communications
September 2015 – April 2016
Western Aikido Club, Western University, London ON
 As the Vice President, I was responsible for planning, organizing and carrying out
daily club responsibilities, and maintaining club communications
Research Assistant
September 2015 – April 2016
Dr. Hegele, Blackburn Cardiovascular Genetics Lab, Robarts Research Institute, London
ON
 I helped run various scientific experiments, assisted in the writing of a provisional
patent, and assisted the Medical Administrator with clerical duties
Child Mentor (Stand by Me Program)
September – April 2013 and 2014
Thames Valley District School Board, London ON
 Acted as a caring adult mentor for at-risk children under the age of 12
 Committed two hours a week to my mentee for one-on-one meetings, and
provided friendship, reinforcement, academic support and encouragement
Daffodil Sales
April 2011, 2012, 2013
Canadian Cancer Society, London ON
 Involved in the Daffodil Month sales to raise money for the Canadian Cancer
Society

